nid,exclude,study_id,author,text_description,first_dose_only,source,location_id,location_id2,location_name,location_name2,interval between doses,vac_before_booster,vaccine_developer,vaccine_candidate,vaccine_type,variant,variant_b1351,symptom_severity,symptom_severity_description,severity,IHME_symptom_classification,severe_vs_all,severe,moderate,mild,asymptomatic,sex_id,age_start,age_end,age_mean,over_65,is_main_analysis,is_sub_analysis,sample_size,efficacy_mean,efficacy_lower,efficacy_upper,booster,vemt,mean_time_since_vaccination,start_interval,end_interval,Period reported in the study,events_vaccine,events_control,ss_vaccine,ss_control,hiv_flag,obesity_flag,comorbidity_flag,ethnicity_flag,race_flag,dose_flag,high_risk_flag,infectious_flag,notes,extractor_id
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Infection,infection,Infection,,0,0,0,0,3,16,60,,0,,,,0.16,0,0.45,0,0,,19,22,Jan-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Infection,infection,Infection,,0,0,0,0,3,16,60,,0,,,,0.44,0.16,0.63,0,0,,15,18,Feb-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Infection,infection,Infection,,0,0,0,0,3,16,60,,0,,,,0.67,0.48,0.8,0,0,,10,14,Mar-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Infection,infection,Infection,,0,0,0,0,3,16,60,,0,,,,0.75,0.59,0.86,0,0,,2,9,April-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Mild, Moderate + Severe",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.16,0,0.45,0,0,,19,22,Jan-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Mild, Moderate + Severe",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.44,0.12,0.63,0,0,,15,18,Feb-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Mild, Moderate + Severe",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.69,0.5,0.8,0,0,,10,14,Mar-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Mild, Moderate + Severe",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.79,0.62,0.88,0,0,,2,9,April-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta Hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Severe,hosp,Severe,,1,0,0,0,3,16,60,,0,,,,0.82,0.66,0.9,0,0,,19,22,Jan-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta Hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Severe,hosp,Severe,,1,0,0,0,3,16,60,,0,,,,0.91,0.81,0.94,0,0,,15,18,Feb-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta Hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Severe,hosp,Severe,,1,0,0,0,3,16,60,,0,,,,0.89,0.77,0.94,0,0,,10,14,Mar-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta Hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Severe,hosp,Severe,,1,0,0,0,3,16,60,,0,,,,0.83,0.47,0.94,0,0,,2,9,April-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta Death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Severe,death,Severe,,1,0,0,0,3,16,60,,0,,,,0.86,0.71,0.94,0,0,,19,22,Jan-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta Death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Severe,death,Severe,,1,0,0,0,3,16,60,,0,,,,0.91,0.79,0.96,0,0,,15,18,Feb-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta Death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Severe,death,Severe,,1,0,0,0,3,16,60,,0,,,,0.94,0.79,0.98,0,0,,10,14,Mar-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,0,500,MoH Israel,MoH Israel,0,https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf,85,85,Israel,Israel Delta Death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Severe,death,Severe,,1,0,0,0,3,16,60,,0,,,,0.84,0.24,0.96,0,0,,2,9,April-Jun,,,,,0,0,0,0,0,0,0,1,Age end: 60+. VE results for delta variant based on last slide (8),cstein87
,1,501,Thomas SJ,medrxiv - multinational 4 months follow-up-  Pfizer - non-variant,0,https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1,"102, 97, 81, 135, 155, 196",102,"United States, Argentina, Brazil, Germany, South Africa and Turkey","US, Argentina, Brazil, Germany, South Africa and Turkey",,,Pfizer & BioNTech,BNT162b2,mRNA,non.variant,,"Mild, Moderate + severe","Laboratory-confirmed COVID-19. Symptomatic period: fever, new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea, and/or vomiting.  Confirmed severe COVID-19.",symptomatic,,,1,1,1,0,3,16,,51,0,,,24472,0.962,0.933,0.981,0,0,,1,8,>=7 days after dose 2 <2 months after dose 2,,,,,0,0,0,0,0,1,0,0,"Results from Table of Figure 2.  Vaccination period: July 27, 2020 and October 29, 2020. CI for VE was derived based on the Clopper and Pearson method adjusted for surveillance time.",cstein87
,1,501,Thomas SJ,medrxiv - multinational 4 months follow-up-  Pfizer - non-variant,0,https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1,"102, 97, 81, 135, 155, 196",102,"United States, Argentina, Brazil, Germany, South Africa and Turkey","US, Argentina, Brazil, Germany, South Africa and Turkey",,,Pfizer & BioNTech,BNT162b2,mRNA,non.variant,,"Mild, Moderate + severe","Laboratory-confirmed COVID-19. Symptomatic period: fever, new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea, and/or vomiting.  Confirmed severe COVID-19.",symptomatic,,,1,1,1,0,3,16,,51,0,,,24472,0.901,0.747,0.899,0,0,,9,16,>=2 months after dose 2 to <4 months after dose 2,,,,,0,0,0,0,0,1,0,0,"Results from Table of Figure 2.  Vaccination period: July 27, 2020 and October 29, 2020. CI for VE was derived based on the Clopper and Pearson method adjusted for surveillance time.",cstein87
,1,501,Thomas SJ,medrxiv - multinational 4 months follow-up-  Pfizer - non-variant,0,https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1,"102, 97, 81, 135, 155, 196",102,"United States, Argentina, Brazil, Germany, South Africa and Turkey","US, Argentina, Brazil, Germany, South Africa and Turkey",,,Pfizer & BioNTech,BNT162b2,mRNA,non.variant,,"Mild, Moderate + severe","Laboratory-confirmed COVID-19. Symptomatic period: fever, new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea, and/or vomiting.  Confirmed severe COVID-19.",symptomatic,,,1,1,1,0,3,16,,51,0,,,24472,0.837,0.747,0.899,0,0,,17,24,>= 4 months after dose 2,,,,,0,0,0,0,0,1,0,0,"Results from Table of Figure 2.  Vaccination period: July 27, 2020 and October 29, 2020. CI for VE was derived based on the Clopper and Pearson method adjusted for surveillance time.",cstein87
,1,502,Self WH,CDC - Pfizer - March–August 2021,0,https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm,102,102,United States,USA Hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,non.variant,,severe,against COVID-19–associated hospitalization,hosp,Severe,,1,0,0,0,3,18,65,,0,,,3100,0.91,0.88,0.93,0,0,,2,16,14–120 days after full vaccination,,,,,0,0,0,0,0,0,0,0,"Age end ?65. Model adjusted for age group (18–49, 50–64, ?65 years) and other variables",cstein87
,1,502,Self WH,CDC - Pfizer - March–August 2021,0,https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm,102,102,United States,USA Hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,non.variant,,severe,against COVID-19–associated hospitalization,hosp,Severe,,1,0,0,0,3,18,65,,0,,,2540,0.77,0.67,0.84,0,0,,17,24,>120 days after full vaccination,,,,,0,0,0,0,0,0,0,0,"Age end ?65. Model adjusted for age group (18–49, 50–64, ?65 years) and other variables",cstein87
,1,502,Self WH,CDC - Moderna March–August 2021,0,https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm,102,102,United States,USA Hosp,0,,Moderna,mRNA-1273,mRNA,non.variant,,severe,against COVID-19–associated hospitalization,hosp,Severe,,1,0,0,0,3,18,65,,0,,,2743,0.93,0.9,0.95,0,0,,2,16,14–120 days after full vaccination,,,,,0,0,0,0,0,0,0,0,"Age end ?65. Model adjusted for age group (18–49, 50–64, ?65 years) and other variables",cstein87
,1,502,Self WH,CDC - Moderna March–August 2021,0,https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm,102,102,United States,USA Hosp,0,,Moderna,mRNA-1273,mRNA,non.variant,,severe,against COVID-19–associated hospitalization,hosp,Severe,,1,0,0,0,3,18,65,,0,,,2457,0.92,0.87,0.96,0,0,,17,24,>120 days after full vaccination,,,,,0,0,0,0,0,0,0,0,"Age end ?65. Model adjusted for age group (18–49, 50–64, ?65 years) and other variables",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Table 4",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar,,,Pfizer & BioNTech,BNT162b2,mRNA,non.variant,,"Mild, Moderate + severe",A symptomatic infection was defined as a PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,74544,0.796,0.779,0.812,0,0,,0,4,0-4 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Table 4",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar,,,Pfizer & BioNTech,BNT162b2,mRNA,non.variant,,"Mild, Moderate + severe",A symptomatic infection was defined as a PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,72312,0.708,0.678,0.736,0,0,,5,9,5-9 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Table 4",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar,,,Pfizer & BioNTech,BNT162b2,mRNA,non.variant,,"Mild, Moderate + severe",A symptomatic infection was defined as a PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,71290,0.606,0.552,0.654,0,0,,10,14,10-14 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Table 4",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar,,,Pfizer & BioNTech,BNT162b2,mRNA,non.variant,,"Mild, Moderate + severe",A symptomatic infection was defined as a PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,70366,0.496,0.391,0.584,0,0,,15,19,15-19 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Table 4",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar,,,Pfizer & BioNTech,BNT162b2,mRNA,non.variant,,"Mild, Moderate + severe",A symptomatic infection was defined as a PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,70210,0.01,0,0.191,0,0,,20,24,20-24 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Table 4",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar,,,Pfizer & BioNTech,BNT162b2,mRNA,non.variant,,"Mild, Moderate + severe",A symptomatic infection was defined as a PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,70188,0.01,0,0.08,0,0,,25,29,?25 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Supplementary Table 3",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Cases (PCR-positive persons) and controls (PCR-negative persons) were matched one-to-one by sex, 10-year age group, nationality, reason for SARSCoV-2 PCR testing, and calendar week of PCR test. Matching of cases and controls was performed to control for known differences in the risk of exposure to SARS-CoV-2 infection in Qatar.",infection,Infection,,,,,,3,20,70,,0,,,3862,0.838,0.736,0.905,0,0,,0,4,0-4 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Supplementary Table 3",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Cases (PCR-positive persons) and controls (PCR-negative persons) were matched one-to-one by sex, 10-year age group, nationality, reason for SARSCoV-2 PCR testing, and calendar week of PCR test. Matching of cases and controls was performed to control for known differences in the risk of exposure to SARS-CoV-2 infection in Qatar.",infection,Infection,,,,,,3,20,70,,0,,,3940,0.72,0.605,0.805,0,0,,5,9,5-9 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Supplementary Table 3",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Cases (PCR-positive persons) and controls (PCR-negative persons) were matched one-to-one by sex, 10-year age group, nationality, reason for SARSCoV-2 PCR testing, and calendar week of PCR test. Matching of cases and controls was performed to control for known differences in the risk of exposure to SARS-CoV-2 infection in Qatar.",infection,Infection,,,,,,3,20,70,,0,,,3944,0.487,0.284,0.636,0,0,,10,14,10-14 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Supplementary Table 3",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Cases (PCR-positive persons) and controls (PCR-negative persons) were matched one-to-one by sex, 10-year age group, nationality, reason for SARSCoV-2 PCR testing, and calendar week of PCR test. Matching of cases and controls was performed to control for known differences in the risk of exposure to SARS-CoV-2 infection in Qatar.",infection,Infection,,,,,,3,20,70,,0,,,4034,0.13,0,0.348,0,0,,15,19,15-19 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Supplementary Table 3",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Cases (PCR-positive persons) and controls (PCR-negative persons) were matched one-to-one by sex, 10-year age group, nationality, reason for SARSCoV-2 PCR testing, and calendar week of PCR test. Matching of cases and controls was performed to control for known differences in the risk of exposure to SARS-CoV-2 infection in Qatar.",infection,Infection,,,,,,3,20,70,,0,,,4106,0.01,0,0.013,0,0,,20,24,20-24 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Supplementary Table 3",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Cases (PCR-positive persons) and controls (PCR-negative persons) were matched one-to-one by sex, 10-year age group, nationality, reason for SARSCoV-2 PCR testing, and calendar week of PCR test. Matching of cases and controls was performed to control for known differences in the risk of exposure to SARS-CoV-2 infection in Qatar.",infection,Infection,,,,,,3,20,70,,0,,,3956,0.01,0,0.213,0,0,,25,29,?25 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Supplementary Table 3",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Classification of COVID-19 case severity (acute-care hospitalizations), criticality (ICU hospitalizations), and fatality followed World Health Organization (WHO) guidelines",,Severe,,1,0,0,0,3,20,70,,0,,,100,0.999,0,0.999,0,0,,0,4,0-4 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Supplementary Table 3",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Classification of COVID-19 case severity (acute-care hospitalizations), criticality (ICU hospitalizations), and fatality followed World Health Organization (WHO) guidelines",,Severe,,1,0,0,0,3,20,70,,0,,,108,0.999,0.743,0.999,0,0,,5,9,5-9 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Supplementary Table 3",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Classification of COVID-19 case severity (acute-care hospitalizations), criticality (ICU hospitalizations), and fatality followed World Health Organization (WHO) guidelines",,Severe,,1,0,0,0,3,20,70,,0,,,100,0.816,0,0.996,0,0,,10,14,10-14 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Supplementary Table 3",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Classification of COVID-19 case severity (acute-care hospitalizations), criticality (ICU hospitalizations), and fatality followed World Health Organization (WHO) guidelines",,Severe,,1,0,0,0,3,20,70,,0,,,100,0.999,0,0.999,0,0,,15,19,15-19 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Supplementary Table 3",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Classification of COVID-19 case severity (acute-care hospitalizations), criticality (ICU hospitalizations), and fatality followed World Health Organization (WHO) guidelines",,Severe,,1,0,0,0,3,20,70,,0,,,102,0.816,0,0.996,0,0,,20,24,20-24 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,503,Chemaitelly H,"medrxiv - Qatar - January 1, 2021 to August 15, 2021. Supplementary Table 3",0,https://www.medrxiv.org/content/10.1101/2021.08.25.21262584v1.full.pdf,151,151,Qatar,Qatar Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Classification of COVID-19 case severity (acute-care hospitalizations), criticality (ICU hospitalizations), and fatality followed World Health Organization (WHO) guidelines",,Severe,,1,0,0,0,3,20,70,,0,,,106,0.679,0,0.994,0,0,,25,29,?25 weeks after the second dose,,,,,0,0,0,0,0,1,0,1,"Age start <20. Age end 70+years. To ensure that vaccine effectiveness estimates were not biased by epidemic phase, the gradual roll-out of vaccination during the study, or other confounders, a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. ‡Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR-confirmed symptomatic disease,symptomatic,"Mild, Moderate + Severe",,0,1,1,1,3,16,65,,0,,,,0.627,0.617,0.638,0,0,,1,1,week 1,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR-confirmed symptomatic disease,symptomatic,"Mild, Moderate + Severe",,0,1,1,1,3,16,65,,0,,,,0.667,0.663,0.67,0,0,,2,9,2 to 9 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR-confirmed symptomatic disease,symptomatic,"Mild, Moderate + Severe",,0,1,1,1,3,16,65,,0,,,,0.593,0.588,0.599,0,0,,10,14,10 to 14 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR-confirmed symptomatic disease,symptomatic,"Mild, Moderate + Severe",,0,1,1,1,3,16,65,,0,,,,0.526,0.517,0.535,0,0,,15,19,15 to 19 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR-confirmed symptomatic disease,symptomatic,"Mild, Moderate + Severe",,0,1,1,1,3,16,65,,0,,,,0.473,0.45,0.496,0,0,,20,24,20+ weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",PCR-confirmed symptomatic disease,symptomatic,"Mild, Moderate + Severe",,0,1,1,1,3,16,65,,0,,,,0.924,0.921,0.927,0,0,,1,1,week 1,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",PCR-confirmed symptomatic disease,symptomatic,"Mild, Moderate + Severe",,0,1,1,1,3,16,65,,0,,,,0.898,0.896,0.9,0,0,,2,9,2 to 9 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",PCR-confirmed symptomatic disease,symptomatic,"Mild, Moderate + Severe",,0,1,1,1,3,16,65,,0,,,,0.803,0.799,0.806,0,0,,10,14,10 to 14 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",PCR-confirmed symptomatic disease,symptomatic,"Mild, Moderate + Severe",,0,1,1,1,3,16,65,,0,,,,0.734,0.729,0.739,0,0,,15,19,15 to 19 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",PCR-confirmed symptomatic disease,symptomatic,"Mild, Moderate + Severe",,0,1,1,1,3,16,65,,0,,,,0.697,0.687,0.705,0,0,,20,24,20+ weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE -  Moderna Spikevax,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",PCR-confirmed symptomatic disease,symptomatic,"Mild, Moderate + Severe",,0,1,1,1,3,16,65,,0,,,,0.952,0.944,0.959,0,0,,1,1,week 1,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE -  Moderna Spikevax,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",PCR-confirmed symptomatic disease,symptomatic,"Mild, Moderate + Severe",,0,1,1,1,3,16,65,,0,,,,0.945,0.941,0.95,0,0,,2,9,2 to 9 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE -  Moderna Spikevax,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",PCR-confirmed symptomatic disease,symptomatic,"Mild, Moderate + Severe",,0,1,1,1,3,16,65,,0,,,,0.903,0.672,0.971,0,0,,10,14,10 to 14 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"hospitalisation with 14 days of PCR confirmation, and death within 28 days of PCR confirmation",hosp,Severe,,1,0,0,0,3,16,65,,0,,,,0.939,0.913,0.957,0,0,,1,1,week 1,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"hospitalisation with 14 days of PCR confirmation, and death within 28 days of PCR confirmation",hosp,Severe,,1,0,0,0,3,16,65,,0,,,,0.952,0.946,0.956,0,0,,2,9,2 to 9 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"hospitalisation with 14 days of PCR confirmation, and death within 28 days of PCR confirmation",hosp,Severe,,1,0,0,0,3,16,65,,0,,,,0.914,0.905,0.922,0,0,,10,14,10 to 14 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"hospitalisation with 14 days of PCR confirmation, and death within 28 days of PCR confirmation",hosp,Severe,,1,0,0,0,3,16,65,,0,,,,0.868,0.851,0.884,0,0,,15,19,15 to 19 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"hospitalisation with 14 days of PCR confirmation, and death within 28 days of PCR confirmation",hosp,Severe,,1,0,0,0,3,16,65,,0,,,,0.77,0.703,0.823,0,0,,20,24,20+ weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"hospitalisation with 14 days of PCR confirmation, and death within 28 days of PCR confirmation",hosp,Severe,,1,0,0,0,3,16,65,,0,,,,0.997,0.976,0.999,0,0,,1,1,week 1,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"hospitalisation with 14 days of PCR confirmation, and death within 28 days of PCR confirmation",hosp,Severe,,1,0,0,0,3,16,65,,0,,,,0.984,0.979,0.988,0,0,,2,9,2 to 9 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"hospitalisation with 14 days of PCR confirmation, and death within 28 days of PCR confirmation",hosp,Severe,,1,0,0,0,3,16,65,,0,,,,0.965,0.959,0.971,0,0,,10,14,10 to 14 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"hospitalisation with 14 days of PCR confirmation, and death within 28 days of PCR confirmation",hosp,Severe,,1,0,0,0,3,16,65,,0,,,,0.944,0.934,0.952,0,0,,15,19,15 to 19 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"hospitalisation with 14 days of PCR confirmation, and death within 28 days of PCR confirmation",hosp,Severe,,1,0,0,0,3,16,65,,0,,,,0.927,0.903,0.946,0,0,,20,24,20+ weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE -  Moderna Spikevax,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta hosp,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"hospitalisation with 14 days of PCR confirmation, and death within 28 days of PCR confirmation",hosp,Severe,,1,0,0,0,3,16,65,,0,,,,0.975,0.823,0.997,0,0,,1,1,week 1,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE -  Moderna Spikevax,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta hosp,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"hospitalisation with 14 days of PCR confirmation, and death within 28 days of PCR confirmation",hosp,Severe,,1,0,0,0,3,16,65,,0,,,,0.975,0.823,0.997,0,0,,2,9,2 to 9 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.Carol note: same VE of the preceding result, because VE was 100%, which did not works well in MR-BRT splines time since vaccination analysis  Carol note: same VE of the preceding result, because VE was 100%, which did not works well in MR-BRT splines time since vaccination analysis",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta death,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,death within 28 days of PCR confirmation,death,Severe,,1,0,0,0,3,16,65,,0,,,,0.941,0.918,0.958,0,0,,2,9,2 to 9 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta death,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,death within 28 days of PCR confirmation,death,Severe,,1,0,0,0,3,16,65,,0,,,,0.924,0.897,0.944,0,0,,10,14,10 to 14 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta death,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,death within 28 days of PCR confirmation,death,Severe,,1,0,0,0,3,16,65,,0,,,,0.891,0.842,0.925,0,0,,15,19,15 to 19 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - AstraZeneca Vaxzevria,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta death,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,death within 28 days of PCR confirmation,death,Severe,,1,0,0,0,3,16,65,,0,,,,0.787,0.527,0.904,0,0,,20,24,20+ weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta death,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,death within 28 days of PCR confirmation,death,Severe,,1,0,0,0,3,16,65,,0,,,,0.982,0.959,0.992,0,0,,2,9,2 to 9 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta death,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,death within 28 days of PCR confirmation,death,Severe,,1,0,0,0,3,16,65,,0,,,,0.952,0.93,0.967,0,0,,10,14,10 to 14 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta death,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,death within 28 days of PCR confirmation,death,Severe,,1,0,0,0,3,16,65,,0,,,,0.939,0.911,0.958,0,0,,15,19,15 to 19 weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,1,504,Andrews N,PHE - Pfizer-BioNTech Comirnaty,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/526279031?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F338928724%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%253Fp_p_id%253Dcom_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig%2526p_p_lifecycle%253D0%2526p_p_state%253Dnormal%2526p_p_mode%253Dview%2526_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_mvcRenderCommandName%253D%25252Fdocument_library%25252Fview,95,95,United Kingdom,UK Delta death,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,death within 28 days of PCR confirmation,death,Severe,,1,0,0,0,3,16,65,,0,,,,0.904,0.851,0.938,0,0,,20,24,20+ weeks,,,,,0,0,0,0,0,0,0,0,"Age: 16+. Age end: 65+. Vaccine effectiveness was adjusted in logistic regression models for age, sex, index of multiple deprivation, ethnic group, care home residence status (for analyses including adults aged >=65 years), geographic region, period (calendar week), health and social care worker status (for analyses with adults aged <65 years), and clinical risk group (only available for <65 year-olds) or a clinically extremely vulnerable group (any age). 13 For deaths, the period was modelled using a cubic spline due to smaller numbers.",cstein87
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v2,102,102,United States,USA Mayo Clinic mixed,0,,Pfizer & BioNTech,mRNA-1273,mRNA,B.1.1.7,,infection,Positive PCR On or after 14 days following second dose,infection,infection,,0,0,0,0,3,18,85,,0,,,,0.99,0.66,0.99,0,0,,2,8,Jan-Feb,,,,,0,0,0,0,0,0,0,0,"Age end = 85+ Carol note: transformed VE = 0.99, instead 1 because of analysis on MR-BRT",han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v3,102,102,United States,USA Mayo Clinic mixed,0,,Moderna,mRNA-1273,mRNA,B.1.1.7,,infection,Positive PCR On or after 14 days following second dose,infection,infection,,0,0,0,0,3,18,85,,0,,,,0.909,0.71,0.982,0,0,,9,12,Feb-Mar,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v4,102,102,United States,USA Mayo Clinic mixed,0,,Moderna,mRNA-1273,mRNA,B.1.1.7,,infection,Positive PCR On or after 14 days following second dose,infection,infection,,0,0,0,0,3,18,85,,0,,,,0.915,0.82,0.967,0,0,,13,16,Mar-Apr,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v5,102,102,United States,USA Mayo Clinic mixed,0,,Moderna,mRNA-1273,mRNA,B.1.1.7,,infection,Positive PCR On or after 14 days following second dose,infection,infection,,0,0,0,0,3,18,85,,0,,,,0.931,0.83,0.978,0,0,,17,20,Apr-May,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v6,102,102,United States,USA Mayo Clinic mixed,0,,Moderna,mRNA-1273,mRNA,B.1.1.7,,infection,Positive PCR On or after 14 days following second dose,infection,infection,,0,0,0,0,3,18,85,,0,,,,0.62,0.12,0.85,0,0,,21,24,May-Jun,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v7,102,102,United States,USA Mayo Clinic mixed,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose,infection,infection,,0,0,0,0,3,18,85,,0,,,,0.76,0.68,0.87,0,0,,25,28,Jun_Jul,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v8,102,102,United States,USA Mayo Clinic mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,infection,Positive PCR On or after 14 days following second dose,infection,infection,,0,0,0,0,3,18,85,,0,,,,0.99,0.61,0.99,0,0,,2,8,Jan-Feb,,,,,0,0,0,0,0,0,0,0,"Age end = 85+ Carol note: transformed VE = 0.99, instead 1 because of analysis on MR-BRT",han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v9,102,102,United States,USA Mayo Clinic mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,infection,Positive PCR On or after 14 days following second dose,infection,infection,,0,0,0,0,3,18,85,,0,,,,0.89,0.69,0.972,0,0,,9,12,Feb-Mar,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v10,102,102,United States,USA Mayo Clinic mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,infection,Positive PCR On or after 14 days following second dose,infection,infection,,0,0,0,0,3,18,85,,0,,,,0.88,0.77,0.941,0,0,,13,16,Mar-Apr,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v11,102,102,United States,USA Mayo Clinic mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,infection,Positive PCR On or after 14 days following second dose,infection,infection,,0,0,0,0,3,18,85,,0,,,,0.83,0.69,0.913,0,0,,17,20,Apr-May,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v12,102,102,United States,USA Mayo Clinic mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,infection,Positive PCR On or after 14 days following second dose,infection,infection,,0,0,0,0,3,18,85,,0,,,,0.82,0.47,0.954,0,0,,21,24,May-Jun,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v12,102,102,United States,USA Mayo Clinic mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose,infection,infection,,0,0,0,0,3,18,85,,0,,,,0.42,0.13,0.62,0,0,,25,28,Jun_Jul,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v13,102,102,United States,USA Mayo Clinic mixed hosp,0,,Moderna,mRNA-1273,mRNA,B.1.1.7,,severe,Hospitalization within 21 days of positive PCR,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.88,0.1,0.9972,0,0,,9,12,Feb-Mar,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v14,102,102,United States,USA Mayo Clinic mixed hosp,0,,Moderna,mRNA-1273,mRNA,B.1.1.7,,severe,Hospitalization within 21 days of positive PCR,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.943,0.64,0.9986,0,0,,13,16,Mar-Apr,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v15,102,102,United States,USA Mayo Clinic mixed hosp,0,,Moderna,mRNA-1273,mRNA,B.1.1.7,,severe,Hospitalization within 21 days of positive PCR,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.954,0.72,0.9989,0,0,,17,20,Apr-May,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v16,102,102,United States,USA Mayo Clinic mixed hosp,0,,Moderna,mRNA-1273,mRNA,B.1.1.7,,severe,Hospitalization within 21 days of positive PCR,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.99,0.2,0.99,0,0,,21,24,May-Jun,,,,,0,0,0,0,0,0,0,0,"Age end = 85+ Carol note: transformed VE = 0.99, instead 1 because of analysis on MR-BRT",han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v17,102,102,United States,USA Mayo Clinic mixed hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Hospitalization within 21 days of positive PCR,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.81,0.33,0.963,0,0,,25,28,Jun_Jul,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v18,102,102,United States,USA Mayo Clinic mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,severe,Hospitalization within 21 days of positive PCR,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.89,0.18,0.9974,0,0,,9,12,Feb-Mar,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v19,102,102,United States,USA Mayo Clinic mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,severe,Hospitalization within 21 days of positive PCR,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.9,0.57,0.988,0,0,,13,16,Mar-Apr,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v20,102,102,United States,USA Mayo Clinic mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,severe,Hospitalization within 21 days of positive PCR,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.87,0.57,0.975,0,0,,17,20,Apr-May,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v21,102,102,United States,USA Mayo Clinic mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,severe,Hospitalization within 21 days of positive PCR,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.84,0.8,0.9965,0,0,,21,24,May-Jun,,,,,0,0,0,0,0,0,0,0,"Age end = 85+ Carol note: According to table 4 the upper bound of the IRR is 1.2 . However, I think it is not possible. So, I assume to extract the data and include in the analysis a value as 0.2 and then the efficacy lower is 0.80.",han20
,0,505,Puranik A,medrxiv - Mayo Clinic - January to July 2021.,0,https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v22,102,102,United States,USA Mayo Clinic mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Hospitalization within 21 days of positive PCR,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.75,0.24,0.939,0,0,,25,28,Jun_Jul,,,,,0,0,0,0,0,0,0,0,Age end = 85+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA DoV Delta,,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1273 or BNT162b2 vaccines or after the single of Ad26.COV2.S vaccine,infection,infection,,0,0,0,0,3,18,65,,0,,,227570,,,,0,0,,0,12.5,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA DoV Delta,,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1273 or BNT162b2 vaccines or after the single of Ad26.COV2.S vaccine,infection,infection,,0,0,0,0,3,18,65,,0,,,227570,,,,0,0,,0,25,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA DoV Delta,,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1273 or BNT162b2 vaccines or after the single of Ad26.COV2.S vaccine,infection,infection,,0,0,0,0,3,18,65,,0,,,227570,,,,0,0,,0,37.5,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA DoV Delta,,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1273 or BNT162b2 vaccines or after the single of Ad26.COV2.S vaccine,infection,infection,,0,0,0,0,3,18,65,,0,,,227570,,,,0,0,,0,50,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA DoV Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1273 or BNT162b2 vaccines or after the single of Ad26.COV2.S vaccine,infection,infection,,0,0,0,0,3,18,65,,0,,,1293609,,,,0,0,,0,12.5,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA DoV Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1273 or BNT162b2 vaccines or after the single of Ad26.COV2.S vaccine,infection,infection,,0,0,0,0,3,18,65,,0,,,1293609,,,,0,0,,0,25,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA DoV Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1273 or BNT162b2 vaccines or after the single of Ad26.COV2.S vaccine,infection,infection,,0,0,0,0,3,18,65,,0,,,1293609,,,,0,0,,0,37.5,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA DoV Delta,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1273 or BNT162b2 vaccines or after the single of Ad26.COV2.S vaccine,infection,infection,,0,0,0,0,3,18,65,,0,,,1293609,,,,0,0,,0,50,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA DoV Delta,,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1273 or BNT162b2 vaccines or after the single of Ad26.COV2.S vaccine,infection,infection,,0,0,0,0,3,18,65,,0,,,1511382,,,,0,0,,0,12.5,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA DoV Delta,,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1273 or BNT162b2 vaccines or after the single of Ad26.COV2.S vaccine,infection,infection,,0,0,0,0,3,18,65,,0,,,1511382,,,,0,0,,0,25,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA DoV Delta,,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1273 or BNT162b2 vaccines or after the single of Ad26.COV2.S vaccine,infection,infection,,0,0,0,0,3,18,65,,0,,,1511382,,,,0,0,,0,37.5,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA DoV Delta,,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1273 or BNT162b2 vaccines or after the single of Ad26.COV2.S vaccine,infection,infection,,0,0,0,0,3,18,65,,0,,,1511382,,,,0,0,,0,50,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA Dov Delta hosp,,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"COVID-19 hospitalization, defined as an admission to an acute care facility accompanied by documented SARS-CoV-2 infection either 14 days before or 3 days after date of admission and a discharge ICD 10 diagnosis code compatible with COVID-19 infection, unspecified pneumonia, or respiratory distress",hosp,severe,,1,0,0,0,3,18,65,,0,,,227570,,,,0,0,,0,12.5,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA Dov Delta hosp,,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"COVID-19 hospitalization, defined as an admission to an acute care facility accompanied by documented SARS-CoV-2 infection either 14 days before or 3 days after date of admission and a discharge ICD 10 diagnosis code compatible with COVID-19 infection, unspecified pneumonia, or respiratory distress",hosp,severe,,1,0,0,0,3,18,65,,0,,,227570,,,,0,0,,0,25,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA Dov Delta hosp,,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"COVID-19 hospitalization, defined as an admission to an acute care facility accompanied by documented SARS-CoV-2 infection either 14 days before or 3 days after date of admission and a discharge ICD 10 diagnosis code compatible with COVID-19 infection, unspecified pneumonia, or respiratory distress",hosp,severe,,1,0,0,0,3,18,65,,0,,,227570,,,,0,0,,0,37.5,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA Dov Delta hosp,,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"COVID-19 hospitalization, defined as an admission to an acute care facility accompanied by documented SARS-CoV-2 infection either 14 days before or 3 days after date of admission and a discharge ICD 10 diagnosis code compatible with COVID-19 infection, unspecified pneumonia, or respiratory distress",hosp,severe,,1,0,0,0,3,18,65,,0,,,227570,,,,0,0,,0,50,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA Dov Delta hosp,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"COVID-19 hospitalization, defined as an admission to an acute care facility accompanied by documented SARS-CoV-2 infection either 14 days before or 3 days after date of admission and a discharge ICD 10 diagnosis code compatible with COVID-19 infection, unspecified pneumonia, or respiratory distress",hosp,severe,,1,0,0,0,3,18,65,,0,,,1293609,,,,0,0,,0,12.5,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA Dov Delta hosp,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"COVID-19 hospitalization, defined as an admission to an acute care facility accompanied by documented SARS-CoV-2 infection either 14 days before or 3 days after date of admission and a discharge ICD 10 diagnosis code compatible with COVID-19 infection, unspecified pneumonia, or respiratory distress",hosp,severe,,1,0,0,0,3,18,65,,0,,,1293609,,,,0,0,,0,25,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA Dov Delta hosp,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"COVID-19 hospitalization, defined as an admission to an acute care facility accompanied by documented SARS-CoV-2 infection either 14 days before or 3 days after date of admission and a discharge ICD 10 diagnosis code compatible with COVID-19 infection, unspecified pneumonia, or respiratory distress",hosp,severe,,1,0,0,0,3,18,65,,0,,,1293609,,,,0,0,,0,37.5,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA Dov Delta hosp,,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"COVID-19 hospitalization, defined as an admission to an acute care facility accompanied by documented SARS-CoV-2 infection either 14 days before or 3 days after date of admission and a discharge ICD 10 diagnosis code compatible with COVID-19 infection, unspecified pneumonia, or respiratory distress",hosp,severe,,1,0,0,0,3,18,65,,0,,,1293609,,,,0,0,,0,50,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA Dov Delta hosp,,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"COVID-19 hospitalization, defined as an admission to an acute care facility accompanied by documented SARS-CoV-2 infection either 14 days before or 3 days after date of admission and a discharge ICD 10 diagnosis code compatible with COVID-19 infection, unspecified pneumonia, or respiratory distress",hosp,severe,,1,0,0,0,3,18,65,,0,,,1511382,,,,0,0,,0,12.5,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA Dov Delta hosp,,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"COVID-19 hospitalization, defined as an admission to an acute care facility accompanied by documented SARS-CoV-2 infection either 14 days before or 3 days after date of admission and a discharge ICD 10 diagnosis code compatible with COVID-19 infection, unspecified pneumonia, or respiratory distress",hosp,severe,,1,0,0,0,3,18,65,,0,,,1511382,,,,0,0,,0,25,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA Dov Delta hosp,,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"COVID-19 hospitalization, defined as an admission to an acute care facility accompanied by documented SARS-CoV-2 infection either 14 days before or 3 days after date of admission and a discharge ICD 10 diagnosis code compatible with COVID-19 infection, unspecified pneumonia, or respiratory distress",hosp,severe,,1,0,0,0,3,18,65,,0,,,1511382,,,,0,0,,0,37.5,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,506,Sharma A,medrix - US Department of Veteran Affairs- January 1 to August 31 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.23.21263864v1.full.pdf,102,102,United States,USA Dov Delta hosp,,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"COVID-19 hospitalization, defined as an admission to an acute care facility accompanied by documented SARS-CoV-2 infection either 14 days before or 3 days after date of admission and a discharge ICD 10 diagnosis code compatible with COVID-19 infection, unspecified pneumonia, or respiratory distress",hosp,severe,,1,0,0,0,3,18,65,,0,,,1511382,,,,0,0,,0,50,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end= 65+,han20
,1,507,Katia J,medrix- Effectiveness of mRNA-1273 against delta and non-variant SARS-CoV-2- January 2021 to July 2021,0,https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v1,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1273,infection,infection,,0,0,0,0,3,18,75,,0,,,,0.941,0.905,0.963,0,0,,2,8,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end =75+,han20
,1,507,Katia J,medrix- Effectiveness of mRNA-1273 against delta and non-variant SARS-CoV-2- January 2021 to July 2022,0,https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v2,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1274,infection,infection,,0,0,0,0,3,18,75,,0,,,,0.887,0.85,0.915,0,0,,9,12,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end =75+,han20
,1,507,Katia J,medrix- Effectiveness of mRNA-1273 against delta and non-variant SARS-CoV-2- January 2021 to July 2023,0,https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v3,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1275,infection,infection,,0,0,0,0,3,18,75,,0,,,,0.859,0.811,0.895,0,0,,12,17,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end =75+,han20
,1,507,Katia J,medrix- Effectiveness of mRNA-1273 against delta and non-variant SARS-CoV-2- January 2021 to July 2024,0,https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v4,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1276,infection,infection,,0,0,0,0,3,18,75,,0,,,,0.77,0.691,0.829,0,0,,18,21,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end =75+,han20
,1,507,Katia J,medrix- Effectiveness of mRNA-1273 against delta and non-variant SARS-CoV-2- January 2021 to July 2025,0,https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v5,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR On or after 14 days following second dose of mRNA-1277,infection,infection,,0,0,0,0,3,18,75,,0,,,,0.8,0.702,0.866,0,0,,22,26,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end =75+,han20
,1,507,Katia J,medrix- Effectiveness of mRNA-1273 against delta and non-variant SARS-CoV-2- January 2021 to July 2026,0,https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v6,102,102,United States,US delta/non-delta,0,,Moderna,mRNA-1273,mRNA,non-variant,,infection,Positive PCR On or after 14 days following second dose of mRNA-1278,infection,infection,,0,0,0,0,3,18,75,,0,,,,0.98,0.975,0.99,0,0,,2,8,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end =75+,han20
,1,507,Katia J,medrix- Effectiveness of mRNA-1273 against delta and non-variant SARS-CoV-2- January 2021 to July 2027,0,https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v7,102,102,United States,US delta/non-delta,0,,Moderna,mRNA-1273,mRNA,non-variant,,infection,Positive PCR On or after 14 days following second dose of mRNA-1279,infection,infection,,0,0,0,0,3,18,75,,0,,,,0.975,0.945,0.99,0,0,,9,12,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end =75+,han20
,1,507,Katia J,medrix- Effectiveness of mRNA-1273 against delta and non-variant SARS-CoV-2- January 2021 to July 2028,0,https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v8,102,102,United States,US delta/non-delta,0,,Moderna,mRNA-1273,mRNA,non-variant,,infection,Positive PCR On or after 14 days following second dose of mRNA-1280,infection,infection,,0,0,0,0,3,18,75,,0,,,,0.92,0.82,0.975,0,0,,12,17,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end =75+,han20
,1,507,Katia J,medrix- Effectiveness of mRNA-1273 against delta and non-variant SARS-CoV-2- January 2021 to July 2029,0,https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v9,102,102,United States,US delta/non-delta,0,,Moderna,mRNA-1273,mRNA,non-variant,,infection,Positive PCR On or after 14 days following second dose of mRNA-1281,infection,infection,,0,0,0,0,3,18,75,,0,,,,0.91,0.75,0.98,0,0,,18,21,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end =75+,han20
,1,507,Katia J,medrix- Effectiveness of mRNA-1273 against delta and non-variant SARS-CoV-2- January 2021 to July 2030,0,https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v10,102,102,United States,US delta/non-delta,0,,Moderna,mRNA-1273,mRNA,non-variant,,infection,Positive PCR On or after 14 days following second dose of mRNA-1282,infection,infection,,0,0,0,0,3,18,75,,0,,,,,,,0,0,,22,26,Days(changed here to weeks) after fully vaccinated,,,,,0,0,0,0,0,0,0,0,Age end =75+,han20
,1,1000,El Sahly H,NEJM- USA- Moderna efficacy double blinded CT,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2113017,102,102,United States,US Alpha,0,,Moderna,mRNA-1273,mRNA,non-variant,,"Mild, Moderate","At least two systemic symptoms, or at least one respiratory symptoms, with a confirmed by positive RT-PCR after 14 days of second injection ",symptomatic,"Mild, Moderate",,0,1,1,0,3,18,75,,0,,,14287,0.959,0.747,0.99,0,0,,0,2,Weeks after second injection,,,,,0,0,0,0,0,0,0,0,Age end =75+,han20
,1,1000,El Sahly H,NEJM- USA- Moderna efficacy double blinded CT,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2113017,102,102,United States,US Alpha,0,,Moderna,mRNA-1273,mRNA,non-variant,,"Mild, Moderate","At least two systemic symptoms, or at least one respiratory symptoms, with a confirmed by positive RT-PCR after 14 days of second injection ",symptomatic,"Mild, Moderate",,0,1,1,0,3,18,75,,0,,,14287,0.918,0.869,0.951,0,0,,3,8,Weeks after second injection,,,,,0,0,0,0,0,0,0,0,Age end =75+,han20
,1,1000,El Sahly H,NEJM- USA- Moderna efficacy double blinded CT,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2113017,102,102,United States,US Alpha,0,,Moderna,mRNA-1273,mRNA,non-variant,,"Mild, Moderate","At least two systemic symptoms, or at least one respiratory symptoms, with a confirmed by positive RT-PCR after 14 days of second injection ",symptomatic,"Mild, Moderate",,0,1,1,0,3,18,75,,0,,,14287,0.94,0.912,0.961,0,0,,9,16,Weeks after second injection,,,,,0,0,0,0,0,0,0,0,Age end =75+,han20
,1,1000,El Sahly H,NEJM- USA- Moderna efficacy double blinded CT,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2113017,102,102,United States,US Alpha,0,,Moderna,mRNA-1273,mRNA,non-variant,,"Mild, Moderate","At least two systemic symptoms, or at least one respiratory symptoms, with a confirmed by positive RT-PCR after 14 days of second injection ",symptomatic,"Mild, Moderate",,0,1,1,0,3,18,75,,0,,,14287,0.924,0.834,0.968,0,0,,17,20,Weeks after second injection,,,,,0,0,0,0,0,0,0,0,"Age end =75+, Study did not specify an end (last group was >16 weeks) so it was specified here as 16 + 4 for sake of the analysis",han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"testing positive for SARS-CoV-2 via a PCR test from any sample (ie, bronchial lavage, nasopharyngeal or nasal swab, oropharyngeal swab, throat swab, saliva, sputum, or tracheal aspirate) in any clinical setting regardless of the presence of symptoms ",infection,infection,,0,0,0,0,3,18,75,,0,,,,0.85,0.83,0.86,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"testing positive for SARS-CoV-2 via a PCR test from any sample (ie, bronchial lavage, nasopharyngeal or nasal swab, oropharyngeal swab, throat swab, saliva, sputum, or tracheal aspirate) in any clinical setting regardless of the presence of symptoms ",infection,infection,,0,0,0,0,3,18,75,,0,,,,0.8,0.79,0.82,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"testing positive for SARS-CoV-2 via a PCR test from any sample (ie, bronchial lavage, nasopharyngeal or nasal swab, oropharyngeal swab, throat swab, saliva, sputum, or tracheal aspirate) in any clinical setting regardless of the presence of symptoms ",infection,infection,,0,0,0,0,3,18,75,,0,,,,0.75,0.73,0.755,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"testing positive for SARS-CoV-2 via a PCR test from any sample (ie, bronchial lavage, nasopharyngeal or nasal swab, oropharyngeal swab, throat swab, saliva, sputum, or tracheal aspirate) in any clinical setting regardless of the presence of symptoms ",infection,infection,,0,0,0,0,3,18,75,,0,,,,0.69,0.685,0.695,0,0,,13,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"testing positive for SARS-CoV-2 via a PCR test from any sample (ie, bronchial lavage, nasopharyngeal or nasal swab, oropharyngeal swab, throat swab, saliva, sputum, or tracheal aspirate) in any clinical setting regardless of the presence of symptoms ",infection,infection,,0,0,0,0,3,18,75,,0,,,,0.65,0.64,0.655,0,0,,18,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"testing positive for SARS-CoV-2 via a PCR test from any sample (ie, bronchial lavage, nasopharyngeal or nasal swab, oropharyngeal swab, throat swab, saliva, sputum, or tracheal aspirate) in any clinical setting regardless of the presence of symptoms ",infection,infection,,0,0,0,0,3,18,75,,0,,,,0.59,0.585,0.61,0,0,,22,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"testing positive for SARS-CoV-2 via a PCR test from any sample (ie, bronchial lavage, nasopharyngeal or nasal swab, oropharyngeal swab, throat swab, saliva, sputum, or tracheal aspirate) in any clinical setting regardless of the presence of symptoms ",infection,infection,,0,0,0,0,3,18,75,,0,,,,0.52,0.51,0.53,0,0,,26,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"testing positive for SARS-CoV-2 via a PCR test from any sample (ie, bronchial lavage, nasopharyngeal or nasal swab, oropharyngeal swab, throat swab, saliva, sputum, or tracheal aspirate) in any clinical setting regardless of the presence of symptoms ",infection,infection,,0,0,0,0,3,18,75,,0,,,,0.49,0.51,0.765,0,0,,30,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study booster Delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"testing positive for SARS-CoV-2 via a PCR test from any sample (ie, bronchial lavage, nasopharyngeal or nasal swab, oropharyngeal swab, throat swab, saliva, sputum, or tracheal aspirate) in any clinical setting regardless of the presence of symptoms ",infection,infection,,0,0,0,0,3,18,75,,0,,,,0.88,0.86,0.9,1,0,,2,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end= 75+, analysis ends at 2+ weeks interval ncluded as 3-8 for sake of the analysis",han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospital admission with a positive SARS-CoV-2 PCR test that was conducted between 14 days before and 3 days after the date of hospital admission,hosp,severe,,1,0,0,0,3,18,75,,0,,,,0.9,0.86,0.915,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospital admission with a positive SARS-CoV-2 PCR test that was conducted between 14 days before and 3 days after the date of hospital admission,hosp,severe,,1,0,0,0,3,18,75,,0,,,,0.91,0.89,0.93,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospital admission with a positive SARS-CoV-2 PCR test that was conducted between 14 days before and 3 days after the date of hospital admission,hosp,severe,,1,0,0,0,3,18,75,,0,,,,0.93,0.92,0.94,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospital admission with a positive SARS-CoV-2 PCR test that was conducted between 14 days before and 3 days after the date of hospital admission,hosp,severe,,1,0,0,0,3,18,75,,0,,,,0.93,0.92,0.94,0,0,,13,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospital admission with a positive SARS-CoV-2 PCR test that was conducted between 14 days before and 3 days after the date of hospital admission,hosp,severe,,1,0,0,0,3,18,75,,0,,,,0.93,0.92,0.935,0,0,,18,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospital admission with a positive SARS-CoV-2 PCR test that was conducted between 14 days before and 3 days after the date of hospital admission,hosp,severe,,1,0,0,0,3,18,75,,0,,,,0.91,0.895,0.92,0,0,,22,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospital admission with a positive SARS-CoV-2 PCR test that was conducted between 14 days before and 3 days after the date of hospital admission,hosp,severe,,1,0,0,0,3,18,75,,0,,,,0.9,0.89,0.91,0,0,,26,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study Delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospital admission with a positive SARS-CoV-2 PCR test that was conducted between 14 days before and 3 days after the date of hospital admission,hosp,severe,,1,0,0,0,3,18,75,,0,,,,0.88,0.86,0.9,0,0,,30,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= 75+,han20
,0,509,Tartof S,Lancet- Kaiser study,0,https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00015-1/fulltext,102,102,United States,US  Kaiser study booster Delta hosp,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospital admission with a positive SARS-CoV-2 PCR test that was conducted between 14 days before and 3 days after the date of hospital admission,hosp,severe,,1,0,0,0,3,18,75,,0,,,,0.97,0.95,0.975,1,0,,2,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end= 75+, analysis ends at 2+ weeks interval ncluded as 3-8 for sake of the analysis",han20
,1,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (alpha),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.771,0.675,0.838,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,1,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (alpha),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.886,0.792,0.937,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,1,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (alpha),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.807,0.632,0.899,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,1,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (alpha),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.607,0.211,0.804,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,1,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (alpha),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.333,0,0.7,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,1,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (alpha),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.8,0,0.977,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,1,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (beta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.351,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.743,0.679,0.795,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,1,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (beta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.351,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.639,0.526,0.725,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,han20,han20
,1,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (beta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.351,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.56,0.373,0.691,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,1,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (beta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.351,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.375,0,0.842,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,1,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (beta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.351,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.545,0,0.842,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,1,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (beta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.351,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.4,0,0.857,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (delta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.876,0.797,0.923,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (delta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.73,0.636,0.804,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (delta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.624,0.502,0.716,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (delta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.351,0.147,0.506,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (delta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.204,-0.19,0.378,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar (delta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms",infection,infetcion,,0,0,0,0,3,20,70,,0,,,,0.179,-0.129,0.403,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70. Data taken from supplementary material (s5)",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,severe,"PCR-positive swab, with severe, critical, or fatal case of Covid-19. Classification of Covid-19 case severity (acute-care hospitalizations), criticality (intensive care unit hospitalizations), and fatality was conducted in accordance with World Health Organization guidelines, and assessments were made by trained medical personnel with the use of individual chart reviews.",hosp,Severe,,1,0,0,0,3,20,70,,0,,,,0.96,0.939,0.974,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,severe,"PCR-positive swab, with severe, critical, or fatal case of Covid-19. Classification of Covid-19 case severity (acute-care hospitalizations), criticality (intensive care unit hospitalizations), and fatality was conducted in accordance with World Health Organization guidelines, and assessments were made by trained medical personnel with the use of individual chart reviews.",hosp,Severe,,1,0,0,0,3,20,70,,0,,,,0.968,0.939,0.983,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,severe,"PCR-positive swab, with severe, critical, or fatal case of Covid-19. Classification of Covid-19 case severity (acute-care hospitalizations), criticality (intensive care unit hospitalizations), and fatality was conducted in accordance with World Health Organization guidelines, and assessments were made by trained medical personnel with the use of individual chart reviews.",hosp,Severe,,1,0,0,0,3,20,70,,0,,,,0.943,0.891,0.97,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,severe,"PCR-positive swab, with severe, critical, or fatal case of Covid-19. Classification of Covid-19 case severity (acute-care hospitalizations), criticality (intensive care unit hospitalizations), and fatality was conducted in accordance with World Health Organization guidelines, and assessments were made by trained medical personnel with the use of individual chart reviews.",hosp,Severe,,1,0,0,0,3,20,70,,0,,,,0.837,0.655,0.923,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,severe,"PCR-positive swab, with severe, critical, or fatal case of Covid-19. Classification of Covid-19 case severity (acute-care hospitalizations), criticality (intensive care unit hospitalizations), and fatality was conducted in accordance with World Health Organization guidelines, and assessments were made by trained medical personnel with the use of individual chart reviews.",hosp,Severe,,1,0,0,0,3,20,70,,0,,,,0.837,0.655,0.923,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated, confidence interval could not be estimated because there were zero events among vaccinated participants. Carol note: same VE of the preceding result, because VE was 100%, which did not works well in MR-BRT splines time since vaccination analysis",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"PCR-positive swab, with severe, critical, or fatal case of Covid-19. Classification of Covid-19 case severity (acute-care hospitalizations), criticality (intensive care unit hospitalizations), and fatality was conducted in accordance with World Health Organization guidelines, and assessments were made by trained medical personnel with the use of individual chart reviews.",hosp,Severe,,1,0,0,0,3,20,70,,0,,,,0.889,0.521,0.974,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"PCR-positive swab, with severe, critical, or fatal case of Covid-19. Classification of Covid-19 case severity (acute-care hospitalizations), criticality (intensive care unit hospitalizations), and fatality was conducted in accordance with World Health Organization guidelines, and assessments were made by trained medical personnel with the use of individual chart reviews.",hosp,Severe,,1,0,0,0,3,20,70,,0,,,,0.556,-0.443,0.863,0,0,,25,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,"Mild, Moderate + severe","PCR-positive swab, in addition to, respiratory and/or constitutional symptoms.",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.815,0.799,0.83,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,"Mild, Moderate + severe","PCR-positive swab, in addition to, respiratory and/or constitutional symptoms. ",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.725,0.696,0.751,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,"Mild, Moderate + severe","PCR-positive swab, in addition to, respiratory and/or constitutional symptoms. ",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.706,0.664,0.743,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,"Mild, Moderate + severe","PCR-positive swab, in addition to, respiratory and/or constitutional symptoms. ",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.57,0.486,0.64,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,"Mild, Moderate + severe","PCR-positive swab, in addition to, respiratory and/or constitutional symptoms. ",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.12,0,0.271,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated, confidence interval could not be estimated because there were zero events among vaccinated participants ",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR-positive swab, in addition to, respiratory and/or constitutional symptoms. ",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.128,-0.091,0.303,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated",han20
,0,510,Chemaitelly H,"NEJM- Qatar Pfizer study- January 1, 2021 to September 5, 2021",0,https://www.nejm.org/doi/full/10.1056/NEJMoa2114114,151,151,Qatar,Qatar mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR-positive swab, in addition to, respiratory and/or constitutional symptoms. ",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.278,-0.014,0.487,0,0,,25,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start= <20, Age end= >70, From January 2021 till June 2021 the dominating variants were alpha and beta, while for the rest of the study the delta variant dominated",han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.914,0.91,0.918,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.878,0.873,0.988,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.826,0.821,0.831,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.752,0.744,0.76,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.646,0.633,0.659,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.496,0.471,0.519,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.927,0.923,0.931,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.9,0.896,0.904,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.862,0.857,0.867,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.811,0.804,0.817,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.74,0.729,0.75,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.642,0.623,0.661,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.883,0.867,0.897,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.822,0.803,0.839,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.728,0.707,0.748,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.585,0.557,0.61,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.366,0.318,0.41,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,511,Cohn B,medrix- US veterans February - August 2021,0,https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf,102,102,United States,US  veterans delta,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or one dose of Janssen vaccines",infection,infection,,0,0,0,0,3,18,65,,0,,,619755,0.11,-0.0662,0.12,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >65,han20
,0,512,Robles-Fontan M,"medrix- Puerto Rico VE Pfizer, Moderna, J&J",0,https://www.medrxiv.org/content/10.1101/2021.10.17.21265101v2.full.pdf,385,385,Puerto Rico,Puerto Rico(delta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,85,,0,,,,0.813,0.795,0.83,0,0,,0,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >85,han20
,0,512,Robles-Fontan M,"medrix- Puerto Rico VE Pfizer, Moderna, J&J",0,https://www.medrxiv.org/content/10.1101/2021.10.17.21265101v2.full.pdf,385,385,Puerto Rico,Puerto Rico(delta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,85,,0,,,,0.63,0.61,0.65,0,0,,8,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >85,han20
,0,512,Robles-Fontan M,"medrix- Puerto Rico VE Pfizer, Moderna, J&J",0,https://www.medrxiv.org/content/10.1101/2021.10.17.21265101v2.full.pdf,385,385,Puerto Rico,Puerto Rico(delta),0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,85,,0,,,,0.56,0.53,0.59,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >85,han20
,0,512,Robles-Fontan M,"medrix- Puerto Rico VE Pfizer, Moderna, J&J",0,https://www.medrxiv.org/content/10.1101/2021.10.17.21265101v2.full.pdf,385,385,Puerto Rico,Puerto Rico(delta),0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,85,,0,,,,0.847,0.83,0.86,0,0,,0,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >85,han20
,0,512,Robles-Fontan M,"medrix- Puerto Rico VE Pfizer, Moderna, J&J",0,https://www.medrxiv.org/content/10.1101/2021.10.17.21265101v2.full.pdf,385,385,Puerto Rico,Puerto Rico(delta),0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,85,,0,,,,0.75,0.735,0.765,0,0,,8,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >85,han20
,0,512,Robles-Fontan M,"medrix- Puerto Rico VE Pfizer, Moderna, J&J",0,https://www.medrxiv.org/content/10.1101/2021.10.17.21265101v2.full.pdf,385,385,Puerto Rico,Puerto Rico(delta),0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,85,,0,,,,0.71,0.68,0.74,0,0,,15,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >85,han20
,0,512,Robles-Fontan M,"medrix- Puerto Rico VE Pfizer, Moderna, J&J",0,https://www.medrxiv.org/content/10.1101/2021.10.17.21265101v2.full.pdf,385,385,Puerto Rico,Puerto Rico(delta),0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,85,,0,,,,0.522,0.48,0.563,0,0,,0,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >85,han20
,0,512,Robles-Fontan M,"medrix- Puerto Rico VE Pfizer, Moderna, J&J",0,https://www.medrxiv.org/content/10.1101/2021.10.17.21265101v2.full.pdf,385,385,Puerto Rico,Puerto Rico(delta),0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,85,,0,,,,0.38,0.33,0.45,0,0,,8,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >85,han20
,0,512,Robles-Fontan M,"medrix- Puerto Rico VE Pfizer, Moderna, J&J",0,https://www.medrxiv.org/content/10.1101/2021.10.17.21265101v2.full.pdf,385,385,Puerto Rico,Puerto Rico(delta),0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,85,,0,,,,0.27,0.17,0.37,0,0,,15,22,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end= >85,han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.95,0.944,0.952,0,0,,4,8,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.895,0.89,0.9,0,0,,9,12,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.86,0.853,0.865,0,0,,13,16,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.825,0.823,0.83,0,0,,17,20,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.78,0.77,0.79,0,0,,21,24,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.7,0.72,0.785,0,0,,25,28,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.72,0.7,0.735,0,0,,29,32,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.351,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.955,0.95,0.96,0,0,,4,8,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.351,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.925,0.92,0.93,0,0,,9,12,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.351,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.92,0.915,0.925,0,0,,13,16,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.351,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.88,0.875,0.885,0,0,,17,20,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.85,0.845,0.855,0,0,,21,24,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.817,0.81,0.825,0,0,,25,28,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.83,0.82,0.84,0,0,,29,32,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.78,0.76,0.805,0,0,,0,4,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.74,0.72,0.765,0,0,,4,8,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.74,0.72,0.765,0,0,,9,12,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.655,0.64,0.67,0,0,,13,16,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.648,0.63,0.66,0,0,,17,20,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"PCR positive, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",infection,infection,,0,0,0,0,3,18,65,,0,,,,0.69,0.66,0.715,0,0,,21,24,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.96,0.948,0.975,0,0,,4,8,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.948,0.925,0.955,0,0,,9,12,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.955,0.94,0.965,0,0,,13,16,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.925,0.9,0.94,0,0,,17,20,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.91,0.88,0.925,0,0,,21,24,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.87,0.848,0.9,0,0,,25,28,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.9,0.83,0.94,0,0,,29,32,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.351,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.975,0.965,0.976,0,0,,4,8,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.351,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.955,0.935,0.96,0,0,,9,12,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.351,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.96,0.948,0.975,0,0,,13,16,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.351,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.95,0.94,0.96,0,0,,17,20,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.94,0.27,0.95,0,0,,21,24,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.925,0.9,0.945,0,0,,25,28,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.945,0.88,0.97,0,0,,29,32,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.65,0.48,0.76,0,0,,0,4,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.9,0.79,0.95,0,0,,4,8,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.9,0.792,0.95,0,0,,9,12,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.818,0.69,0.89,0,0,,13,16,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.9,0.822,0.95,0,0,,17,20,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna and one dose of Janssen",hosp,Severe,,1,0,0,0,3,18,65,,0,,,,0.61,0.09,0.844,0,0,,21,24,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.953,0.925,0.975,0,0,,4,8,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.95,0.925,0.97,0,0,,9,12,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.938,0.87,0.96,0,0,,13,16,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.351,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.95,0.91,0.98,0,0,,17,20,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.935,0.897,0.957,0,0,,21,24,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.88,0.84,0.87,0,0,,25,28,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.85,0.7,0.92,0,0,,29,32,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.351,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.77,0.7,0.84,0,0,,4,8,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.351,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.955,0.925,0.975,0,0,,9,12,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.351,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.955,0.92,0.975,0,0,,13,16,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.351,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.975,0.95,0.98,0,0,,17,20,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.91,0.86,0.94,0,0,,21,24,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.94,0.9,0.954,0,0,,25,28,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.9,0.79,0.95,0,0,,29,32,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.845,0.52,0.95,0,0,,4,8,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.896,0.53,0.97,0,0,,9,12,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.84,0.5,0.95,0,0,,13,16,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.7 and B.1.351,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.8,0.56,0.91,0,0,,17,20,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,513,Dan-Yu L,medrix- North Carolina VE 9 months span,0,https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1.full.pdf,102,102,United States,US NC mixed deaths,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Death due to Covid-19 infection,death,Severe,,1,0,0,0,3,18,65,,0,,,,0.62,0.03,0.85,0,0,,21,24,weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >65, graphs represent data with time since vaccination after the 1st dose. The 1st months was cut and data was collected starting from the second months to account for this, hence, assuming that this will be the time since the second dose (except for Janssen since it is one dose)",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.91,0.82,0.95,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.98,0.94,0.99,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.99,0.98,0.99,0,0,,4,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.98,0.97,0.98,0,0,,8,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.97,0.96,0.98,0,0,,12,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.98,0.88,0.99,0,0,,16,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.92,0.41,0.99,0,0,,20,23,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.98,0.91,0.99,0,0,,24,27,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.95,0.8,0.99,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.98,0.89,0.99,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.99,0.96,0.99,0,0,,4,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.98,0.95,0.99,0,0,,8,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.96,0.92,0.98,0,0,,12,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.84,0.63,0.93,0,0,,16,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,1,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,,,,0,0,,20,23,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,1,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,,,,0,0,,24,27,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.71,0.69,0.74,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.94,0.93,0.95,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.92,0.92,0.93,0,0,,4,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.9,0.9,0.91,0,0,,8,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.89,0.88,0.9,0,0,,12,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.86,0.81,0.89,0,0,,16,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.77,0.67,0.84,0,0,,20,23,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.83,0.79,0.86,0,0,,24,27,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.8,0.76,0.84,0,0,,28,31,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.8,0.76,0.83,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.96,0.94,0.97,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.94,0.93,0.95,0,0,,4,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.91,0.9,0.93,0,0,,8,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.88,0.86,0.9,0,0,,12,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.83,0.76,0.88,0,0,,16,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.89,0.76,0.95,0,0,,20,23,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.8,0.73,0.85,0,0,,24,27,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.7,0.66,0.74,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.92,0.9,0.93,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.9,0.89,0.91,0,0,,4,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.88,0.87,0.89,0,0,,8,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.85,0.84,0.86,0,0,,12,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.89,0.87,0.9,0,0,,16,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.92,0.89,0.94,0,0,,20,23,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.76,0.57,0.87,0,0,,24,27,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.76,0.48,0.88,0,0,,28,31,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 28+ weeks, interval is included as 28-31 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.81,0.76,0.86,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.94,0.91,0.96,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.92,0.91,0.93,0,0,,4,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.91,0.89,0.92,0,0,,8,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.88,0.86,0.9,0,0,,12,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.87,0.81,0.91,0,0,,16,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.91,0.81,0.95,0,0,,20,23,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.85,0.61,0.95,0,0,,24,27,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 24+ weeks, interval is included as 24-27 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.76,0.1,0.94,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.77,0.38,0.92,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.68,0.6,0.75,0,0,,4,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.72,0.67,0.76,0,0,,8,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.65,0.57,0.72,0,0,,12,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,1,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,,,,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.74,-0.07,0.94,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.78,0.58,0.89,0,0,,4,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.76,0.67,0.83,0,0,,8,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(Quebec/Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",infection,infection,,0,0,0,0,3,18,80,,0,,,,0.72,0.66,0.77,0,0,,12,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,1,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,,,,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,1,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,,,,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.84,0.51,0.95,0,0,,4,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.93,0.84,0.97,0,0,,8,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,0,1001,Skowronski D,"medrix- Canada (Quebec, BC) VE Pfizer, Moderna, AstraZeneca",0,https://www.medrxiv.org/content/10.1101/2021.10.26.21265397v1.full.pdf,101,101,Canada,Canada(British Columbia/Delta) hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization within 21 days of positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech or Moderna or AstraZeneca",hosp,Severe,,1,0,0,0,3,18,80,,0,,,,0.92,0.81,0.97,0,0,,12,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 12+ weeks, interval is included as 12-15 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec2,93,93,Sweden,Sweden Delta and Alpha,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.92,0.92,0.93,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 31+ weeks, interval is included as 31-34 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec3,93,93,Sweden,Sweden Delta and Alpha,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.89,0.88,0.9,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 31+ weeks, interval is included as 31-34 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec4,93,93,Sweden,Sweden Delta and Alpha,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.85,0.84,0.85,0,0,,9,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 31+ weeks, interval is included as 31-34 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec5,93,93,Sweden,Sweden Delta and Alpha,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.47,0.39,0.55,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 31+ weeks, interval is included as 31-34 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec6,93,93,Sweden,Sweden Delta and Alpha,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.29,0.15,0.42,0,0,,26,30,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 31+ weeks, interval is included as 31-34 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec7,93,93,Sweden,Sweden Delta and Alpha,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.23,-0.02,0.41,0,0,,31,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 31+ weeks, interval is included as 31-34 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec8,93,93,Sweden,Sweden Delta and Alpha,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.96,0.94,0.97,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 26+ weeks, interval is included as 26-30 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec9,93,93,Sweden,Sweden Delta and Alpha,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.93,0.9,0.94,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 26+ weeks, interval is included as 26-30 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec10,93,93,Sweden,Sweden Delta and Alpha,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.85,0.82,0.88,0,0,,9,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 26+ weeks, interval is included as 26-30 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec11,93,93,Sweden,Sweden Delta and Alpha,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.71,0.56,0.81,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 26+ weeks, interval is included as 26-30 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec12,93,93,Sweden,Sweden Delta and Alpha,0,,Moderna,mRNA-1273,mRNA,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.59,0.18,0.79,0,0,,26,30,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 26+ weeks, interval is included as 26-30 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec13,93,93,Sweden,Sweden Delta and Alpha,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.68,0.52,0.79,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 18+ weeks, interval is included as 18-21 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec14,93,93,Sweden,Sweden Delta and Alpha,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.49,0.28,0.64,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 18+ weeks, interval is included as 18-21 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec15,93,93,Sweden,Sweden Delta and Alpha,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,0.41,0.29,0.51,0,0,,9,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 18+ weeks, interval is included as 18-21 weeks for sake of analysis",han20
,0,1002,Nordstrom P,Lancet- VE Sweden 12 Januaru- 4 October 2021,0,https://www.sciencedirect.com/science/article/pii/S0140673622000897#sec16,93,93,Sweden,Sweden Delta and Alpha,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.7 and B.1.617.2,,"Mild, Moderate + severe","The term “symptomatic” was defined on the basis that in Sweden, health authorities have urged citizens to take a test if they experience any symptoms of Covid-19, end point is a positive pcr 14 days after the second dose of any of the listed vacines",symptomatic,Symptomatic infection,,0,1,1,0,3,18,80,,0,,,,-0.19,-0.97,0.28,0,0,,18,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 18+ weeks, interval is included as 18-21 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.87,0.855,0.9,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.78,0.77,0.8,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.77,0.76,0.78,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.63,0.61,0.65,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta),1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.628,0.605,0.65,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.78,0.62,0.82,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.635,0.58,0.72,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.49,0.43,0.53,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.45,0.43,0.46,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta),1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.42,0.4,0.44,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",hosp,severe,,1,0,0,0,3,16,80,,0,,,,0.99,0.98,0.99,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",hosp,severe,,1,0,0,0,3,16,80,,0,,,,0.985,0.98,0.99,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",hosp,severe,,1,0,0,0,3,16,80,,0,,,,0.975,0.97,0.99,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",hosp,severe,,1,0,0,0,3,16,80,,0,,,,0.97,0.96,0.98,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",hosp,severe,,1,0,0,0,3,16,80,,0,,,,0.965,0.95,0.97,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",hosp,severe,,1,0,0,0,3,16,80,,0,,,,0.93,0.9,0.95,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",hosp,severe,,1,0,0,0,3,16,80,,0,,,,0.94,0.93,0.96,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",hosp,severe,,1,0,0,0,3,16,80,,0,,,,0.9,0.89,0.91,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",hosp,severe,,1,0,0,0,3,16,80,,0,,,,0.86,0.84,0.88,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",hosp,severe,,1,0,0,0,3,16,80,,0,,,,0.78,0.71,0.82,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) deaths,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,death due to covid-19,death,severe,,1,0,0,0,3,16,80,,0,,,,0.99,0.975,0.99,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) deaths,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,death due to covid-19,death,severe,,1,0,0,0,3,16,80,,0,,,,0.96,0.95,0.98,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) deaths,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,death due to covid-19,death,severe,,1,0,0,0,3,16,80,,0,,,,0.95,0.92,0.96,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) deaths,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,death due to covid-19,death,severe,,1,0,0,0,3,16,80,,0,,,,0.91,0.86,0.96,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) deaths,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,death due to covid-19,death,severe,,1,0,0,0,3,16,80,,0,,,,0.94,0.93,0.95,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) deaths,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,death due to covid-19,death,severe,,1,0,0,0,3,16,80,,0,,,,0.93,0.9,0.94,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) deaths,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,death due to covid-19,death,severe,,1,0,0,0,3,16,80,,0,,,,0.89,0.84,0.91,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta) deaths,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,death due to covid-19,death,severe,,1,0,0,0,3,16,80,,0,,,,0.79,0.53,0.89,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, time in the study is 20+ weeks, interval is included as 20-24 weeks for sake of analysis",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.98,0.97,0.99,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, ",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.98,0.97,0.99,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, ",han20
,1,516,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032671/Vaccine_surveillance_report_-_week_44.pdf,95,95,United Kingdom,UK(Delta),1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.93,0.69,0.99,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >80, ",han20
,1,517,Bianchi F,VE Italy Pfizer 5 months study HCWs,0,https://www.mdpi.com/2076-393X/9/10/1143,86,86,Italy,Italy (no specific variant),0,,Pfizer & BioNTech,BNT162b2,mRNA,,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech ",infection,infection,,0,0,0,0,3,25,64,,0,,,,0.948,0.87,0.978,0,0,,2,5,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >64, study ends at 9 weeks+, interval 9-12 included for sake of the analysis ",han20
,1,517,Bianchi F,VE Italy Pfizer 5 months study HCWs,0,https://www.mdpi.com/2076-393X/9/10/1143,86,86,Italy,Italy (no specific variant),0,,Pfizer & BioNTech,BNT162b2,mRNA,,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech ",infection,infection,,0,0,0,0,3,25,64,,0,,,,0.83,0.65,0.92,0,0,,6,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >64, study ends at 9 weeks+, interval 9-12 included for sake of the analysis ",han20
,1,517,Bianchi F,VE Italy Pfizer 5 months study HCWs,0,https://www.mdpi.com/2076-393X/9/10/1143,86,86,Italy,Italy (no specific variant),0,,Pfizer & BioNTech,BNT162b2,mRNA,,,infection,"Positive PCR, 14 days after receipt of the second dose of Pfizer-BioNTech ",infection,infection,,0,0,0,0,3,25,64,,0,,,,0.81,0.42,0.94,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >64, study ends at 9 weeks+, interval 9-12 included for sake of the analysis ",han20
,1,517,Bianchi F,VE Italy Pfizer 5 months study HCWs,0,https://www.mdpi.com/2076-393X/9/10/1143,86,86,Italy,Italy (no specific variant),0,,Pfizer & BioNTech,BNT162b2,mRNA,,,"Mild, Moderate + severe",symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,25,64,,0,,,,0.972,0.903,0.992,0,0,,2,5,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >64, study ends at 9 weeks+, interval 9-12 included for sake of the analysis ",han20
,1,517,Bianchi F,VE Italy Pfizer 5 months study HCWs,0,https://www.mdpi.com/2076-393X/9/10/1143,86,86,Italy,Italy (no specific variant),0,,Pfizer & BioNTech,BNT162b2,mRNA,,,"Mild, Moderate + severe",symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,25,64,,0,,,,0.85,0.63,0.942,0,0,,6,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >64, study ends at 9 weeks+, interval 9-12 included for sake of the analysis ",han20
,1,517,Bianchi F,VE Italy Pfizer 5 months study HCWs,0,https://www.mdpi.com/2076-393X/9/10/1143,86,86,Italy,Italy (no specific variant),0,,Pfizer & BioNTech,BNT162b2,mRNA,,,"Mild, Moderate + severe",symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,25,64,,0,,,,0.88,0.42,0.976,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0," Age end= >64, study ends at 9 weeks+, interval 9-12 included for sake of the analysis ",han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 18-49,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,18,49,,0,,,,0.964,0.945,0.977,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 18-49,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,18,49,,0,,,,0.947,0.908,0.972,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 18-49,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,18,49,,0,,,,0.959,0.93,0.977,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 18-49,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,18,49,,0,,,,0.955,0.94,0.967,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 18-49,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,18,49,,0,,,,0.968,0.947,0.982,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 18-49,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,18,49,,0,,,,0.92,0.866,0.955,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 18-49,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,18,49,,0,,,,0.961,0.929,0.982,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 18-49,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,18,49,,0,,,,0.975,0.961,0.985,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 18-49,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,18,49,,0,,,,0.959,0.916,0.984,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 18-49,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,18,49,,0,,,,0.883,0.769,0.95,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 18-49,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,18,49,,0,,,,0.948,0.877,0.983,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 18-49,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,18,49,,0,,,,0.938,0.902,0.963,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 50-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,50,64,,0,,,,0.958,0.945,0.969,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 50-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,50,64,,0,,,,0.952,0.926,0.97,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 50-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,50,64,,0,,,,0.939,0.914,0.958,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 50-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,50,64,,0,,,,0.951,0.941,0.96,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 50-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,50,64,,0,,,,0.973,0.961,0.983,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 50-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,50,64,,0,,,,0.97,0.945,0.986,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 50-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,50,64,,0,,,,0.967,0.944,0.982,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 50-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,50,64,,0,,,,0.969,0.959,0.977,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 50-64,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,50,64,,0,,,,0.882,0.833,0.918,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 50-64,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,50,64,,0,,,,0.91,0.826,0.959,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 50-64,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,50,64,,0,,,,0.904,0.83,0.951,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp 50-64,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,50,64,,0,,,,0.928,0.901,0.95,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp =>65,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,65,100,,0,,,,0.95,0.942,0.957,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age is =>65, however it is recorded as 65-100 for sake on analysis",han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp =>65,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,65,100,,0,,,,0.938,0.923,0.951,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age is =>65, however it is recorded as 65-100 for sake on analysis",han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp =>65,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,65,100,,0,,,,0.896,0.874,0.914,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age is =>65, however it is recorded as 65-100 for sake on analysis",han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp =>65,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,65,100,,0,,,,0.892,0.881,0.902,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age is =>65, however it is recorded as 65-100 for sake on analysis",han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp =>65,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,65,100,,0,,,,0.972,0.967,0.977,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age is =>65, however it is recorded as 65-100 for sake on analysis",han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp =>65,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,65,100,,0,,,,0.964,0.953,0.974,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age is =>65, however it is recorded as 65-100 for sake on analysis",han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp =>65,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,65,100,,0,,,,0.952,0.939,0.963,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age is =>65, however it is recorded as 65-100 for sake on analysis",han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp =>65,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,65,100,,0,,,,0.941,0.933,0.948,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age is =>65, however it is recorded as 65-100 for sake on analysis",han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp =>65,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,65,100,,0,,,,0.855,0.815,0.888,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age is =>65, however it is recorded as 65-100 for sake on analysis",han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp =>65,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,65,100,,0,,,,0.809,0.727,0.871,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age is =>65, however it is recorded as 65-100 for sake on analysis",han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp =>65,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,65,100,,0,,,,0.824,0.745,0.884,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age is =>65, however it is recorded as 65-100 for sake on analysis",han20
,0,518,Rosenberg E,VE New York by Age group May-August,0,https://www.medrxiv.org/content/10.1101/2021.10.08.21264595v1.full.pdf,102,102,United States,USA NY delta hosp =>65,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"new admission with a laboratory-confirmed positive COVID-19 result, between May and August 2021",hosp,Severe,,1,0,0,0,3,65,100,,0,,,,0.828,0.79,0.861,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age is =>65, however it is recorded as 65-100 for sake on analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.99,0.98,0.99,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.99,0.97,0.99,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.97,0.95,0.98,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.94,0.85,0.98,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.93,0.82,0.97,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.94,0.85,0.98,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.99,0.98,0.99,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.99,0.98,0.99,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.97,0.97,0.98,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.98,0.97,0.98,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.98,0.95,0.99,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.94,0.9,0.96,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.91,0.86,0.94,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.91,0.89,0.93,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.91,0.89,0.92,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.9,0.88,0.91,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.89,0.87,0.91,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.87,0.85,0.9,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,1,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.99,,,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.96,0.85,0.99,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.91,0.76,0.97,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.96,0.74,0.99,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.68,-0.3,0.92,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,1,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.99,,,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.97,0.95,0.98,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.95,0.93,0.96,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.93,0.91,0.95,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.92,0.88,0.94,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.89,0.78,0.95,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.84,-0.16,0.98,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.77,0.58,0.87,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.8,0.61,0.9,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.74,0.58,0.84,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.62,0.07,0.84,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,1,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,,,,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,1,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,,,,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.99,0.95,0.99,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.99,0.95,0.99,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.99,0.91,0.99,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.94,0.57,0.99,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.86,0.01,0.98,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.79,-0.5,0.97,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.97,0.94,0.99,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.97,0.93,0.99,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.98,0.95,0.99,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.88,0.72,0.95,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.95,0.65,0.99,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.85,0.39,0.96,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,1,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.99,,,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,1,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.99,,,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.85,0.54,0.95,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.94,0.77,0.99,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.88,0.68,0.96,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 70+ hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,70,99,,0,,,,0.95,0.82,0.99,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age interval rnd =>70 included as 70-99 for sake of analysis, time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.93,0.84,0.97,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.96,0.89,0.99,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.93,0.82,0.97,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.91,0.64,0.98,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,1,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,0.99,,,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,1,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 12-49 hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,12,49,,0,,,,,,,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.87,0.79,0.92,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.96,0.92,0.98,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.95,0.89,0.97,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.98,0.91,0.99,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,1,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,0.99,,,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,1,519,RIVM COVID-19 group,Netherlands VE by Age group July-October,0,https://www.rijksoverheid.nl/documenten/publicaties/2021/11/03/effectiviteit-van-covid-19-vaccinatie-tegen-ziekenhuis-en-intensive-care-opname,89,89,Netherlands,Netherlands delta 50-69 hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Hospitalization due to covid-19 after 14 days of taking the second dose of Pfizer-BionTech, Moderna, AstraZeneca or one dose of Janssen",hosp,Severe,,1,0,0,0,3,50,69,,0,,,,,,,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"time period ends at 25 weeks+, time period included is 25-29 for sake of the analysis",han20
,0,520,Hall V,medrix- UK VE SIREN cohort study Mar2020-Sep2021,0,https://www.medrxiv.org/content/10.1101/2021.11.29.21267006v1,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"a PCR-confirmed SARS-CoV-2 infection, irrespective of symptom status, that met the definition of a reinfection in the positive cohort of two PCR positives ?90 days or one new PCR positive ?28 days after an antibody positive result consistent with previous infection.",infection,infection,,1,1,1,1,3,25,65,,0,,,,0.81,0.68,0.89,0,0,,2,10,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age <=25, >= 65, time period end in >28, interval added as 28-35 for sake of the analysis",han20
,0,520,Hall V,medrix- UK VE SIREN cohort study Mar2020-Sep2021,0,https://www.medrxiv.org/content/10.1101/2021.11.29.21267006v1,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"a PCR-confirmed SARS-CoV-2 infection, irrespective of symptom status, that met the definition of a reinfection in the positive cohort of two PCR positives ?90 days or one new PCR positive ?28 days after an antibody positive result consistent with previous infection.",infection,infection,,1,1,1,1,3,25,65,,0,,,,0.65,0.56,0.73,0,0,,11,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age <=25, >= 65, time period end in >28, interval added as 28-35 for sake of the analysis",han20
,0,520,Hall V,medrix- UK VE SIREN cohort study Mar2020-Sep2021,0,https://www.medrxiv.org/content/10.1101/2021.11.29.21267006v1,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"a PCR-confirmed SARS-CoV-2 infection, irrespective of symptom status, that met the definition of a reinfection in the positive cohort of two PCR positives ?90 days or one new PCR positive ?28 days after an antibody positive result consistent with previous infection.",infection,infection,,1,1,1,1,3,25,65,,0,,,,0.67,0.58,0.75,0,0,,20,27,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age <=25, >= 65, time period end in >28, interval added as 28-35 for sake of the analysis",han20
,0,520,Hall V,medrix- UK VE SIREN cohort study Mar2020-Sep2021,0,https://www.medrxiv.org/content/10.1101/2021.11.29.21267006v1,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"a PCR-confirmed SARS-CoV-2 infection, irrespective of symptom status, that met the definition of a reinfection in the positive cohort of two PCR positives ?90 days or one new PCR positive ?28 days after an antibody positive result consistent with previous infection.",infection,infection,,1,1,1,1,3,25,65,,0,,,,0.43,0.17,0.61,0,0,,28,35,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age <=25, >= 65, time period end in >28, interval added as 28-35 for sake of the analysis",han20
,0,520,Hall V,medrix- UK VE SIREN cohort study Mar2020-Sep2021,0,https://www.medrxiv.org/content/10.1101/2021.11.29.21267006v1,95,95,United Kingdom,UK delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"a PCR-confirmed SARS-CoV-2 infection, irrespective of symptom status, that met the definition of a reinfection in the positive cohort of two PCR positives ?90 days or one new PCR positive ?28 days after an antibody positive result consistent with previous infection.",infection,infection,,1,1,1,1,3,25,65,,0,,,,0.85,0.71,0.92,0,0,,2,10,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age <=25, >= 65, time period end in >28, interval added as 28-35 for sake of the analysis",han20
,0,520,Hall V,medrix- UK VE SIREN cohort study Mar2020-Sep2021,0,https://www.medrxiv.org/content/10.1101/2021.11.29.21267006v1,95,95,United Kingdom,UK delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"a PCR-confirmed SARS-CoV-2 infection, irrespective of symptom status, that met the definition of a reinfection in the positive cohort of two PCR positives ?90 days or one new PCR positive ?28 days after an antibody positive result consistent with previous infection.",infection,infection,,1,1,1,1,3,25,65,,0,,,,0.72,0.42,0.86,0,0,,11,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age <=25, >= 65, time period end in >28, interval added as 28-35 for sake of the analysis",han20
,0,520,Hall V,medrix- UK VE SIREN cohort study Mar2020-Sep2021,0,https://www.medrxiv.org/content/10.1101/2021.11.29.21267006v1,95,95,United Kingdom,UK delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"a PCR-confirmed SARS-CoV-2 infection, irrespective of symptom status, that met the definition of a reinfection in the positive cohort of two PCR positives ?90 days or one new PCR positive ?28 days after an antibody positive result consistent with previous infection.",infection,infection,,1,1,1,1,3,25,65,,0,,,,0.55,0.37,0.67,0,0,,20,27,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age <=25, >= 65, time period end in >28, interval added as 28-35 for sake of the analysis",han20
,0,520,Hall V,medrix- UK VE SIREN cohort study Mar2020-Sep2021,0,https://www.medrxiv.org/content/10.1101/2021.11.29.21267006v1,95,95,United Kingdom,UK delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"a PCR-confirmed SARS-CoV-2 infection, irrespective of symptom status, that met the definition of a reinfection in the positive cohort of two PCR positives ?90 days or one new PCR positive ?28 days after an antibody positive result consistent with previous infection.",infection,infection,,1,1,1,1,3,25,65,,0,,,,0.58,0.4,0.71,0,0,,28,35,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age <=25, >= 65, time period end in >28, interval added as 28-35 for sake of the analysis",han20
,0,520,Hall V,medrix- UK VE SIREN cohort study Mar2020-Sep2021,0,https://www.medrxiv.org/content/10.1101/2021.11.29.21267006v1,95,95,United Kingdom,UK delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"a PCR-confirmed SARS-CoV-2 infection, irrespective of symptom status, that met the definition of a reinfection in the positive cohort of two PCR positives ?90 days or one new PCR positive ?28 days after an antibody positive result consistent with previous infection.",infection,infection,,1,1,1,1,3,25,65,,0,,,,0.49,0.16,0.69,0,0,,2,10,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age <=25, >= 65, time period end in >20, interval added as 20-27 for sake of the analysis",han20
,0,520,Hall V,medrix- UK VE SIREN cohort study Mar2020-Sep2021,0,https://www.medrxiv.org/content/10.1101/2021.11.29.21267006v1,95,95,United Kingdom,UK delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"a PCR-confirmed SARS-CoV-2 infection, irrespective of symptom status, that met the definition of a reinfection in the positive cohort of two PCR positives ?90 days or one new PCR positive ?28 days after an antibody positive result consistent with previous infection.",infection,infection,,1,1,1,1,3,25,65,,0,,,,0.47,0.26,0.63,0,0,,11,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age <=25, >= 65, time period end in >20, interval added as 20-27 for sake of the analysis",han20
,0,520,Hall V,medrix- UK VE SIREN cohort study Mar2020-Sep2021,0,https://www.medrxiv.org/content/10.1101/2021.11.29.21267006v1,95,95,United Kingdom,UK delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"a PCR-confirmed SARS-CoV-2 infection, irrespective of symptom status, that met the definition of a reinfection in the positive cohort of two PCR positives ?90 days or one new PCR positive ?28 days after an antibody positive result consistent with previous infection.",infection,infection,,1,1,1,1,3,25,65,,0,,,,0.51,0.18,0.71,0,0,,20,27,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age <=25, >= 65, time period end in >20, interval added as 20-27 for sake of the analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119432,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection,infetcion,infection,,0,0,0,1,3,20,70,,0,,,,0.758,0.746,0.77,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119433,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection,infetcion,infection,,0,0,0,1,3,20,70,,0,,,,0.697,0.674,0.718,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119434,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection,infetcion,infection,,0,0,0,1,3,20,70,,0,,,,0.637,0.599,0.671,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119435,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection,infetcion,infection,,0,0,0,1,3,20,70,,0,,,,0.391,0.299,0.47,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119436,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection,infetcion,infection,,0,0,0,1,3,20,70,,0,,,,0.114,-0.035,0.241,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119437,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection,infetcion,infection,,0,0,0,1,3,20,70,,0,,,,0.092,-0.091,0.245,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119438,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection,infetcion,infection,,0,0,0,1,3,20,70,,0,,,,-0.044,-0.413,0.229,0,0,,25,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119439,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",defined as a PCRpositive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.815,0.799,0.83,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119440,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",defined as a PCRpositive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.725,0.696,0.751,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119441,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",defined as a PCRpositive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.706,0.664,0.743,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119442,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",defined as a PCRpositive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.57,0.486,0.64,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119443,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",defined as a PCRpositive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.12,-0.061,0.271,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119444,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",defined as a PCRpositive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.128,-0.091,0.303,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119445,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",defined as a PCRpositive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,0.278,-0.014,0.487,0,0,,25,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119446,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"defined as a PCR-positive swab + severe, 21 critical, 21 or fatal22 COVID-19. Classification of COVID-19 case severity (acute-care hospitalizations), 21 criticality (ICU hospitalizations), 21 and fatality22 followed World Health Organization (WHO) guidelines, and assessments were made by trained medical personnel using individual chart reviews",hosp&death,severe,,1,0,0,0,3,20,70,,0,,,,0.959,0.936,0.973,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119447,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"defined as a PCR-positive swab + severe, 21 critical, 21 or fatal22 COVID-19. Classification of COVID-19 case severity (acute-care hospitalizations), 21 criticality (ICU hospitalizations), 21 and fatality22 followed World Health Organization (WHO) guidelines, and assessments were made by trained medical personnel using individual chart reviews",hosp&death,severe,,1,0,0,0,3,20,70,,0,,,,0.963,0.929,0.98,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119448,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"defined as a PCR-positive swab + severe, 21 critical, 21 or fatal22 COVID-19. Classification of COVID-19 case severity (acute-care hospitalizations), 21 criticality (ICU hospitalizations), 21 and fatality22 followed World Health Organization (WHO) guidelines, and assessments were made by trained medical personnel using individual chart reviews",hosp&death,severe,,1,0,0,0,3,20,70,,0,,,,0.934,0.875,0.965,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119449,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"defined as a PCR-positive swab + severe, 21 critical, 21 or fatal22 COVID-19. Classification of COVID-19 case severity (acute-care hospitalizations), 21 criticality (ICU hospitalizations), 21 and fatality22 followed World Health Organization (WHO) guidelines, and assessments were made by trained medical personnel using individual chart reviews",hosp&death,severe,,1,0,0,0,3,20,70,,0,,,,0.808,0.569,0.914,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,1,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119450,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"defined as a PCR-positive swab + severe, 21 critical, 21 or fatal22 COVID-19. Classification of COVID-19 case severity (acute-care hospitalizations), 21 criticality (ICU hospitalizations), 21 and fatality22 followed World Health Organization (WHO) guidelines, and assessments were made by trained medical personnel using individual chart reviews",hosp&death,severe,,1,0,0,0,3,20,70,,0,,,,0.99,,,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119451,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"defined as a PCR-positive swab + severe, 21 critical, 21 or fatal22 COVID-19. Classification of COVID-19 case severity (acute-care hospitalizations), 21 criticality (ICU hospitalizations), 21 and fatality22 followed World Health Organization (WHO) guidelines, and assessments were made by trained medical personnel using individual chart reviews",hosp&death,severe,,1,0,0,0,3,20,70,,0,,,,0.818,0.185,0.959,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,521,Chemaitelly H,NEJM- Qatar Moderna VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2119452,151,151,Qatar,Qatar delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"defined as a PCR-positive swab + severe, 21 critical, 21 or fatal22 COVID-19. Classification of COVID-19 case severity (acute-care hospitalizations), 21 criticality (ICU hospitalizations), 21 and fatality22 followed World Health Organization (WHO) guidelines, and assessments were made by trained medical personnel using individual chart reviews",hosp&death,severe,,1,0,0,0,3,20,70,,0,,,,0.441,-0.865,0.833,0,0,,25,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start =< 20 and Age end >=70, period end is  >28, period included is 29-32 for sake of analysis",han20
,0,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 Omicron 12-15,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,15,,0,,,,0.831,0.782,0.869,0,0,,1,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,End of interval was 14+ days included as 3-5 weeks for sake of the analysis,han20
,0,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 Omicron 12-15,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,15,,0,,,,0.73,0.664,0.783,0,0,,2,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,End of interval was 14+ days included as 3-5 weeks for sake of the analysis,han20
,0,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 delta 12-15,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,15,,0,,,,0.932,0.815,0.975,0,0,,1,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,End of interval was 14+ days included as 3-5 weeks for sake of the analysis,han20
,0,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 delta 12-15,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,15,,0,,,,0.872,0.737,0.938,0,0,,2,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,End of interval was 14+ days included as 3-5 weeks for sake of the analysis,han20
,0,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 delta 16-17,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,17,,0,,,,0.931,0.916,0.944,0,0,,1,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,End of interval was 70+ days included as 10-13 weeks for sake of the analysis,han20
,0,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 delta 16-17,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,17,,0,,,,0.961,0.952,0.968,0,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,End of interval was 70+ days included as 10-13 weeks for sake of the analysis,han20
,0,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 delta 16-17,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,17,,0,,,,0.915,0.899,0.93,0,0,,5,10,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,End of interval was 70+ days included as 10-13 weeks for sake of the analysis,han20
,0,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 delta 16-17,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,17,,0,,,,0.837,0.72,0.905,0,0,,11,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,End of interval was 70+ days included as 10-13 weeks for sake of the analysis,han20
,0,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 Omicron 16-17,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,17,,0,,,,0.761,0.734,0.786,0,0,,1,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,End of interval was 70+ days included as 10-13 weeks for sake of the analysis,han20
,0,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 Omicron 16-17,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,17,,0,,,,0.716,0.693,0.731,0,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,End of interval was 70+ days included as 10-13 weeks for sake of the analysis,han20
,0,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 Omicron 16-17,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,17,,0,,,,0.495,0.457,0.53,0,0,,5,10,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,End of interval was 70+ days included as 10-13 weeks for sake of the analysis,han20
,0,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 Omicron 16-17,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,17,,0,,,,0.226,0.145,0.299,0,0,,11,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,End of interval was 70+ days included as 10-13 weeks for sake of the analysis,han20
,1,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 delta 18-39,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,39,,0,,,,0.929,0.919,0.925,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,1,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 delta 18-39,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,39,,0,,,,0.887,0.885,0.888,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,1,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 delta 40-64,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,40,64,,0,,,,0.871,0.858,0.885,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,1,522,Powell A,medrix- UK Pfizer national test-negative case-control study,0,https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00177-3/fulltext,95,95,United Kingdom,UK 3 delta 40-64,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,40,64,,0,,,,0.841,0.836,0.845,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.867,0.846,0.886,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.809,0.79,0.826,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.728,0.717,0.738,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.538,0.529,0.546,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.882,0.831,0.918,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.815,0.777,0.846,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.722,0.704,0.74,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.65,0.636,0.663,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.552,0.235,0.737,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.161,-0.208,0.417,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.098,-0.1,0.261,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,-0.765,-0.953,-0.595,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Omicron,0,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.367,-0.699,0.764,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Omicron,0,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.3,-0.413,0.654,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Omicron,0,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.042,-0.308,0.298,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Omicron,0,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,-0.393,-0.616,-0.2,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Omicron booster,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.546,0.304,0.704,1,0,,0,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Delta booster,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.812,0.792,0.829,1,0,,0,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,523,Hansen C,medrix- Denmark Pfizer/Moderna VE cohort study,0,https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v1,78,78,Denmark,Denmark Delta booster,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Positive PCR for COVID-19 regardless of symptoms,infection,infection,,1,1,1,1,3,12,85,,0,,,,0.828,0.585,0.929,1,0,,0,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 85,han20
,0,1003,Florea A,medrix- Moderna VE delta cohort study,0,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0267824,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,s SARS-CoV-2 infection defined as a positive molecular test or a COVID-19 diagnosis code for both symptomatic and asymptomatic infections,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.88,0.868,0.891,0,0,,0,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 75,han20
,0,1003,Florea A,medrix- Moderna VE delta cohort study,0,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0267825,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,s SARS-CoV-2 infection defined as a positive molecular test or a COVID-19 diagnosis code for both symptomatic and asymptomatic infections,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.845,0.838,0.852,0,0,,9,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 75,han20
,0,1003,Florea A,medrix- Moderna VE delta cohort study,0,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0267826,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,s SARS-CoV-2 infection defined as a positive molecular test or a COVID-19 diagnosis code for both symptomatic and asymptomatic infections,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.77,0.757,0.782,0,0,,17,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 75,han20
,0,1003,Florea A,medrix- Moderna VE delta cohort study,0,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0267827,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,s SARS-CoV-2 infection defined as a positive molecular test or a COVID-19 diagnosis code for both symptomatic and asymptomatic infections,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.755,0.704,0.797,0,0,,25,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 75,han20
,0,1003,Florea A,medrix- Moderna VE delta cohort study,0,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0267828,102,102,United States,US delta hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"COVID-19 hospitalization (hospitalization with a SARS-CoV-2 positive test or a COVID-19 diagnosis code, or a hospitalization ?7 days after a SARS-CoV-2 positive test)",hosp,severe,,1,0,0,0,3,18,75,,0,,,,0.959,0.935,0.974,0,0,,0,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 75,han20
,0,1003,Florea A,medrix- Moderna VE delta cohort study,0,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0267829,102,102,United States,US delta hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"COVID-19 hospitalization (hospitalization with a SARS-CoV-2 positive test or a COVID-19 diagnosis code, or a hospitalization ?7 days after a SARS-CoV-2 positive test)",hosp,severe,,1,0,0,0,3,18,75,,0,,,,0.974,0.966,0.98,0,0,,9,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 75,han20
,0,1003,Florea A,medrix- Moderna VE delta cohort study,0,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0267830,102,102,United States,US delta hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"COVID-19 hospitalization (hospitalization with a SARS-CoV-2 positive test or a COVID-19 diagnosis code, or a hospitalization ?7 days after a SARS-CoV-2 positive test)",hosp,severe,,1,0,0,0,3,18,75,,0,,,,0.948,0.936,0.957,0,0,,17,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 75,han20
,0,1003,Florea A,medrix- Moderna VE delta cohort study,0,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0267831,102,102,United States,US delta hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"COVID-19 hospitalization (hospitalization with a SARS-CoV-2 positive test or a COVID-19 diagnosis code, or a hospitalization ?7 days after a SARS-CoV-2 positive test)",hosp,severe,,1,0,0,0,3,18,75,,0,,,,0.945,0.909,0.967,0,0,,25,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 75,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.489,0.392,0.571,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.337,0.25,0.415,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.286,0.209,0.356,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.178,0.134,0.219,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.04,0.019,0.061,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,-0.027,-0.042,-0.012,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.655,0.639,0.67,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.487,0.471,0.502,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.301,0.287,0.315,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.154,0.142,0.166,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.115,0.101,0.129,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.088,0.07,0.105,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.751,0.708,0.787,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.528,0.482,0.571,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.356,0.327,0.384,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.253,0.232,0.274,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.15,0.16,0.182,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.149,0.039,0.247,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp all brand,1,,all brands,,,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.72,0.55,0.83,0,0,,2,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp all brand,1,,all brands,,,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.52,0.21,0.71,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster all brand,1,all brands,all brands,,,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.88,0.78,0.93,1,0,,2,6,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 2+ weeks, included here as 2-6 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron death all brand,1,,all brands,,,B.1.1.529.1,,severe,"death 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",death,severe,,1,0,0,0,3,50,80,,0,,,,0.59,0.04,0.82,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 50, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron death booster all brand,1,all brands,all brands,,,B.1.1.529.1,,severe,"death 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",death,severe,,1,0,0,0,3,50,80,,0,,,,0.95,0.9,0.98,1,0,,2,6,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 50, end period is reported as 2+ weeks, included here as 2-6 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.945,0.905,0.969,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.918,0.896,0.936,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.841,0.827,0.853,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.828,0.818,0.837,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.762,0.747,0.777,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.804,0.673,0.882,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.909,0.896,0.92,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.855,0.845,0.865,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.787,0.78,0.794,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.744,0.738,0.749,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.674,0.665,0.682,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.627,0.616,0.637,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.828,0.745,0.884,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.765,0.703,0.815,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.692,0.647,0.731,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.536,0.516,0.555,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.474,0.462,0.485,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,80,,0,,,,0.435,0.424,0.445,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (AZ 1st two doses),1,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.915,0.909,0.921,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (AZ 1st two doses),1,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.97,0.967,0.973,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (AZ 1st two doses),1,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.949,0.938,0.959,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.937,0.927,0.946,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.966,0.96,0.971,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.949,0.93,0.962,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (AZ 1st two doses),1,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.68,0.67,0.689,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (AZ 1st two doses),1,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.701,0.695,0.707,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (AZ 1st two doses),1,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.609,0.597,0.621,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (AZ 1st two doses),1,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.39,0.19,0.56,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.74,0.731,0.749,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.739,0.731,0.746,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.644,0.626,0.661,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.63,0.5,0.74,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.887,0.881,0.892,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.954,0.951,0.956,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.926,0.922,0.929,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.881,0.867,0.893,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.588,0.578,0.597,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.624,0.618,0.63,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.529,0.521,0.537,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.396,0.38,0.411,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.3,0.2,0.39,1,0,,15,19,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (AZ 1st two doses),1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.577,0.376,0.713,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (AZ 1st two doses),1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.556,0.444,0.646,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (AZ 1st two doses),1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.467,0.343,0.567,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (AZ 1st two doses),1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.771,0.551,0.883,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (AZ 1st two doses),1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.823,0.713,0.89,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (AZ 1st two doses),1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.833,0.697,0.908,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.923,0.916,0.929,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.951,0.948,0.954,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.918,0.914,0.921,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.899,0.892,0.905,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.669,0.661,0.676,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.672,0.665,0.678,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.55,0.542,0.558,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.457,0.447,0.467,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.395,0.37,0.43,1,0,,15,19,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Moderna 1st two doses),1,Moderna,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.681,0.656,0.705,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Moderna 1st two doses),1,Moderna,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.663,0.637,0.688,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Moderna 1st two doses),1,Moderna,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.58,0.36,0.72,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (Moderna 1st two doses),1,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.955,0.925,0.973,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (Moderna 1st two doses),1,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.947,0.893,0.973,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (Moderna 1st two doses),1,Moderna,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.953,0.921,0.972,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta booster (Moderna 1st two doses),1,Moderna,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.964,0.914,0.985,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Moderna 1st two doses),1,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.643,0.617,0.668,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Moderna 1st two doses),1,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.649,0.623,0.673,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron booster (Moderna 1st two doses),1,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.51,0.3,0.64,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron BA.1 all brand,1,all brands,all brands,,,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,0,0,0,3,18,80,,0,,,,0.63,0.63,0.64,1,0,,2,6,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron BA.1 all brand,1,,all brands,,,B.1.1.529.1,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,0,0,0,3,18,80,,0,,,,0.09,0.07,0.1,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron BA.2 all brand,1,all brands,all brands,,,B.1.1.529.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,0,0,0,3,18,80,,0,,,,0.7,0.58,0.79,1,0,,2,6,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 2+ weeks, included here as 2-6 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron BA.2 all brand,1,,all brands,,,B.1.1.529.2,,"Mild, Moderate + severe","symptomatic disease + positive PCR 14 days after the second dose of Pfizer-BionTech, Moderna, or AstraZeneca",Symptomatic,"Mild, Moderate + Severe",,1,0,0,0,3,50,80,,0,,,,0.13,-0.26,0.4,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 50, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.74,0.405,0.887,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.72,0.5,0.85,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.54,0.36,0.68,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.6,0.49,0.69,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.57,0.43,0.68,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.35,0.18,0.49,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, end period is reported as 25+ weeks, included here as 25-29 for the sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,16,80,,0,,,,0.94,0.82,0.98,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,16,80,,0,,,,0.99,0.95,0.99,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,16,80,,0,,,,0.99,0.97,0.99,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,16,80,,0,,,,0.99,0.98,0.99,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,16,80,,0,,,,0.98,0.96,0.99,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,16,80,,0,,,,0.95,0.94,0.96,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.99,0.98,0.999,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.99,0.98,0.999,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.99,0.98,0.99,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.99,0.98,0.99,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.79,0.69,0.87,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.88,0.82,0.92,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.84,0.8,0.86,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.75,0.7,0.81,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.99,0.96,0.99,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.89,0.73,0.95,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.92,0.83,0.96,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (Pfizer 1st two doses),1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.94,0.8,0.98,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.56,0.34,0.7,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.32,0.2,0.44,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.92,0.91,0.94,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.91,0.9,0.92,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.99,0.98,0.999,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.99,0.98,0.999,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.99,0.98,0.99,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.98,0.96,0.99,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.9,0.83,0.93,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.87,0.83,0.9,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.85,0.81,0.88,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (AZ 1st two doses),1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.77,0.7,0.835,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp booster (AZ 1st two doses),1,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.99,0.98,0.99,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK delta hosp booster (AZ 1st two doses),1,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.99,0.98,0.99,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (AZ 1st two doses),1,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.9,0.81,0.96,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (AZ 1st two doses),1,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.92,0.86,0.94,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,0,525,UK HSA,UK Health Security Agency,0,https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf,95,95,United Kingdom,UK Omicron hosp booster (AZ 1st two doses),1,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,severe,"Hospitalization 14 days after vaccination with Moderna, Pfizer, or AstraZeneca",hosp,severe,,1,1,1,0,3,18,80,,0,,,,0.91,0.83,0.96,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, period ends 10+ included as 10-14 for sake analysis",han20
,1,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,confirmed COVID-19 cases irrespective of symptoms or severity,infection,infection,,1,1,1,1,3,18,80,,0,,,,-0.13,-0.38,0.06,0,0,,1,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is 34 weeks+ it is included as 34-39 weeks for sake of the analysis",han20
,1,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,confirmed COVID-19 cases irrespective of symptoms or severity,infection,infection,,1,1,1,1,3,18,80,,0,,,,-0.22,-0.51,0.02,0,0,,9,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is 34 weeks+ it is included as 34-39 weeks for sake of the analysis",han20
,1,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,confirmed COVID-19 cases irrespective of symptoms or severity,infection,infection,,1,1,1,1,3,18,80,,0,,,,-0.37,-0.62,-0.17,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is 34 weeks+ it is included as 34-39 weeks for sake of the analysis",han20
,1,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,confirmed COVID-19 cases irrespective of symptoms or severity,infection,infection,,1,1,1,1,3,18,80,,0,,,,-0.48,-0.79,-0.23,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is 34 weeks+ it is included as 34-39 weeks for sake of the analysis",han20
,1,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,confirmed COVID-19 cases irrespective of symptoms or severity,infection,infection,,1,1,1,1,3,18,80,,0,,,,-0.23,-0.76,0.13,0,0,,35,39,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is 34 weeks+ it is included as 34-39 weeks for sake of the analysis",han20
,1,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,confirmed COVID-19 cases irrespective of symptoms or severity,infection,infection,,1,1,1,1,3,18,80,,0,,,,0.82,0.79,0.85,0,0,,1,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is 34 weeks+ it is included as 34-39 weeks for sake of the analysis",han20
,1,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,confirmed COVID-19 cases irrespective of symptoms or severity,infection,infection,,1,1,1,1,3,18,80,,0,,,,0.78,0.76,0.8,0,0,,9,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is 34 weeks+ it is included as 34-39 weeks for sake of the analysis",han20
,1,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,confirmed COVID-19 cases irrespective of symptoms or severity,infection,infection,,1,1,1,1,3,18,80,,0,,,,0.77,0.76,0.79,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is 34 weeks+ it is included as 34-39 weeks for sake of the analysis",han20
,1,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,confirmed COVID-19 cases irrespective of symptoms or severity,infection,infection,,1,1,1,1,3,18,80,,0,,,,0.73,0.7,0.76,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is 34 weeks+ it is included as 34-39 weeks for sake of the analysis",han20
,1,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,confirmed COVID-19 cases irrespective of symptoms or severity,infection,infection,,1,1,1,1,3,18,80,,0,,,,0.66,0.6,0.71,0,0,,35,39,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is 34 weeks+ it is included as 34-39 weeks for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Omicron Booster,1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","individuals who had at least one COVID-19-related symptom (self-reported or measured) at the time of testing, as identified in the laboratory testing data",Symptomatic,"Mild, Moderate + Severe",,1,1,1,1,3,18,80,,0,,,,0.43,0.32,0.52,1,0,,0,6,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Omicron Booster,1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","individuals who had at least one COVID-19-related symptom (self-reported or measured) at the time of testing, as identified in the laboratory testing data",Symptomatic,"Mild, Moderate + Severe",,1,1,1,1,3,18,80,,0,,,,0.65,0.55,0.72,1,0,,7,14,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Omicron Booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","individuals who had at least one COVID-19-related symptom (self-reported or measured) at the time of testing, as identified in the laboratory testing data",Symptomatic,"Mild, Moderate + Severe",,1,1,1,1,3,18,80,,0,,,,0.34,0.26,0.41,1,0,,0,6,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Omicron Booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","individuals who had at least one COVID-19-related symptom (self-reported or measured) at the time of testing, as identified in the laboratory testing data",Symptomatic,"Mild, Moderate + Severe",,1,1,1,1,3,18,80,,0,,,,0.6,0.55,0.65,1,0,,7,14,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Delta Booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","individuals who had at least one COVID-19-related symptom (self-reported or measured) at the time of testing, as identified in the laboratory testing data",Symptomatic,"Mild, Moderate + Severe",,1,1,1,1,3,18,80,,0,,,,0.94,0.92,0.95,1,0,,0,6,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Delta Booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","individuals who had at least one COVID-19-related symptom (self-reported or measured) at the time of testing, as identified in the laboratory testing data",Symptomatic,"Mild, Moderate + Severe",,1,1,1,1,3,18,80,,0,,,,0.97,0.96,0.98,1,0,,7,14,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Delta Booster,1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","individuals who had at least one COVID-19-related symptom (self-reported or measured) at the time of testing, as identified in the laboratory testing data",Symptomatic,"Mild, Moderate + Severe",,1,1,1,1,3,18,80,,0,,,,0.95,0.92,0.97,1,0,,0,6,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Delta Booster,1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","individuals who had at least one COVID-19-related symptom (self-reported or measured) at the time of testing, as identified in the laboratory testing data",Symptomatic,"Mild, Moderate + Severe",,1,1,1,1,3,18,80,,0,,,,0.97,0.95,0.98,1,0,,7,14,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,1,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Omicron Booster,1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,severe,"hospital admission or death using the earliest of the specimen collection date, hospital admission date, or death date as the index date",hosp&death,severe,,1,1,1,1,3,18,80,,0,,,,,,,1,0,,0,6,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Omicron Booster,1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,severe,"hospital admission or death using the earliest of the specimen collection date, hospital admission date, or death date as the index date",hosp&death,severe,,1,1,1,1,3,18,80,,0,,,,0.93,0.74,0.98,1,0,,7,14,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Omicron Booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"hospital admission or death using the earliest of the specimen collection date, hospital admission date, or death date as the index date",hosp&death,severe,,1,1,1,1,3,18,80,,0,,,,0.88,0.62,0.96,1,0,,0,6,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Omicron Booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"hospital admission or death using the earliest of the specimen collection date, hospital admission date, or death date as the index date",hosp&death,severe,,1,1,1,1,3,18,80,,0,,,,0.95,0.87,0.98,1,0,,7,14,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Delta Booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"hospital admission or death using the earliest of the specimen collection date, hospital admission date, or death date as the index date",hosp&death,severe,,1,1,1,1,3,18,80,,0,,,,0.98,0.96,0.99,1,0,,0,6,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Delta Booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"hospital admission or death using the earliest of the specimen collection date, hospital admission date, or death date as the index date",hosp&death,severe,,1,1,1,1,3,18,80,,0,,,,0.99,0.98,0.99,1,0,,7,14,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,1,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Delta Booster,1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"hospital admission or death using the earliest of the specimen collection date, hospital admission date, or death date as the index date",hosp&death,severe,,1,1,1,1,3,18,80,,0,,,,,,,1,0,,0,6,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,0,526,Buchan S,medrix- Canada VE Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v1,101,101,Canada,Canada Delta Booster,1,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"hospital admission or death using the earliest of the specimen collection date, hospital admission date, or death date as the index date",hosp&death,severe,,1,1,1,1,3,18,80,,0,,,,0.99,0.98,0.99,1,0,,7,14,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=80, reported period is +1 week included as 2-6 for sake of the analysis",han20
,1,527,Gray G,medrix- South Africa J&J booster efficacy Omicron Sisonke 2 Study,0,https://www.medrxiv.org/content/10.1101/2021.12.28.21268436v1.full.pdf,196,196,South Africa,SA Omicron hosp booster,0,Johnson & Johnson,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.529.1,,severe,hospital admissions of a homologous boost of the Ad26.COV.2 vaccine given 6-9 months after the initial vaccination in HCW,hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.63,0.31,0.81,1,0,,0,2,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,1,527,Gray G,medrix- South Africa J&J booster efficacy Omicron Sisonke 2 Study,0,https://www.medrxiv.org/content/10.1101/2021.12.28.21268436v1.full.pdf,196,196,South Africa,SA Omicron hosp booster,0,Johnson & Johnson,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.529.1,,severe,hospital admissions of a homologous boost of the Ad26.COV.2 vaccine given 6-9 months after the initial vaccination in HCW,hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.84,0.67,0.92,1,0,,3,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,1,527,Gray G,medrix- South Africa J&J booster efficacy Omicron Sisonke 2 Study,0,https://www.medrxiv.org/content/10.1101/2021.12.28.21268436v1.full.pdf,196,196,South Africa,SA Omicron hosp booster,0,Johnson & Johnson,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.529.1,,severe,hospital admissions of a homologous boost of the Ad26.COV.2 vaccine given 6-9 months after the initial vaccination in HCW,hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.85,0.54,0.95,1,0,,5,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta severe,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Hospital admission and/or death from Covid-9,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.777,0.719,0.823,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta severe,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Hospital admission and/or death from Covid-10,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.837,0.797,0.87,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta severe,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Hospital admission and/or death from Covid-11,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.866,0.836,0.89,0,0,,4,5,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta severe,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Hospital admission and/or death from Covid-12,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.868,0.842,0.889,0,0,,6,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta severe,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Hospital admission and/or death from Covid-13,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.79,0.759,0.817,0,0,,8,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta severe,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Hospital admission and/or death from Covid-14,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.796,0.768,0.821,0,0,,10,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta severe,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Hospital admission and/or death from Covid-15,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.774,0.746,0.8,0,0,,12,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta severe,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Hospital admission and/or death from Covid-16,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.759,0.729,0.786,0,0,,14,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta severe,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Hospital admission and/or death from Covid-17,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.705,0.67,0.737,0,0,,16,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta severe,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Hospital admission and/or death from Covid-18,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.637,0.596,0.674,0,0,,18,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta severe,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Hospital admission and/or death from Covid-19,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.536,0.484,0.583,0,0,,20,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR confirmed Covid-19 infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.502,0.467,0.535,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR confirmed Covid-19 infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.679,0.659,0.698,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR confirmed Covid-19 infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.673,0.653,0.691,0,0,,4,5,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR confirmed Covid-19 infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.638,0.617,0.657,0,0,,6,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR confirmed Covid-19 infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.633,0.613,0.653,0,0,,8,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR confirmed Covid-19 infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.593,0.572,0.614,0,0,,10,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR confirmed Covid-19 infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.553,0.53,0.575,0,0,,12,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR confirmed Covid-19 infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.529,0.504,0.552,0,0,,14,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR confirmed Covid-19 infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.487,0.459,0.514,0,0,,16,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR confirmed Covid-19 infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.446,0.415,0.476,0,0,,18,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,528,Katikireddi S,Lancet- AZ VE vs Delta in Scotland,0,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02754-9/fulltext,434,434,Scotland,Scotland delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",PCR confirmed Covid-19 infection,symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.391,0.354,0.426,0,0,,20,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 80,han20
,0,1010,Bajema K,CDC MMWR Moderna and Pfizer VE Veteran Affairs Medical Center,0,https://www.cdc.gov/mmwr/volumes/70/wr/mm7049a2.htm?s_cid=mm7049a2_w,102,102,United States,US delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Hospitalization due to Covid-19 infection,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.86,0.776,0.913,0,0,,2,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, period ends at 16+ weeks it is included as 16-20 for sake of the analysis",han20
,0,1010,Bajema K,CDC MMWR Moderna and Pfizer VE Veteran Affairs Medical Center,0,https://www.cdc.gov/mmwr/volumes/70/wr/mm7049a2.htm?s_cid=mm7049a2_w,102,102,United States,US delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Hospitalization due to Covid-19 infection,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.751,0.646,0.824,0,0,,16,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, period ends at 16+ weeks it is included as 16-20 for sake of the analysis",han20
,0,1010,Bajema K,CDC MMWR Moderna and Pfizer VE Veteran Affairs Medical Center,0,https://www.cdc.gov/mmwr/volumes/70/wr/mm7049a2.htm?s_cid=mm7049a2_w,102,102,United States,US delta hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Hospitalization due to Covid-19 infection,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.896,0.801,0.945,0,0,,2,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, period ends at 16+ weeks it is included as 16-20 for sake of the analysis",han20
,0,1010,Bajema K,CDC MMWR Moderna and Pfizer VE Veteran Affairs Medical Center,0,https://www.cdc.gov/mmwr/volumes/70/wr/mm7049a2.htm?s_cid=mm7049a2_w,102,102,United States,US delta hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Hospitalization due to Covid-19 infection,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.961,0.777,0.913,0,0,,16,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, period ends at 16+ weeks it is included as 16-20 for sake of the analysis",han20
,0,530,Tseng H,nature- Kaiser Moderna VE Omicron vs Delta,0,https://www.nature.com/articles/s41591-022-01753-y,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Test positive cases included individuals who tested positive by the RT-PCR TaqPath COVID-19 kit,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.802,0.682,0.877,0,0,,2,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, period ends at 38+ weeks it is included as 39-50 for sake of the analysis",han20
,0,530,Tseng H,nature- Kaiser Moderna VE Omicron vs Delta,0,https://www.nature.com/articles/s41591-022-01753-y,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Test positive cases included individuals who tested positive by the RT-PCR TaqPath COVID-19 kit,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.689,0.601,0.758,0,0,,13,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, period ends at 38+ weeks it is included as 39-50 for sake of the analysis",han20
,0,530,Tseng H,nature- Kaiser Moderna VE Omicron vs Delta,0,https://www.nature.com/articles/s41591-022-01753-y,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Test positive cases included individuals who tested positive by the RT-PCR TaqPath COVID-19 kit,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.637,0.598,0.672,0,0,,26,38,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, period ends at 38+ weeks it is included as 39-50 for sake of the analysis",han20
,0,530,Tseng H,nature- Kaiser Moderna VE Omicron vs Delta,0,https://www.nature.com/articles/s41591-022-01753-y,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Test positive cases included individuals who tested positive by the RT-PCR TaqPath COVID-19 kit,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.613,0.55,0.667,0,0,,39,50,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, period ends at 38+ weeks it is included as 39-50 for sake of the analysis",han20
,0,530,Tseng H,nature- Kaiser Moderna VE Omicron vs Delta,0,https://www.nature.com/articles/s41591-022-01753-y,102,102,United States,US Omicron,0,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,infection,Test positive cases included individuals who tested positive by the RT-PCR TaqPath COVID-19 kit,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.44,0.351,0.516,0,0,,2,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, period ends at 38+ weeks it is included as 39-50 for sake of the analysis",han20
,0,530,Tseng H,nature- Kaiser Moderna VE Omicron vs Delta,0,https://www.nature.com/articles/s41591-022-01753-y,102,102,United States,US Omicron,0,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,infection,Test positive cases included individuals who tested positive by the RT-PCR TaqPath COVID-19 kit,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.235,0.164,0.3,0,0,,13,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, period ends at 38+ weeks it is included as 39-50 for sake of the analysis",han20
,0,530,Tseng H,nature- Kaiser Moderna VE Omicron vs Delta,0,https://www.nature.com/articles/s41591-022-01753-y,102,102,United States,US Omicron,0,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,infection,Test positive cases included individuals who tested positive by the RT-PCR TaqPath COVID-19 kit,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.138,0.102,0.173,0,0,,26,38,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, period ends at 38+ weeks it is included as 39-50 for sake of the analysis",han20
,0,530,Tseng H,nature- Kaiser Moderna VE Omicron vs Delta,0,https://www.nature.com/articles/s41591-022-01753-y,102,102,United States,US Omicron,0,,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,infection,Test positive cases included individuals who tested positive by the RT-PCR TaqPath COVID-19 kit,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.059,0.004,0.11,0,0,,39,50,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, period ends at 38+ weeks it is included as 39-50 for sake of the analysis",han20
,0,530,Tseng H,nature- Kaiser Moderna VE Omicron vs Delta,0,https://www.nature.com/articles/s41591-022-01753-y,102,102,United States,US delta booster,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Test positive cases included individuals who tested positive by the RT-PCR TaqPath COVID-19 kit,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.937,0.922,0.949,1,0,,2,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, ",han20
,0,530,Tseng H,nature- Kaiser Moderna VE Omicron vs Delta,0,https://www.nature.com/articles/s41591-022-01753-y,102,102,United States,US delta booster,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,Test positive cases included individuals who tested positive by the RT-PCR TaqPath COVID-19 kit,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.86,0.781,0.911,1,0,,9,15,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, ",han20
,0,530,Tseng H,nature- Kaiser Moderna VE Omicron vs Delta,0,https://www.nature.com/articles/s41591-022-01753-y,102,102,United States,US Omicron booster,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,infection,Test positive cases included individuals who tested positive by the RT-PCR TaqPath COVID-19 kit,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.716,0.697,0.734,1,0,,2,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, ",han20
,0,530,Tseng H,nature- Kaiser Moderna VE Omicron vs Delta,0,https://www.nature.com/articles/s41591-022-01753-y,102,102,United States,US Omicron booster,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,infection,Test positive cases included individuals who tested positive by the RT-PCR TaqPath COVID-19 kit,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.474,0.405,0.535,1,0,,9,15,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,0,,,,0.72,0.7,0.735,0,0,,12,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,0,,,,0.56,0.545,0.57,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,0,,,,0.695,0.68,0.71,0,0,,12,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,0,,,,0.67,0.65,0.69,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,0,,,,0.75,0.746,0.755,0,0,,12,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,0,,,,0.675,0.67,0.68,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,0,,,,0.535,0.525,0.55,0,0,,29,36,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,0,,,,0.86,0.85,0.87,0,0,,12,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,0,,,,0.78,0.765,0.8,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection defined as a PCR confirmed positive test of a person from any sample regardless of the presence of symptoms,infection,infection,,1,1,1,1,3,12,65,,0,,,,0.65,0.635,0.67,0,0,,29,36,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Hospital admission of a person tested positive via a PCR test (within two weeks before hospital admission and whenever during hospitalization),hosp,severe,,1,0,0,0,3,12,65,,0,,,,0.77,0.75,0.8,0,0,,12,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta hosp,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Hospital admission of a person tested positive via a PCR test (within two weeks before hospital admission and whenever during hospitalization),hosp,severe,,1,0,0,0,3,12,65,,0,,,,0.7,0.67,0.725,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Hospital admission of a person tested positive via a PCR test (within two weeks before hospital admission and whenever during hospitalization),hosp,severe,,1,0,0,0,3,12,65,,0,,,,0.745,0.68,0.78,0,0,,12,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Hospital admission of a person tested positive via a PCR test (within two weeks before hospital admission and whenever during hospitalization),hosp,severe,,1,0,0,0,3,12,65,,0,,,,0.67,0.62,0.73,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Hospital admission of a person tested positive via a PCR test (within two weeks before hospital admission and whenever during hospitalization),hosp,severe,,1,0,0,0,3,12,65,,0,,,,0.91,0.9,0.92,0,0,,12,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Hospital admission of a person tested positive via a PCR test (within two weeks before hospital admission and whenever during hospitalization),hosp,severe,,1,0,0,0,3,12,65,,0,,,,0.86,0.85,0.87,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Hospital admission of a person tested positive via a PCR test (within two weeks before hospital admission and whenever during hospitalization),hosp,severe,,1,0,0,0,3,12,65,,0,,,,0.755,0.74,0.765,0,0,,29,36,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Hospital admission of a person tested positive via a PCR test (within two weeks before hospital admission and whenever during hospitalization),hosp,severe,,1,0,0,0,3,12,65,,0,,,,0.9,0.82,0.875,0,0,,12,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Hospital admission of a person tested positive via a PCR test (within two weeks before hospital admission and whenever during hospitalization),hosp,severe,,1,0,0,0,3,12,65,,0,,,,0.86,0.845,0.88,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Hospital admission of a person tested positive via a PCR test (within two weeks before hospital admission and whenever during hospitalization),hosp,severe,,1,0,0,0,3,12,65,,0,,,,0.815,0.78,0.845,0,0,,29,36,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta death,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Death due to covid-19,death,severe,,1,0,0,0,3,12,65,,0,,,,0.87,0.8,0.905,0,0,,12,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta death,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Death due to covid-20,death,severe,,1,0,0,0,3,12,65,,0,,,,0.825,0.78,0.85,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta death,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Death due to covid-21,death,severe,,1,0,0,0,3,12,65,,0,,,,0.75,0.59,0.85,0,0,,12,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta death,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Death due to covid-22,death,severe,,1,0,0,0,3,12,65,,0,,,,0.68,0.53,0.78,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Death due to covid-23,death,severe,,1,0,0,0,3,12,65,,0,,,,0.93,0.9,0.945,0,0,,12,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Death due to covid-24,death,severe,,1,0,0,0,3,12,65,,0,,,,0.9,0.88,0.92,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Death due to covid-25,death,severe,,1,0,0,0,3,12,65,,0,,,,0.83,0.805,0.855,0,0,,29,36,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta death,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Death due to covid-26,death,severe,,1,0,0,0,3,12,65,,0,,,,0.96,0.898,0.985,0,0,,12,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta death,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Death due to covid-27,death,severe,,1,0,0,0,3,12,65,,0,,,,0.91,0.86,0.94,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,531,Berec L,medrix- Czech VE whole country retrospective study,0,https://www.medrxiv.org/content/10.1101/2021.12.10.21267590v1.full.pdf,47,47,Czechia,Czech delta death,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Death due to covid-28,death,severe,,1,0,0,0,3,12,65,,0,,,,0.87,0.82,0.92,0,0,,29,36,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, the first peroid in the study 0-2 months was not included becuase it was an alpha dominant peroid. ",han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,0.87,0.83,0.89,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,0.76,0.72,0.81,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,0.72,0.61,0.8,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,0.65,0.56,0.71,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,1,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 60-85,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,60,85,,0,,,,,,,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >60, peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis",han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 60-85,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,60,85,,0,,,,0.65,0.37,0.8,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >60, peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis",han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 60-85,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,60,85,,0,,,,0.66,0.48,0.78,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >60, peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis",han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 60-85,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,60,85,,0,,,,0.64,0.44,0.77,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >60, peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis",han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,0.72,0.52,0.83,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,0.67,0.57,0.75,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,0.65,0.48,0.76,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,1,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,,,,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,0.98,0.93,0.99,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,0.91,0.85,0.95,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,0.9,0.76,0.96,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,1,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,,,,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,1,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,,,,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,0.5,0.36,0.62,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,0,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,0.52,0.33,0.66,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,1,532,Kissling E,Europe multicenter study analysis VE delta I-MOVE-COVID-19 and ECDC,0,https://osf.io/3nhps/,"4749, 80, 92, 91, 89, 46, 52, 84, 434","4749, 80, 92, 91, 89, 46, 52, 84, 434","England, France, Spain, Portugal, Netherlands, Croatia, Romania, Ireland, Scotland",Europe delta 30-59,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","PCR positive patients with COVID-19 symptoms (at least one of the following symptoms: fever, cough, shortness of breath, sudden onset of anosmia/ageusia)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,30,59,,0,,,,,,,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,peroid of study end in >13 weeks peroid included as 13-16 for sake of the analysis,han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.619,0.609,0.628,0,0,,12,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.436,0.424,0.446,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.911,0.907,0.915,0,0,,12,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.83,0.823,0.836,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta death,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.95,0.948,0.953,0,0,,12,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta death,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.901,0.896,0.906,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.206,0.172,0.244,0,0,,12,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.11,0.09,0.133,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.621,0.567,0.672,0,0,,12,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron hosp,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.439,0.384,0.492,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron death,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.754,0.708,0.793,0,0,,12,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron death,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.593,0.536,0.645,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.395,0.386,0.404,0,0,,12,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.237,0.228,0.245,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.805,0.798,0.811,0,0,,12,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.662,0.652,0.672,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta death,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.885,0.88,0.89,0,0,,12,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta death,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.786,0.776,0.794,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.095,0.078,0.115,0,0,,12,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.047,0.038,0.058,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.397,0.346,0.451,0,0,,12,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron hosp,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.239,0.201,0.281,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron death,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.552,0.496,0.607,0,0,,12,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron death,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529.1,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.37,0.318,0.423,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 26+ weeks interval included as 26-34 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.868,0.859,0.878,1,0,,4,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.828,0.815,0.84,1,0,,9,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.786,0.769,0.802,1,0,,13,16,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta hosp booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.977,0.975,0.979,1,0,,4,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta hosp booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.968,0.965,0.971,1,0,,9,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta hosp booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.959,0.954,0.963,1,0,,13,16,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta death booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.987,0.986,0.988,1,0,,4,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta death booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.983,0.981,0.984,1,0,,9,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta death booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.977,0.975,0.98,1,0,,13,16,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.514,0.463,0.565,1,0,,4,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.434,0.384,0.486,1,0,,9,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.37,0.322,0.42,1,0,,13,16,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron hosp booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.87,0.844,0.891,1,0,,4,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron hosp booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.829,0.797,0.856,1,0,,9,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron hosp booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.788,0.75,0.821,1,0,,13,16,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron death booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.926,0.909,0.939,1,0,,4,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron death booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.901,0.88,0.918,1,0,,9,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron death booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.874,0.848,0.896,1,0,,13,16,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.868,0.859,0.878,1,0,,4,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.828,0.815,0.84,1,0,,9,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.786,0.769,0.802,1,0,,13,16,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta hosp booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.977,0.975,0.979,1,0,,4,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta hosp booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.968,0.965,0.971,1,0,,9,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK2  delta hosp booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.959,0.954,0.963,1,0,,13,16,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta death booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.987,0.986,0.988,1,0,,4,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta death booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.983,0.981,0.984,1,0,,9,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 delta death booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.977,0.975,0.98,1,0,,13,16,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.514,0.463,0.565,1,0,,4,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.434,0.384,0.486,1,0,,9,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,(PCR+ tests which include symptomatic cases and asymptomatic infections detected through screening in schools and workplaces,infection,infection,,0,1,1,1,3,10,60,,0,,,,0.37,0.322,0.42,1,0,,13,16,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron hosp booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.87,0.844,0.891,1,0,,4,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron hosp booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.829,0.797,0.856,1,0,,9,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron hosp booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,hospitalisations due to covid-19,hosp,severe,,1,0,0,0,3,10,60,,0,,,,0.788,0.75,0.821,1,0,,13,16,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron death booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.926,0.909,0.939,1,0,,4,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron death booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.901,0.88,0.918,1,0,,9,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,0,533,Hogan A,medrix- VE Omicron vs Delta Imperial College,0,https://www.medrxiv.org/content/10.1101/2022.01.17.22269222v1.full.pdf,95,95,United Kingdom,UK 2 Omicron death booster,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,deaths within 28 days of a positive test,death,severe,,1,0,0,0,3,10,60,,0,,,,0.874,0.848,0.896,1,0,,13,16,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 60, study ended at 12+ weeks after booster, interval included as 13-16 for sake of the analysis",han20
,1,534,Thompson M,CDC MMWR Booster efficacy,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_w,102,102,United States,US delta,0,,All mRNA vaccines,,mRNA,B.1.617.2,,"Mild, Moderate + severe",COVID-19–like illness diagnosis** who had received molecular testing (primarily reverse transcription–polymerase chain reaction assay),Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,85,,0,,,,0.86,0.85,0.87,0,0,,2,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, study ended at  26+ weeks after booster, interval included as 26-38 for sake of the analysis",han20
,1,534,Thompson M,CDC MMWR Booster efficacy,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_w,102,102,United States,US delta,0,,All mRNA vaccines,,mRNA,B.1.617.2,,"Mild, Moderate + severe",COVID-19–like illness diagnosis** who had received molecular testing (primarily reverse transcription–polymerase chain reaction assay),Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,85,,0,,,,0.76,0.75,0.77,0,0,,26,38,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, study ended at  26+ weeks after booster, interval included as 26-38 for sake of the analysis",han20
,1,534,Thompson M,CDC MMWR Booster efficacy,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_w,102,102,United States,US delta booster,0,All mRNA vaccines,All mRNA vaccines,,mRNA,B.1.617.2,,"Mild, Moderate + severe",COVID-19–like illness diagnosis** who had received molecular testing (primarily reverse transcription–polymerase chain reaction assay),Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,85,,0,,,,0.94,0.93,0.94,1,0,,0,6,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, ",han20
,1,534,Thompson M,CDC MMWR Booster efficacy,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_w,102,102,United States,US delta hosp,0,,All mRNA vaccines,,mRNA,B.1.617.2,,severe,virus that causes COVID-19) within 14 days before or 72 hours after the admission or encounter.,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.9,0.89,0.9,0,0,,2,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, study ended at  26+ weeks after booster, interval included as 26-38 for sake of the analysis",han20
,1,534,Thompson M,CDC MMWR Booster efficacy,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_w,102,102,United States,US delta hosp,0,,All mRNA vaccines,,mRNA,B.1.617.2,,severe,virus that causes COVID-19) within 14 days before or 72 hours after the admission or encounter.,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.81,0.8,0.82,0,0,,26,38,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, study ended at  26+ weeks after booster, interval included as 26-38 for sake of the analysis",han20
,1,534,Thompson M,CDC MMWR Booster efficacy,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_w,102,102,United States,US delta hosp booster,0,All mRNA vaccines,All mRNA vaccines,,mRNA,B.1.617.2,,severe,virus that causes COVID-19) within 14 days before or 72 hours after the admission or encounter.,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.94,0.93,0.95,1,0,,0,6,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, ",han20
,1,534,Thompson M,CDC MMWR Booster efficacy,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_w,102,102,United States,US Omicron,0,,All mRNA vaccines,,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",COVID-19–like illness diagnosis** who had received molecular testing (primarily reverse transcription–polymerase chain reaction assay),Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,85,,0,,,,0.52,0.46,0.58,0,0,,2,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, study ended at  26+ weeks after booster, interval included as 26-38 for sake of the analysis",han20
,1,534,Thompson M,CDC MMWR Booster efficacy,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_w,102,102,United States,US Omicron,0,,All mRNA vaccines,,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",COVID-19–like illness diagnosis** who had received molecular testing (primarily reverse transcription–polymerase chain reaction assay),Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,85,,0,,,,0.38,0.32,0.43,0,0,,26,38,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, study ended at  26+ weeks after booster, interval included as 26-38 for sake of the analysis",han20
,1,534,Thompson M,CDC MMWR Booster efficacy,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_w,102,102,United States,US Omicron booster,0,All mRNA vaccines,All mRNA vaccines,,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",COVID-19–like illness diagnosis** who had received molecular testing (primarily reverse transcription–polymerase chain reaction assay),Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,85,,0,,,,0.82,0.79,0.84,1,0,,0,6,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, ",han20
,1,534,Thompson M,CDC MMWR Booster efficacy,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_w,102,102,United States,US Omicron hosp,0,,All mRNA vaccines,,mRNA,B.1.1.529.1,,severe,virus that causes COVID-19) within 14 days before or 72 hours after the admission or encounter.,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.81,0.65,0.9,0,0,,2,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, study ended at  26+ weeks after booster, interval included as 26-38 for sake of the analysis",han20
,1,534,Thompson M,CDC MMWR Booster efficacy,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_w,102,102,United States,US Omicron hosp,0,,All mRNA vaccines,,mRNA,B.1.1.529.1,,severe,virus that causes COVID-19) within 14 days before or 72 hours after the admission or encounter.,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.57,0.39,0.7,0,0,,26,38,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, study ended at  26+ weeks after booster, interval included as 26-38 for sake of the analysis",han20
,1,534,Thompson M,CDC MMWR Booster efficacy,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_w,102,102,United States,US Omicron hosp booster,0,All mRNA vaccines,All mRNA vaccines,,mRNA,B.1.1.529.1,,severe,virus that causes COVID-19) within 14 days before or 72 hours after the admission or encounter.,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.9,0.8,0.94,1,0,,0,6,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 85, ",han20
,0,535,Abu-Raddad Laith,NEJM- Booster efficacy againt Omicron in Qatar,0,https://www.nejm.org/doi/10.1056/NEJMoa2200797,151,151,Qatar,Qatar Omicron booster,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,0,75,,0,,,,0.501,0.473,0.528,1,0,,2,6,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, ",han20
,0,535,Abu-Raddad Laith,NEJM- Booster efficacy againt Omicron in Qatar,0,https://www.nejm.org/doi/10.1056/NEJMoa2200798,151,151,Qatar,Qatar Omicron booster,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,0,75,,0,,,,0.508,0.434,0.573,1,0,,2,6,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, ",han20
,0,535,Abu-Raddad Laith,NEJM- Booster efficacy againt Omicron in Qatar,0,https://www.nejm.org/doi/10.1056/NEJMoa2200797,151,151,Qatar,Qatar delta booster,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",PCR-positive nasopharyngeal swab conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,0,75,,0,,,,0.861,0.673,0.941,1,0,,2,6,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, ",han20
,0,535,Abu-Raddad Laith,NEJM- Booster efficacy againt Omicron in Qatar,0,https://www.nejm.org/doi/10.1056/NEJMoa2200797,151,151,Qatar,Qatar Omicron booster hosp&death,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,"Classification of severe Covid-19 cases (acute-care hospitalizations), critical Covid-19 cases (hospitalizations in an intensive care unit), and fatal Covid-19 cases (Covid-19–related deaths) followed WHO guidelines, and assessments were made by trained medical personnel, independent of the study investigators, through individual chart reviews, as part of a national protocol for every hospitalized patient with Covid-19",hosp&death,severe,,1,0,0,0,3,0,75,,0,,,,0.765,0.559,0.875,1,0,,2,6,Weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >= 75, ",han20
,0,1003,Chiew C,SSRN- Pfizer VE adolescents singapore,0,https://deliverypdf.ssrn.com/delivery.php?ID=617022022121092094086027010072080028016053089047061003065024085088085103029008067066100029017023042116110120107115089113127089012054046028049083085079116102089126101062069008103126064097106117117104089064102090071103116006004079007104098074075127020001&EXT=pdf&INDEX=TRUE,69,69,Singapore,Singapore delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,12,18,,0,,,,0.78,0.7,0.84,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 17+ weeks will be included as 18-22 for sake of the analysis,han20
,0,1003,Chiew C,SSRN- Pfizer VE adolescents singapore,0,https://deliverypdf.ssrn.com/delivery.php?ID=617022022121092094086027010072080028016053089047061003065024085088085103029008067066100029017023042116110120107115089113127089012054046028049083085079116102089126101062069008103126064097106117117104089064102090071103116006004079007104098074075127020001&EXT=pdf&INDEX=TRUE,69,69,Singapore,Singapore delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,12,18,,0,,,,0.61,0.55,0.66,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 17+ weeks will be included as 18-22 for sake of the analysis,han20
,0,1003,Chiew C,SSRN- Pfizer VE adolescents singapore,0,https://deliverypdf.ssrn.com/delivery.php?ID=617022022121092094086027010072080028016053089047061003065024085088085103029008067066100029017023042116110120107115089113127089012054046028049083085079116102089126101062069008103126064097106117117104089064102090071103116006004079007104098074075127020001&EXT=pdf&INDEX=TRUE,69,69,Singapore,Singapore delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,12,18,,0,,,,0.58,0.55,0.63,0,0,,10,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 17+ weeks will be included as 18-22 for sake of the analysis,han20
,0,1003,Chiew C,SSRN- Pfizer VE adolescents singapore,0,https://deliverypdf.ssrn.com/delivery.php?ID=617022022121092094086027010072080028016053089047061003065024085088085103029008067066100029017023042116110120107115089113127089012054046028049083085079116102089126101062069008103126064097106117117104089064102090071103116006004079007104098074075127020001&EXT=pdf&INDEX=TRUE,69,69,Singapore,Singapore delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,12,18,,0,,,,0.56,0.52,0.62,0,0,,14,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 17+ weeks will be included as 18-22 for sake of the analysis,han20
,0,1003,Chiew C,SSRN- Pfizer VE adolescents singapore,0,https://deliverypdf.ssrn.com/delivery.php?ID=617022022121092094086027010072080028016053089047061003065024085088085103029008067066100029017023042116110120107115089113127089012054046028049083085079116102089126101062069008103126064097106117117104089064102090071103116006004079007104098074075127020001&EXT=pdf&INDEX=TRUE,69,69,Singapore,Singapore delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,12,18,,0,,,,0.54,0.45,0.63,0,0,,18,22,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 17+ weeks will be included as 18-22 for sake of the analysis,han20
,0,1003,Chiew C,SSRN- Pfizer VE adolescents singapore,0,https://deliverypdf.ssrn.com/delivery.php?ID=617022022121092094086027010072080028016053089047061003065024085088085103029008067066100029017023042116110120107115089113127089012054046028049083085079116102089126101062069008103126064097106117117104089064102090071103116006004079007104098074075127020001&EXT=pdf&INDEX=TRUE,69,69,Singapore,Singapore delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",all PCR-confirmed COVID-19 infection that presented with symptoms at the time of testing,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,18,,0,,,,0.8,0.7,0.87,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 17+ weeks will be included as 18-22 for sake of the analysis,han20
,0,1003,Chiew C,SSRN- Pfizer VE adolescents singapore,0,https://deliverypdf.ssrn.com/delivery.php?ID=617022022121092094086027010072080028016053089047061003065024085088085103029008067066100029017023042116110120107115089113127089012054046028049083085079116102089126101062069008103126064097106117117104089064102090071103116006004079007104098074075127020001&EXT=pdf&INDEX=TRUE,69,69,Singapore,Singapore delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",all PCR-confirmed COVID-19 infection that presented with symptoms at the time of testing,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,18,,0,,,,0.63,0.57,0.69,0,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 17+ weeks will be included as 18-22 for sake of the analysis,han20
,0,1003,Chiew C,SSRN- Pfizer VE adolescents singapore,0,https://deliverypdf.ssrn.com/delivery.php?ID=617022022121092094086027010072080028016053089047061003065024085088085103029008067066100029017023042116110120107115089113127089012054046028049083085079116102089126101062069008103126064097106117117104089064102090071103116006004079007104098074075127020001&EXT=pdf&INDEX=TRUE,69,69,Singapore,Singapore delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",all PCR-confirmed COVID-19 infection that presented with symptoms at the time of testing,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,18,,0,,,,0.62,0.57,0.67,0,0,,10,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 17+ weeks will be included as 18-22 for sake of the analysis,han20
,0,1003,Chiew C,SSRN- Pfizer VE adolescents singapore,0,https://deliverypdf.ssrn.com/delivery.php?ID=617022022121092094086027010072080028016053089047061003065024085088085103029008067066100029017023042116110120107115089113127089012054046028049083085079116102089126101062069008103126064097106117117104089064102090071103116006004079007104098074075127020001&EXT=pdf&INDEX=TRUE,69,69,Singapore,Singapore delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",all PCR-confirmed COVID-19 infection that presented with symptoms at the time of testing,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,18,,0,,,,0.56,0.5,0.63,0,0,,14,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 17+ weeks will be included as 18-22 for sake of the analysis,han20
,0,1003,Chiew C,SSRN- Pfizer VE adolescents singapore,0,https://deliverypdf.ssrn.com/delivery.php?ID=617022022121092094086027010072080028016053089047061003065024085088085103029008067066100029017023042116110120107115089113127089012054046028049083085079116102089126101062069008103126064097106117117104089064102090071103116006004079007104098074075127020001&EXT=pdf&INDEX=TRUE,69,69,Singapore,Singapore delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",all PCR-confirmed COVID-19 infection that presented with symptoms at the time of testing,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,18,,0,,,,0.53,0.05,0.78,0,0,,18,22,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 17+ weeks will be included as 18-22 for sake of the analysis,han20
,0,537,Prunas O,medrix- Pfizer VE adolescents Israel,0,https://www.medrxiv.org/content/10.1101/2022.01.04.22268776v1.full.pdf,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,12,16,,0,,,,0.52,0.489,0.552,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 25+ weeks will be included as 26-30 for sake of the analysis,han20
,0,537,Prunas O,medrix- Pfizer VE adolescents Israel,0,https://www.medrxiv.org/content/10.1101/2022.01.04.22268776v1.full.pdf,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,12,16,,0,,,,0.85,0.84,0.864,0,0,,2,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 25+ weeks will be included as 26-30 for sake of the analysis,han20
,0,537,Prunas O,medrix- Pfizer VE adolescents Israel,0,https://www.medrxiv.org/content/10.1101/2022.01.04.22268776v1.full.pdf,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,12,16,,0,,,,0.75,0.71,0.79,0,0,,13,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 25+ weeks will be included as 26-30 for sake of the analysis,han20
,0,537,Prunas O,medrix- Pfizer VE adolescents Israel,0,https://www.medrxiv.org/content/10.1101/2022.01.04.22268776v1.full.pdf,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,12,16,,0,,,,0.586,0.526,0.64,0,0,,22,26,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 21+ weeks will be included as 22-26 for sake of the analysis,han20
,0,537,Prunas O,medrix- Pfizer VE adolescents Israel,0,https://www.medrxiv.org/content/10.1101/2022.01.04.22268776v1.full.pdf,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,"Mild, Moderate + severe",all PCR-confirmed COVID-19 infection that presented with symptoms at the time of testing,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,16,,0,,,,0.556,0.516,0.593,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 25+ weeks will be included as 26-30 for sake of the analysis,han20
,0,537,Prunas O,medrix- Pfizer VE adolescents Israel,0,https://www.medrxiv.org/content/10.1101/2022.01.04.22268776v1.full.pdf,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.7,,"Mild, Moderate + severe",all PCR-confirmed COVID-19 infection that presented with symptoms at the time of testing,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,16,,0,,,,0.9,0.89,0.91,0,0,,2,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 25+ weeks will be included as 26-30 for sake of the analysis,han20
,0,537,Prunas O,medrix- Pfizer VE adolescents Israel,0,https://www.medrxiv.org/content/10.1101/2022.01.04.22268776v1.full.pdf,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",all PCR-confirmed COVID-19 infection that presented with symptoms at the time of testing,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,16,,0,,,,0.78,0.727,0.82,0,0,,13,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 25+ weeks will be included as 26-30 for sake of the analysis,han20
,0,537,Prunas O,medrix- Pfizer VE adolescents Israel,0,https://www.medrxiv.org/content/10.1101/2022.01.04.22268776v1.full.pdf,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",all PCR-confirmed COVID-19 infection that presented with symptoms at the time of testing,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,16,,0,,,,0.646,0.57,0.703,0,0,,22,26,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,the study time ended at 21+ weeks will be included as 22-26 for sake of the analysis,han20
,0,538,Petras M,Pfizer VE Czech cohort study 8 months follow up,0,https://www.mdpi.com/2076-393X/10/1/9/htm#app1-vaccines-10-00009,47,47,Czechia,Czech delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,30,60,,0,,,,0.962,0.916,0.987,0,0,,0,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start  <= 30, Age end >= 60.",han20
,0,538,Petras M,Pfizer VE Czech cohort study 8 months follow up,0,https://www.mdpi.com/2076-393X/10/1/9/htm#app1-vaccines-10-00009,47,47,Czechia,Czech delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,30,60,,0,,,,0.902,0.815,0.957,0,0,,4,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start  <= 30, Age end >= 60.",han20
,0,538,Petras M,Pfizer VE Czech cohort study 8 months follow up,0,https://www.mdpi.com/2076-393X/10/1/9/htm#app1-vaccines-10-00009,47,47,Czechia,Czech delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,30,60,,0,,,,0.754,0.408,0.942,0,0,,8,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start  <= 30, Age end >= 60.",han20
,0,538,Petras M,Pfizer VE Czech cohort study 8 months follow up,0,https://www.mdpi.com/2076-393X/10/1/9/htm#app1-vaccines-10-00009,47,47,Czechia,Czech delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection regardless of symptoms,infection,infection,,1,1,1,1,3,30,60,,0,,,,0.65,0,0.966,0,0,,14,23,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age start  <= 30, Age end >= 60.",han20
,0,1004,Bruxvoort K,BMJ- KPSC delta VE,0,https://www.bmj.com/content/375/bmj-2021-068848,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.941,0.905,0.963,0,0,,2,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 75.,han20
,0,1004,Bruxvoort K,BMJ- KPSC delta VE,0,https://www.bmj.com/content/375/bmj-2021-068848,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.887,0.85,0.915,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 75.,han20
,0,1004,Bruxvoort K,BMJ- KPSC delta VE,0,https://www.bmj.com/content/375/bmj-2021-068848,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.859,0.811,0.895,0,0,,13,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 75.,han20
,0,1004,Bruxvoort K,BMJ- KPSC delta VE,0,https://www.bmj.com/content/375/bmj-2021-068848,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.77,0.691,0.829,0,0,,18,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 75.,han20
,0,1004,Bruxvoort K,BMJ- KPSC delta VE,0,https://www.bmj.com/content/375/bmj-2021-068848,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,all PCR-confirmed COVID-19 infection,infection,infection,,1,1,1,1,3,18,75,,0,,,,0.8,0.702,0.866,0,0,,22,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >= 75.,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,5,11,,0,,,,0.68,0.63,0.72,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,5,11,,0,,,,0.57,0.55,0.6,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,5,11,,0,,,,0.5,0.48,0.52,0,0,,4,5,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,5,11,,0,,,,0.48,0.47,0.5,0,0,,6,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,5,11,,0,,,,0.34,0.31,0.36,0,0,,8,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,5,11,,0,,,,0.2,0.16,0.23,0,0,,10,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,5,11,,0,,,,0.2,0.06,0.16,0,0,,12,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,12,17,,0,,,,0.85,0.84,0.86,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,12,17,,0,,,,0.82,0.81,0.83,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,12,17,,0,,,,0.66,0.64,0.67,0,0,,4,5,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,12,17,,0,,,,0.57,0.56,0.58,0,0,,6,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,12,17,,0,,,,0.55,0.54,0.56,0,0,,8,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,12,17,,0,,,,0.53,0.52,0.54,0,0,,10,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,12,17,,0,,,,0.5,0.48,0.51,0,0,,12,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,12,17,,0,,,,0.5,0.48,0.52,0,0,,14,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,infection,"COVID-19 cases, defined as positive NAAT or antigen results reported to ECLRS",infection,infection,,1,1,1,1,3,12,17,,0,,,,0.51,0.48,0.54,0,0,,16,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,5,11,,0,,,,0.99,-1.89,0.99,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,5,11,,0,,,,0.73,-0.07,0.97,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,5,11,,0,,,,0.82,0.45,0.96,0,0,,4,5,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,5,11,,0,,,,0.74,0.36,0.96,0,0,,6,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,5,11,,0,,,,0.68,0.28,0.91,0,0,,8,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,5,11,,0,,,,0.46,-0.15,0.77,0,0,,10,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,5,11,,0,,,,0.48,-0.12,0.75,0,0,,12,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,12,17,,0,,,,0.94,0.76,0.99,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,12,17,,0,,,,0.95,0.64,0.99,0,0,,2,3,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,12,17,,0,,,,0.85,0.63,0.95,0,0,,4,5,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,12,17,,0,,,,0.78,0.63,0.88,0,0,,6,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,12,17,,0,,,,0.74,0.61,0.84,0,0,,8,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,12,17,,0,,,,0.74,0.63,0.82,0,0,,10,11,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,12,17,,0,,,,0.75,0.64,0.86,0,0,,12,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,12,17,,0,,,,0.75,0.61,0.83,0,0,,14,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,540,Dorabawila V,medrix- Omicron VE among children 5-11 and 12-17 New York,0,https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1.full.pdf,102,102,United States,US Omicron hosp 12-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,New COVID-19 admissions as reported in HERDS,hosp,severe,,1,0,0,0,3,12,17,,0,,,,0.73,0.53,0.87,0,0,,16,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090192,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.882,0.855,0.884,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090193,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.777,0.763,0.79,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090194,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.722,0.71,0.734,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090195,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.648,0.626,0.669,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090196,95,95,United Kingdom,UK delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.635,0.614,0.655,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090197,95,95,United Kingdom,UK delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.762,0.637,0.844,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090198,95,95,United Kingdom,UK delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.649,0.552,0.724,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090199,95,95,United Kingdom,UK delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.485,0.447,0.52,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090200,95,95,United Kingdom,UK delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.454,0.43,0.476,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090201,95,95,United Kingdom,UK delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.418,0.394,0.441,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090192,95,95,United Kingdom,UK Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.88,0.659,0.958,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090193,95,95,United Kingdom,UK Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.485,0.243,0.65,0,0,,10,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090194,95,95,United Kingdom,UK Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.341,0.097,0.52,0,0,,15,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090195,95,95,United Kingdom,UK Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.366,0.04,0.596,0,0,,20,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,1,541,Andrews N,NEJM- UKHSA VE Omicron vs delta,0,https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/573844935?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%3A%2F%2Fkhub.net%3A443%2Fweb%2Fphe-national%2Fpublic-library%2F-%2Fdocument_library%2Fv2WsRK3ZlEig%2Fview%2F430986542%3F_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect%3Dhttps%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%252Fdocument_library%252Fv2WsRK3ZlEig%252Fview%252F174090196,95,95,United Kingdom,UK Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe","Positive SARS-CoV-2 Testing Polymerase-chain-reaction (PCR) to anyone with symptoms consistent with COVID-19 (high temperature, new continuous cough, or loss or change in sense of smell or taste)",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,60,,0,,,,0.342,-0.05,0.587,0,0,,25,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=60, last interval was included as 25+ in the study we specified the end as 29 weeks for sake of the analysis",han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,16,39,,0,,,,0.8,0.75,0.84,0,0,,6,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,16,39,,0,,,,0.77,0.74,0.8,0,0,,10,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,16,39,,0,,,,0.7,0.68,0.73,0,0,,14,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,16,39,,0,,,,0.66,0.63,0.68,0,0,,17,22,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,16,39,,0,,,,0.62,0.59,0.65,0,0,,19,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,16,39,,0,,,,0.52,0.48,0.57,0,0,,21,26,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,16,39,,0,,,,0.55,0.5,0.6,0,0,,23,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,40,59,,0,,,,0.83,0.75,0.88,0,0,,6,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,40,59,,0,,,,0.79,0.74,0.82,0,0,,10,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,40,59,,0,,,,0.73,0.7,0.77,0,0,,14,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,40,59,,0,,,,0.66,0.63,0.7,0,0,,17,22,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,40,59,,0,,,,0.63,0.59,0.66,0,0,,19,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,40,59,,0,,,,0.61,0.57,0.64,0,0,,21,26,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,40,59,,0,,,,0.57,0.53,0.61,0,0,,23,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.82,0.7,0.89,0,0,,6,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.81,0.73,0.86,0,0,,10,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.73,0.67,0.79,0,0,,14,19,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.74,0.68,0.79,0,0,,17,22,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.67,0.59,0.73,0,0,,19,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.63,0.58,0.67,0,0,,21,26,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,documented SARS-CoV-2 infections 7 days after receipt of the second dose of the Covid-19 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.57,0.52,0.62,0,0,,23,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta severe,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths due to covid 19,death,severe,,1,0,0,0,3,40,59,,0,,,,0.98,0.94,0.99,0,0,,14,22,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta severe,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths due to covid 19,death,severe,,1,0,0,0,3,40,59,,0,,,,0.96,0.93,0.98,0,0,,19,26,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta severe,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths due to covid 19,death,severe,,1,0,0,0,3,40,59,,0,,,,0.93,0.86,0.97,0,0,,23,30,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta severe,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths due to covid 19,death,severe,,1,0,0,0,3,60,90,,0,,,,0.92,0.87,0.95,0,0,,14,22,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta severe,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths due to covid 19,death,severe,,1,0,0,0,3,60,90,,0,,,,0.88,0.84,0.91,0,0,,19,26,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,542,Goldberg Y,NEJM- Delta VE in elderly,0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609604/,85,85,Israel,Israel delta severe,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths due to covid 19,death,severe,,1,0,0,0,3,60,90,,0,,,,0.85,0.81,0.88,0,0,,23,30,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age start >= 60,han20
,0,543,Klein N,MMWR- adolescents VE delta vs omicron,0,cdc.gov/mmwr/volumes/71/wr/mm7109e3.htm?s_cid=mm7109e3_w,102,102,United States,US Omicron 5-11,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",ED or UC presentations with Covid 19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,5,11,,0,,,,0.51,0.3,0.65,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period interval ends at 150+ days included as 22-32 weeks for sake of the analysis,han20
,0,543,Klein N,MMWR- adolescents VE delta vs omicron,0,cdc.gov/mmwr/volumes/71/wr/mm7109e3.htm?s_cid=mm7109e3_w,102,102,United States,US Omicron 12-15,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",ED or UC presentations with Covid 19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,15,,0,,,,0.45,0.3,0.57,0,0,,2,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period interval ends at 150+ days included as 22-32 weeks for sake of the analysis,han20
,0,543,Klein N,MMWR- adolescents VE delta vs omicron,0,cdc.gov/mmwr/volumes/71/wr/mm7109e3.htm?s_cid=mm7109e3_w,102,102,United States,US Omicron 12-15,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",ED or UC presentations with Covid 19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,15,,0,,,,-0.02,-0.25,0.17,0,0,,22,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period interval ends at 150+ days included as 22-32 weeks for sake of the analysis,han20
,0,543,Klein N,MMWR- adolescents VE delta vs omicron,0,cdc.gov/mmwr/volumes/71/wr/mm7109e3.htm?s_cid=mm7109e3_w,102,102,United States,US Omicron 16-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",ED or UC presentations with Covid 19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,17,,0,,,,0.34,0.08,0.53,0,0,,2,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period interval ends at 150+ days included as 22-32 weeks for sake of the analysis,han20
,0,543,Klein N,MMWR- adolescents VE delta vs omicron,0,cdc.gov/mmwr/volumes/71/wr/mm7109e3.htm?s_cid=mm7109e3_w,102,102,United States,US Omicron 16-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",ED or UC presentations with Covid 19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,17,,0,,,,-0.03,-0.3,0.18,0,0,,22,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period interval ends at 150+ days included as 22-32 weeks for sake of the analysis,han20
,0,543,Klein N,MMWR- adolescents VE delta vs omicron,0,cdc.gov/mmwr/volumes/71/wr/mm7109e3.htm?s_cid=mm7109e3_w,102,102,United States,US delta 12-15,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",ED or UC presentations with Covid 19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,15,,0,,,,0.92,0.89,0.94,0,0,,2,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period interval ends at 150+ days included as 22-32 weeks for sake of the analysis,han20
,0,543,Klein N,MMWR- adolescents VE delta vs omicron,0,cdc.gov/mmwr/volumes/71/wr/mm7109e3.htm?s_cid=mm7109e3_w,102,102,United States,US delta 12-15,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",ED or UC presentations with Covid 19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,15,,0,,,,0.79,0.68,0.86,0,0,,22,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period interval ends at 150+ days included as 22-32 weeks for sake of the analysis,han20
,0,543,Klein N,MMWR- adolescents VE delta vs omicron,0,cdc.gov/mmwr/volumes/71/wr/mm7109e3.htm?s_cid=mm7109e3_w,102,102,United States,US delta 16-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",ED or UC presentations with Covid 19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,17,,0,,,,0.85,0.81,0.89,0,0,,2,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period interval ends at 150+ days included as 22-32 weeks for sake of the analysis,han20
,0,543,Klein N,MMWR- adolescents VE delta vs omicron,0,cdc.gov/mmwr/volumes/71/wr/mm7109e3.htm?s_cid=mm7109e3_w,102,102,United States,US delta 16-17,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",ED or UC presentations with Covid 19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,17,,0,,,,0.77,0.67,0.84,0,0,,22,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period interval ends at 150+ days included as 22-32 weeks for sake of the analysis,han20
,0,543,Klein N,MMWR- adolescents VE delta vs omicron,0,cdc.gov/mmwr/volumes/71/wr/mm7109e3.htm?s_cid=mm7109e3_w,102,102,United States,US Omicron booster 16-17,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",ED or UC presentations with Covid 19,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,16,17,,0,,,,0.81,0.59,0.91,1,0,,1,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,interval is 7+ days included as 1-12 weeks for sake of the analysis,han20
,0,544,Ranzani O,CMI- Brazil AstraZeneca VE,0,https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00056-8/fulltext,135,135,Brazil,Brazil delta and gamma,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2 & P.1,,infection,positive covid 19 pcr regardless of symptoms,infection,infection,,1,1,1,1,3,,,,0,,,,0.179,-0.439,0.531,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,interval is 14+ days included as 3-42 weeks for sake of the analysis,han20
,0,544,Ranzani O,CMI- Brazil AstraZeneca VE,0,https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00056-8/fulltext,135,135,Brazil,Brazil delta and gamma,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2 & P.1,,infection,positive covid 19 pcr regardless of symptoms,infection,infection,,1,1,1,1,3,,,,0,,,,0.59,0.331,0.748,0,0,,3,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,interval is 14+ days included as 3-42 weeks for sake of the analysis,han20
,0,544,Ranzani O,CMI- Brazil AstraZeneca VE,0,https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00056-8/fulltext,135,135,Brazil,Brazil delta and gamma,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2 & P.1,,"Mild, Moderate + severe",postiive covid 19 pcr accompanied with covid 19 symptoms,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,,,,0,,,,0.331,-0.271,0.648,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,interval is 14+ days included as 3-42 weeks for sake of the analysis,han20
,0,544,Ranzani O,CMI- Brazil AstraZeneca VE,0,https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00056-8/fulltext,135,135,Brazil,Brazil delta and gamma,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2 & P.1,,"Mild, Moderate + severe",postiive covid 19 pcr accompanied with covid 19 symptoms,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,,,,0,,,,0.651,0.409,0.794,0,0,,3,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,interval is 14+ days included as 3-42 weeks for sake of the analysis,han20
,0,545,Baum U,medrix- Finland VE in eldrely,0,https://www.medrxiv.org/content/10.1101/2022.03.11.22272140v1.full.pdf,79,79,Finland,Finland delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19-related hospital admission timely associated with a laboratoryconfirmed (by polymerase chain reaction or antigen detection assay) SARS-CoV-2 infection,hosp,severe,,1,0,0,0,3,70,115,,0,,,,0.9,0.778,0.96,0,0,,2,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,interval ends at 25+ weeks however period is included as 25_38 for sake of the analysis,han20
,0,545,Baum U,medrix- Finland VE in eldrely,0,https://www.medrxiv.org/content/10.1101/2022.03.11.22272140v1.full.pdf,79,79,Finland,Finland delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19-related hospital admission timely associated with a laboratoryconfirmed (by polymerase chain reaction or antigen detection assay) SARS-CoV-2 infection,hosp,severe,,1,0,0,0,3,70,115,,0,,,,0.887,0.857,0.913,0,0,,13,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,interval ends at 25+ weeks however period is included as 25_38 for sake of the analysis,han20
,0,545,Baum U,medrix- Finland VE in eldrely,0,https://www.medrxiv.org/content/10.1101/2022.03.11.22272140v1.full.pdf,79,79,Finland,Finland delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19-related hospital admission timely associated with a laboratoryconfirmed (by polymerase chain reaction or antigen detection assay) SARS-CoV-2 infection,hosp,severe,,1,0,0,0,3,70,115,,0,,,,0.787,0.713,0.842,0,0,,26,38,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,interval ends at 25+ weeks however period is included as 25_38 for sake of the analysis,han20
,0,545,Baum U,medrix- Finland VE in eldrely,0,https://www.medrxiv.org/content/10.1101/2022.03.11.22272140v1.full.pdf,79,79,Finland,Finland booster delta hosp,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19-related hospital admission timely associated with a laboratoryconfirmed (by polymerase chain reaction or antigen detection assay) SARS-CoV-2 infection,hosp,severe,,1,0,0,0,3,70,115,,0,,,,0.96,0.93,0.984,1,0,,2,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,interval ends at 8+ weeks however period is included as 9_17 for sake of the analysis,han20
,0,545,Baum U,medrix- Finland VE in eldrely,0,https://www.medrxiv.org/content/10.1101/2022.03.11.22272140v1.full.pdf,79,79,Finland,Finland booster delta hosp,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19-related hospital admission timely associated with a laboratoryconfirmed (by polymerase chain reaction or antigen detection assay) SARS-CoV-2 infection,hosp,severe,,1,0,0,0,3,70,115,,0,,,,0.93,0.714,0.98,1,0,,9,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,interval ends at 8+ weeks however period is included as 9_17 for sake of the analysis,han20
,0,545,Baum U,medrix- Finland VE in eldrely,0,https://www.medrxiv.org/content/10.1101/2022.03.11.22272140v1.full.pdf,79,79,Finland,Finland Omicron hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,Covid-19-related hospital admission timely associated with a laboratoryconfirmed (by polymerase chain reaction or antigen detection assay) SARS-CoV-2 infection,hosp,severe,,1,0,0,0,3,70,115,,0,,,,0.91,0.797,0.96,0,0,,2,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,interval ends at 25+ weeks however period is included as 25_38 for sake of the analysis,han20
,0,545,Baum U,medrix- Finland VE in eldrely,0,https://www.medrxiv.org/content/10.1101/2022.03.11.22272140v1.full.pdf,79,79,Finland,Finland Omicron hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,Covid-19-related hospital admission timely associated with a laboratoryconfirmed (by polymerase chain reaction or antigen detection assay) SARS-CoV-2 infection,hosp,severe,,1,0,0,0,3,70,115,,0,,,,0.759,0.56,0.86,0,0,,13,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,interval ends at 25+ weeks however period is included as 25_38 for sake of the analysis,han20
,0,545,Baum U,medrix- Finland VE in eldrely,0,https://www.medrxiv.org/content/10.1101/2022.03.11.22272140v1.full.pdf,79,79,Finland,Finland Omicron hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,Covid-19-related hospital admission timely associated with a laboratoryconfirmed (by polymerase chain reaction or antigen detection assay) SARS-CoV-2 infection,hosp,severe,,1,0,0,0,3,70,115,,0,,,,0.612,0.48,0.709,0,0,,26,38,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,interval ends at 25+ weeks however period is included as 25_38 for sake of the analysis,han20
,0,545,Baum U,medrix- Finland VE in eldrely,0,https://www.medrxiv.org/content/10.1101/2022.03.11.22272140v1.full.pdf,79,79,Finland,Finland booster Omicron hosp,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,Covid-19-related hospital admission timely associated with a laboratoryconfirmed (by polymerase chain reaction or antigen detection assay) SARS-CoV-2 infection,hosp,severe,,1,0,0,0,3,70,115,,0,,,,0.956,0.939,0.98,1,0,,2,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,interval ends at 8+ weeks however period is included as 9_17 for sake of the analysis,han20
,0,545,Baum U,medrix- Finland VE in eldrely,0,https://www.medrxiv.org/content/10.1101/2022.03.11.22272140v1.full.pdf,79,79,Finland,Finland booster Omicron hosp,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,Covid-19-related hospital admission timely associated with a laboratoryconfirmed (by polymerase chain reaction or antigen detection assay) SARS-CoV-2 infection,hosp,severe,,1,0,0,0,3,70,115,,0,,,,0.903,0.87,0.932,1,0,,9,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,interval ends at 8+ weeks however period is included as 9_17 for sake of the analysis,han20
,0,546,Patalon T,JAMA- Israel booster efficacy,0,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786890,85,85,Israel,Israel booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,positive PCR test result for SARS-CoV-2,infection,infection,,1,1,1,1,3,40,80,,0,,,,0.123,0.078,0.164,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,546,Patalon T,JAMA- Israel booster efficacy,0,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786890,85,85,Israel,Israel booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,positive PCR test result for SARS-CoV-3,infection,infection,,1,1,1,1,3,40,80,,0,,,,0.584,0.556,0.61,1,0,,1,2,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,546,Patalon T,JAMA- Israel booster efficacy,0,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786890,85,85,Israel,Israel booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,positive PCR test result for SARS-CoV-4,infection,infection,,1,1,1,1,3,40,80,,0,,,,0.848,0.83,0.86,1,0,,2,3,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,546,Patalon T,JAMA- Israel booster efficacy,0,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786890,85,85,Israel,Israel booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,positive PCR test result for SARS-CoV-5,infection,infection,,1,1,1,1,3,40,80,,0,,,,0.847,0.835,0.864,1,0,,3,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,546,Patalon T,JAMA- Israel booster efficacy,0,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786890,85,85,Israel,Israel booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,positive PCR test result for SARS-CoV-6,infection,infection,,1,1,1,1,3,40,80,,0,,,,0.861,0.85,0.872,1,0,,4,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,546,Patalon T,JAMA- Israel booster efficacy,0,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786890,85,85,Israel,Israel booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Hospitalization due to covid 19,hosp,severe,,1,0,0,0,3,40,80,,0,,,,0.87,0.8,0.91,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,546,Patalon T,JAMA- Israel booster efficacy,0,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786890,85,85,Israel,Israel booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Hospitalization due to covid 20,hosp,severe,,1,0,0,0,3,40,80,,0,,,,0.91,0.86,0.94,1,0,,1,2,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,546,Patalon T,JAMA- Israel booster efficacy,0,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786890,85,85,Israel,Israel booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Hospitalization due to covid 21,hosp,severe,,1,0,0,0,3,40,80,,0,,,,0.92,0.87,0.95,1,0,,2,3,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,546,Patalon T,JAMA- Israel booster efficacy,0,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786890,85,85,Israel,Israel booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Hospitalization due to covid 22,hosp,severe,,1,0,0,0,3,40,80,,0,,,,0.96,0.92,0.98,1,0,,3,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,546,Patalon T,JAMA- Israel booster efficacy,0,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786890,85,85,Israel,Israel booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Hospitalization due to covid 23,hosp,severe,,1,0,0,0,3,40,80,,0,,,,0.97,0.95,0.98,1,0,,4,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 80.,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",RT–PCR positivity and split according to self-reported symptoms,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,64,,0,,,,0.93,0.89,0.96,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",RT–PCR positivity and split according to self-reported symptoms,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,64,,0,,,,0.92,0.87,0.95,0,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",RT–PCR positivity and split according to self-reported symptoms,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,64,,0,,,,0.86,0.82,0.9,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",RT–PCR positivity and split according to self-reported symptoms,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,64,,0,,,,0.78,0.72,0.82,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,positive pcr for covid 19 regardless of symptoms,infection,infection,,1,1,1,1,3,18,64,,0,,,,0.85,0.79,0.9,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,positive pcr for covid 19 regardless of symptoms,infection,infection,,1,1,1,1,3,18,64,,0,,,,0.83,0.78,0.88,0,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,positive pcr for covid 19 regardless of symptoms,infection,infection,,1,1,1,1,3,18,64,,0,,,,0.8,0.76,0.83,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,positive pcr for covid 19 regardless of symptoms,infection,infection,,1,1,1,1,3,18,64,,0,,,,0.75,0.7,0.8,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",RT–PCR positivity and split according to self-reported symptoms,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,64,,0,,,,0.72,0.64,0.78,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",RT–PCR positivity and split according to self-reported symptoms,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,64,,0,,,,0.7,0.64,0.76,0,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",RT–PCR positivity and split according to self-reported symptoms,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,64,,0,,,,0.67,0.6,0.72,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",RT–PCR positivity and split according to self-reported symptoms,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,64,,0,,,,0.63,0.53,0.71,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,positive pcr for covid 19 regardless of symptoms,infection,infection,,1,1,1,1,3,18,64,,0,,,,0.68,0.61,0.73,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,positive pcr for covid 19 regardless of symptoms,infection,infection,,1,1,1,1,3,18,64,,0,,,,0.66,0.61,0.71,0,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,positive pcr for covid 19 regardless of symptoms,infection,infection,,1,1,1,1,3,18,64,,0,,,,0.64,0.58,0.69,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1005,Pouwels K,Nature- UK VE Delta,0,https://www-nature-com.offcampus.lib.washington.edu/articles/s41591-021-01548-7#Tab3,95,95,United Kingdom,UK 5 delta,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,positive pcr for covid 19 regardless of symptoms,infection,infection,,1,1,1,1,3,18,64,,0,,,,0.61,0.53,0.68,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,548,Moriera E,NEJM- RCT Booster dose efficacy,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2200674,"102, 135, 196","102, 135, 196","United States, Brazil, South Africa",Mix Country booster Efficacy,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,laboratory-confirmed Covid-19 beginning at least 7 days after the administration of dose 3,infection,infection,,1,1,1,1,3,16,65,,0,,,,0.473,-0.323,0.807,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 65,han20
,0,548,Moriera E,NEJM- RCT Booster dose efficacy,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2200674,"102, 135, 196","102, 135, 196","United States, Brazil, South Africa",Mix Country booster Efficacy,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,laboratory-confirmed Covid-19 beginning at least 7 days after the administration of dose 3,infection,infection,,1,1,1,1,3,16,65,,0,,,,0.948,0.84,0.981,1,0,,2,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 65,han20
,0,548,Moriera E,NEJM- RCT Booster dose efficacy,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2200674,"102, 135, 196","102, 135, 196","United States, Brazil, South Africa",Mix Country booster Efficacy,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,laboratory-confirmed Covid-19 beginning at least 7 days after the administration of dose 3,infection,infection,,1,1,1,1,3,16,65,,0,,,,0.933,0.561,0.998,1,0,,5,8,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >= 65,han20
,0,549,Veneti L,medrix- VE Norway Delta vs Omicron,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272854v1,90,90,Norway,Norway Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,We defined SARS-CoV-2 infection as a positive SARS-CoV-2 PCR test reported to the Norwegian Surveillance System for Communicable Diseases (MSIS) registry. We use testing date as time of infection (positive PCR test). Both symptomatic and asymptomatic reported cases have been included as it is not possible to distinguish between these in MSIS,infection,infection,,1,1,1,1,3,16,17,,0,,,,0.508,0.43,0.583,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Analysis period end >= 63 days. included as 9-14 weeks for sake of the analysis,han20
,0,549,Veneti L,medrix- VE Norway Delta vs Omicron,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272854v1,90,90,Norway,Norway Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,We defined SARS-CoV-2 infection as a positive SARS-CoV-2 PCR test reported to the Norwegian Surveillance System for Communicable Diseases (MSIS) registry. We use testing date as time of infection (positive PCR test). Both symptomatic and asymptomatic reported cases have been included as it is not possible to distinguish between these in MSIS,infection,infection,,1,1,1,1,3,16,17,,0,,,,0.902,0.864,0.94,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Analysis period end >= 63 days. included as 9-14 weeks for sake of the analysis,han20
,0,549,Veneti L,medrix- VE Norway Delta vs Omicron,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272854v1,90,90,Norway,Norway Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,We defined SARS-CoV-2 infection as a positive SARS-CoV-2 PCR test reported to the Norwegian Surveillance System for Communicable Diseases (MSIS) registry. We use testing date as time of infection (positive PCR test). Both symptomatic and asymptomatic reported cases have been included as it is not possible to distinguish between these in MSIS,infection,infection,,1,1,1,1,3,16,17,,0,,,,0.92,0.89,0.953,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Analysis period end >= 63 days. included as 9-14 weeks for sake of the analysis,han20
,0,549,Veneti L,medrix- VE Norway Delta vs Omicron,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272854v1,90,90,Norway,Norway Delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,We defined SARS-CoV-2 infection as a positive SARS-CoV-2 PCR test reported to the Norwegian Surveillance System for Communicable Diseases (MSIS) registry. We use testing date as time of infection (positive PCR test). Both symptomatic and asymptomatic reported cases have been included as it is not possible to distinguish between these in MSIS,infection,infection,,1,1,1,1,3,16,17,,0,,,,0.825,0.75,0.882,0,0,,9,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Analysis period end >= 63 days. included as 9-14 weeks for sake of the analysis,han20
,0,549,Veneti L,medrix- VE Norway Delta vs Omicron,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272854v1,90,90,Norway,Norway Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,We defined SARS-CoV-2 infection as a positive SARS-CoV-2 PCR test reported to the Norwegian Surveillance System for Communicable Diseases (MSIS) registry. We use testing date as time of infection (positive PCR test). Both symptomatic and asymptomatic reported cases have been included as it is not possible to distinguish between these in MSIS,infection,infection,,1,1,1,1,3,16,17,,0,,,,0.1,-0.55,0.47,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Analysis period end >= 63 days. included as 9-14 weeks for sake of the analysis,han20
,0,549,Veneti L,medrix- VE Norway Delta vs Omicron,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272854v1,90,90,Norway,Norway Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,We defined SARS-CoV-2 infection as a positive SARS-CoV-2 PCR test reported to the Norwegian Surveillance System for Communicable Diseases (MSIS) registry. We use testing date as time of infection (positive PCR test). Both symptomatic and asymptomatic reported cases have been included as it is not possible to distinguish between these in MSIS,infection,infection,,1,1,1,1,3,16,17,,0,,,,0.53,0.426,0.622,0,0,,2,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Analysis period end >= 63 days. included as 9-14 weeks for sake of the analysis,han20
,0,549,Veneti L,medrix- VE Norway Delta vs Omicron,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272854v1,90,90,Norway,Norway Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,We defined SARS-CoV-2 infection as a positive SARS-CoV-2 PCR test reported to the Norwegian Surveillance System for Communicable Diseases (MSIS) registry. We use testing date as time of infection (positive PCR test). Both symptomatic and asymptomatic reported cases have been included as it is not possible to distinguish between these in MSIS,infection,infection,,1,1,1,1,3,16,17,,0,,,,0.46,0.35,0.55,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Analysis period end >= 63 days. included as 9-14 weeks for sake of the analysis,han20
,0,549,Veneti L,medrix- VE Norway Delta vs Omicron,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272854v1,90,90,Norway,Norway Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,We defined SARS-CoV-2 infection as a positive SARS-CoV-2 PCR test reported to the Norwegian Surveillance System for Communicable Diseases (MSIS) registry. We use testing date as time of infection (positive PCR test). Both symptomatic and asymptomatic reported cases have been included as it is not possible to distinguish between these in MSIS,infection,infection,,1,1,1,1,3,16,17,,0,,,,0.23,0.02,0.4,0,0,,9,14,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Analysis period end >= 63 days. included as 9-14 weeks for sake of the analysis,han20
,0,1006,Oliveira C,JAMA- US Adolscents delta pfizer VE,0,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789579,102,102,United States,US delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Individuals with a positive result for SARS-CoV-2 infection by RT-PCR assay of a nasopharyngeal swab were included as case participants.,infection,infection,,1,1,1,1,3,12,18,,0,,,,0.91,0.33,0.99,0,0,,1,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1006,Oliveira C,JAMA- US Adolscents delta pfizer VE,0,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789579,102,102,United States,US delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Individuals with a positive result for SARS-CoV-2 infection by RT-PCR assay of a nasopharyngeal swab were included as case participants.,infection,infection,,1,1,1,1,3,12,18,,0,,,,0.9,0.67,0.97,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1006,Oliveira C,JAMA- US Adolscents delta pfizer VE,0,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789579,102,102,United States,US delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Individuals with a positive result for SARS-CoV-2 infection by RT-PCR assay of a nasopharyngeal swab were included as case participants.,infection,infection,,1,1,1,1,3,12,18,,0,,,,0.95,0.79,0.99,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1006,Oliveira C,JAMA- US Adolscents delta pfizer VE,0,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789579,102,102,United States,US delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Individuals with a positive result for SARS-CoV-2 infection by RT-PCR assay of a nasopharyngeal swab were included as case participants.,infection,infection,,1,1,1,1,3,12,18,,0,,,,0.83,0.34,0.95,0,0,,13,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1007,Fowlkes A,MMWR- US adolscents omicron vs delta pfizer VE,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7111e1.htm?s_cid=mm7111e1_w,102,102,United States,US delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Active surveillance for SARS-CoV-2 infection and any COVID-19–associated symptoms within the preceding 7 days occurred through weekly submission of a survey and nasal swab for reverse transcription–polymerase chain reaction testing and viral whole genome sequencing.** Specific symptoms and duration, hours of school missed because of illness, and receipt of medical care were documented through the electronic surveys",infection,infection,,1,1,1,1,3,12,15,,0,,,,0.87,0.49,0.97,0,0,,2,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period ends at >150 days included as 22_32 weeks for sake of the analysis,han20
,0,1007,Fowlkes A,MMWR- US adolscents omicron vs delta pfizer VE,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7111e1.htm?s_cid=mm7111e1_w,102,102,United States,US delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"Active surveillance for SARS-CoV-2 infection and any COVID-19–associated symptoms within the preceding 7 days occurred through weekly submission of a survey and nasal swab for reverse transcription–polymerase chain reaction testing and viral whole genome sequencing.** Specific symptoms and duration, hours of school missed because of illness, and receipt of medical care were documented through the electronic surveys",infection,infection,,1,1,1,1,3,12,15,,0,,,,0.6,-0.35,0.88,0,0,,22,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period ends at >150 days included as 22_32 weeks for sake of the analysis,han20
,0,1007,Fowlkes A,MMWR- US adolscents omicron vs delta pfizer VE,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7111e1.htm?s_cid=mm7111e1_w,102,102,United States,US Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,"Active surveillance for SARS-CoV-2 infection and any COVID-19–associated symptoms within the preceding 7 days occurred through weekly submission of a survey and nasal swab for reverse transcription–polymerase chain reaction testing and viral whole genome sequencing.** Specific symptoms and duration, hours of school missed because of illness, and receipt of medical care were documented through the electronic surveys",infection,infection,,1,1,1,1,3,12,15,,0,,,,0.59,0.22,0.79,0,0,,2,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period ends at >150 days included as 22_32 weeks for sake of the analysis,han20
,0,1007,Fowlkes A,MMWR- US adolscents omicron vs delta pfizer VE,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7111e1.htm?s_cid=mm7111e1_w,102,102,United States,US Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,"Active surveillance for SARS-CoV-2 infection and any COVID-19–associated symptoms within the preceding 7 days occurred through weekly submission of a survey and nasal swab for reverse transcription–polymerase chain reaction testing and viral whole genome sequencing.** Specific symptoms and duration, hours of school missed because of illness, and receipt of medical care were documented through the electronic surveys",infection,infection,,1,1,1,1,3,12,15,,0,,,,0.62,-0.28,0.89,0,0,,22,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period ends at >150 days included as 22_32 weeks for sake of the analysis,han20
,0,1008,Price A,NEJM- adolscents VE omicron vs delta,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2202826,102,102,United States,US delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,All case patients had to have had a positive SARS-CoV-2 reverse-transcriptase–polymerase-chain-reaction (RT-PCR) or antigen test result within 10 days after symptom onset or within 72 hours after hospital admission,severe,severe,,1,0,0,0,3,12,18,,0,,,,0.93,0.89,0.95,0,0,,2,22,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1008,Price A,NEJM- adolscents VE omicron vs delta,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2202826,102,102,United States,US delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,All case patients had to have had a positive SARS-CoV-2 reverse-transcriptase–polymerase-chain-reaction (RT-PCR) or antigen test result within 10 days after symptom onset or within 72 hours after hospital admission,severe,severe,,1,0,0,0,3,12,18,,0,,,,0.92,0.8,0.97,0,0,,23,44,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1008,Price A,NEJM- adolscents VE omicron vs delta,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2202826,102,102,United States,US Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,All case patients had to have had a positive SARS-CoV-2 reverse-transcriptase–polymerase-chain-reaction (RT-PCR) or antigen test result within 10 days after symptom onset or within 72 hours after hospital admission,severe,severe,,1,0,0,0,3,12,18,,0,,,,0.43,-0.01,0.68,0,0,,2,22,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,1008,Price A,NEJM- adolscents VE omicron vs delta,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2202826,102,102,United States,US Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,All case patients had to have had a positive SARS-CoV-2 reverse-transcriptase–polymerase-chain-reaction (RT-PCR) or antigen test result within 10 days after symptom onset or within 72 hours after hospital admission,severe,severe,,1,0,0,0,3,12,18,,0,,,,0.38,-0.03,0.62,0,0,,23,44,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,553,Gazit S,medrix- Fourth dose efficacy Pfizer,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272835v1.full.pdf,85,85,Israel,Israel Omicron fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,defined as a positive PCR test performed 7 or more days after inoculation with the BNT162b2 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.5605,0.5341,0.5853,2,0,,1,2,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age start >60,han20
,0,553,Gazit S,medrix- Fourth dose efficacy Pfizer,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272835v1.full.pdf,85,85,Israel,Israel Omicron fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,defined as a positive PCR test performed 7 or more days after inoculation with the BNT162b2 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.6429,0.6173,0.6668,2,0,,2,3,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age start >60,han20
,0,553,Gazit S,medrix- Fourth dose efficacy Pfizer,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272835v1.full.pdf,85,85,Israel,Israel Omicron fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,defined as a positive PCR test performed 7 or more days after inoculation with the BNT162b2 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.6302,0.6003,0.6578,2,0,,3,4,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age start >60,han20
,0,553,Gazit S,medrix- Fourth dose efficacy Pfizer,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272835v1.full.pdf,85,85,Israel,Israel Omicron fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,defined as a positive PCR test performed 7 or more days after inoculation with the BNT162b2 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.5951,0.5563,0.6305,2,0,,4,5,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age start >60,han20
,0,553,Gazit S,medrix- Fourth dose efficacy Pfizer,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272835v1.full.pdf,85,85,Israel,Israel Omicron fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,defined as a positive PCR test performed 7 or more days after inoculation with the BNT162b2 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.5632,0.5094,0.6111,2,0,,5,6,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age start >60,han20
,0,553,Gazit S,medrix- Fourth dose efficacy Pfizer,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272835v1.full.pdf,85,85,Israel,Israel Omicron fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,defined as a positive PCR test performed 7 or more days after inoculation with the BNT162b2 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.4902,0.4104,0.5592,2,0,,6,7,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age start >60,han20
,0,553,Gazit S,medrix- Fourth dose efficacy Pfizer,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272835v1.full.pdf,85,85,Israel,Israel Omicron fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,defined as a positive PCR test performed 7 or more days after inoculation with the BNT162b2 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.4193,0.3156,0.5072,2,0,,7,8,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age start >60,han20
,0,553,Gazit S,medrix- Fourth dose efficacy Pfizer,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272835v1.full.pdf,85,85,Israel,Israel Omicron fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,defined as a positive PCR test performed 7 or more days after inoculation with the BNT162b2 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.415,0.2958,0.5141,2,0,,8,9,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age start >60,han20
,0,553,Gazit S,medrix- Fourth dose efficacy Pfizer,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272835v1.full.pdf,85,85,Israel,Israel Omicron fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,defined as a positive PCR test performed 7 or more days after inoculation with the BNT162b2 vaccine,infection,infection,,1,1,1,1,3,60,90,,0,,,,0.2708,0.0424,0.4447,2,0,,9,10,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age start >60,han20
,0,553,Gazit S,medrix- Fourth dose efficacy Pfizer,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272835v1.full.pdf,85,85,Israel,Israel Omicron fourth dose hosp,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,COVID-19-related hospitalization or COVID-19 associated mortality,hosp,severe,,1,0,0,0,3,60,90,,0,,,,0.825,0.7048,0.8959,2,0,,1,4,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age start >60,han20
,0,553,Gazit S,medrix- Fourth dose efficacy Pfizer,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272835v1.full.pdf,85,85,Israel,Israel Omicron fourth dose hosp,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,COVID-19-related hospitalization or COVID-19 associated mortality,hosp,severe,,1,0,0,0,3,60,90,,0,,,,0.703,0.3737,0.859,2,0,,5,6,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age start >60,han20
,0,553,Gazit S,medrix- Fourth dose efficacy Pfizer,0,https://www.medrxiv.org/content/10.1101/2022.03.24.22272835v1.full.pdf,85,85,Israel,Israel Omicron fourth dose hosp,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,COVID-19-related hospitalization or COVID-19 associated mortality,hosp,severe,,1,0,0,0,3,60,90,,0,,,,0.871,0,0.9836,2,0,,7,10,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age start >60,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp 18-64,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.385,0.202,0.526,0,0,,2,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >175 included as 25_32 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp 18-64,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.316,0.223,0.397,0,0,,25,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >175 included as 25_32 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Pfizer & BioNTech,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.852,0.779,0.901,1,0,,1,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Pfizer & BioNTech,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.841,0.805,0.87,1,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Pfizer & BioNTech,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.763,0.723,0.796,1,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Pfizer & BioNTech,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.656,0.585,0.716,1,0,,10,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Pfizer & BioNTech,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.382,0.16,0.545,1,0,,16,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Moderna,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.881,0.783,0.935,1,0,,1,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Moderna,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.883,0.843,0.913,1,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Moderna,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.807,0.755,0.848,1,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Moderna,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.741,0.563,0.847,1,0,,10,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp 18-64,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.528,0.181,0.728,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >175 included as 25_32 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp 18-64,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.61,0.553,0.659,0,0,,3,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >175 included as 25_32 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp 18-64,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.33,0.213,0.429,0,0,,25,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >175 included as 25_32 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.775,0.684,0.839,1,0,,1,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.828,0.784,0.863,1,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.786,0.746,0.82,1,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.725,0.671,0.77,1,0,,10,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.677,0.582,0.75,1,0,,16,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.885,0.768,0.943,1,0,,1,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.873,0.812,0.913,1,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.845,0.779,0.892,1,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 18-64,1,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.606,0.277,0.785,1,0,,10,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp 65-90,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.553,-0.201,0.833,0,0,,2,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >175 included as 25_32 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp 65-90,1,,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.563,0.396,0.683,0,0,,25,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >175 included as 25_32 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Pfizer & BioNTech,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.93,0.775,0.978,1,0,,1,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Pfizer & BioNTech,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.935,0.893,0.96,1,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Pfizer & BioNTech,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.927,0.903,0.946,1,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Pfizer & BioNTech,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.91,0.881,0.933,1,0,,10,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Pfizer & BioNTech,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.829,0.754,0.881,1,0,,16,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,1,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Moderna,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,,,,1,0,,1,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Moderna,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.981,0.921,0.995,1,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Moderna,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.949,0.9,0.974,1,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Moderna,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.896,0.738,0.959,1,0,,10,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp 65-90,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.858,0.694,0.934,0,0,,2,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >175 included as 25_32 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp 65-90,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.756,0.614,0.846,0,0,,25,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >175 included as 25_32 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.901,0.586,0.976,1,0,,1,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.974,0.928,0.991,1,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.917,0.888,0.939,1,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.902,0.872,0.914,1,0,,10,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.88,0.834,0.914,1,0,,16,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period end is >105 days included as 16_24 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.89,0.172,0.985,1,0,,1,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,0.912,0.755,0.969,1,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,1,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,,,,1,0,,5,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,1,554,Stowe J,medrix- UK Omicron hospitalization VE,0,https://www.medrxiv.org/content/10.1101/2022.04.01.22273281v1.full.pdf,95,95,United Kingdom,UK 4 Omicron hosp booster 65-90,1,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,Admissions with the reason for attending emergency care being a SNOMED CT (Systematized Nomenclature of Medicine–Clinical Terms) coded acute respiratory illness (ARI) were flagged,hosp,severe,,1,0,0,0,3,65,90,,0,,,,,,,1,0,,10,15,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,period here included as 70+ days included as 10_15 for sake of the analysis,han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.528,0.494,0.56,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.777,0.768,0.785,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.6,0.589,0.61,0,0,,10,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.439,0.421,0.457,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.343,0.314,0.371,0,0,,26,33,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.082,0.034,0.128,0,0,,34,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.677,0.627,0.72,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.866,0.856,0.876,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.723,0.709,0.735,0,0,,10,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.552,0.524,0.579,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.444,0.401,0.483,0,0,,26,33,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.286,0.096,0.436,0,0,,34,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,,,,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.975,0.956,0.986,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.954,0.939,0.965,0,0,,10,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.875,0.848,0.897,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.818,0.777,0.852,0,0,,26,33,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.639,0.543,0.715,0,0,,34,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,,,,0,0,,0,1,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,,,,0,0,,2,9,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,,,,0,0,,10,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.953,0.915,0.974,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.911,0.849,0.948,0,0,,26,33,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,,,,0,0,,34,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta booster,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.453,0.398,0.502,1,0,,0,1,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >1 included as 2-16",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta booster,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.753,0.725,0.778,1,0,,2,16,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta booster,0,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.399,0.22,0.537,1,0,,0,1,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta booster,0,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.682,0.576,0.761,1,0,,2,16,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta hosp booster,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.891,0.83,0.93,1,0,,0,1,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta hosp booster,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.956,0.931,0.972,1,0,,2,16,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta hosp booster,0,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,,,,1,0,,0,1,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta hosp booster,0,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Individuals who were hospitalised or 116 admitted to an ICU with COVID-19 are registered in the Norwegian Intensive Care and Pandemic Registry 117 (NIPaR). We included all hospitalisation where COVID-19 was registered as the primary diagnosis for 118 admission and ICU admission of individuals who tested positive for SARS-CoV-2 and were admitted to an 119 ICU (length of stay ?24 hours), required mechanical ventilatory support (invasive or non-invasive), or 120 persistent administration of vasoactive medication",hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.735,0.457,0.871,1,0,,2,16,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta booster,0,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.676,0.484,0.797,1,0,,0,1,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >1 included as 2-16",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta booster,0,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.871,0.801,0.916,1,0,,2,16,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta booster,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.561,0.33,0.712,1,0,,0,1,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,555,Starrfelt J,medrix- Norway Delta VE,0,https://www.medrxiv.org/content/10.1101/2022.03.29.22273086v1.full.pdf,90,90,Norway,Norway 2 delta booster,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,SARS-CoV-2 infection is defined as a positive SARS-CoV-2 PCR test reported to the Norwegian 115 Surveillance System for Communicable Diseases (MSIS) registry,infection,infection,,1,1,1,1,3,18,85,,0,,,,0.849,0.718,0.919,1,0,,2,16,weeks after booster,,,,,0,0,0,0,0,0,0,0,"Age end >=85, period end is >33 included as 34-42",han20
,0,556,Bar-On Y,NEJM- fourth dose VE,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2201570,85,85,Israel,Israel 2 fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,SARS-CoV-2 infection (confirmed either by state-regulated rapid antigen test or by PCR) ,infection,infection,,1,1,1,1,3,60,80,,0,,,,0.33,0.33,0.375,2,0,,1,2,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age end >=80,han20
,0,556,Bar-On Y,NEJM- fourth dose VE,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2201570,85,85,Israel,Israel 2 fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,SARS-CoV-2 infection (confirmed either by state-regulated rapid antigen test or by PCR) ,infection,infection,,1,1,1,1,3,60,80,,0,,,,0.523,0.5,0.523,2,0,,2,3,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age end >=80,han20
,0,556,Bar-On Y,NEJM- fourth dose VE,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2201570,85,85,Israel,Israel 2 fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,SARS-CoV-2 infection (confirmed either by state-regulated rapid antigen test or by PCR) ,infection,infection,,1,1,1,1,3,60,80,,0,,,,0.5,0.473,0.523,2,0,,3,4,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age end >=80,han20
,0,556,Bar-On Y,NEJM- fourth dose VE,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2201570,85,85,Israel,Israel 2 fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,SARS-CoV-2 infection (confirmed either by state-regulated rapid antigen test or by PCR) ,infection,infection,,1,1,1,1,3,60,80,,0,,,,0.411,0.375,0.411,2,0,,4,5,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age end >=80,han20
,0,556,Bar-On Y,NEJM- fourth dose VE,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2201570,85,85,Israel,Israel 2 fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,SARS-CoV-2 infection (confirmed either by state-regulated rapid antigen test or by PCR) ,infection,infection,,1,1,1,1,3,60,80,,0,,,,0.33,0.285,0.375,2,0,,5,6,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age end >=80,han20
,0,556,Bar-On Y,NEJM- fourth dose VE,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2201570,85,85,Israel,Israel 2 fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,SARS-CoV-2 infection (confirmed either by state-regulated rapid antigen test or by PCR) ,infection,infection,,1,1,1,1,3,60,80,,0,,,,0.167,0.167,0.23,2,0,,6,7,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age end >=80,han20
,0,556,Bar-On Y,NEJM- fourth dose VE,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2201570,85,85,Israel,Israel 2 fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,SARS-CoV-2 infection (confirmed either by state-regulated rapid antigen test or by PCR) ,infection,infection,,1,1,1,1,3,60,80,,0,,,,0.09,0,0.167,2,0,,7,8,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age end >=80,han20
,0,556,Bar-On Y,NEJM- fourth dose VE,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2201570,85,85,Israel,Israel 2 fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe," severe Covid-19 (defined with the use of the National Institutes of Health definition2 as a resting respiratory rate of >30 breaths per minute, an oxygen saturation of <94% while breathing ambient air, or a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen of <300) during the 14 days after confirmation of infection",hosp,severe,,1,0,0,0,3,60,80,,0,,,,0.583,0.5,0.655,2,0,,1,2,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age end >=80,han20
,0,556,Bar-On Y,NEJM- fourth dose VE,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2201570,85,85,Israel,Israel 2 fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe," severe Covid-19 (defined with the use of the National Institutes of Health definition2 as a resting respiratory rate of >30 breaths per minute, an oxygen saturation of <94% while breathing ambient air, or a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen of <300) during the 14 days after confirmation of infection",hosp,severe,,1,0,0,0,3,60,80,,0,,,,0.655,0.565,0.722,2,0,,2,3,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age end >=80,han20
,0,556,Bar-On Y,NEJM- fourth dose VE,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2201570,85,85,Israel,Israel 2 fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe," severe Covid-19 (defined with the use of the National Institutes of Health definition2 as a resting respiratory rate of >30 breaths per minute, an oxygen saturation of <94% while breathing ambient air, or a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen of <300) during the 14 days after confirmation of infection",hosp,severe,,1,0,0,0,3,60,80,,0,,,,0.714,0.629,0.782,2,0,,3,4,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age end >=80,han20
,0,556,Bar-On Y,NEJM- fourth dose VE,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2201570,85,85,Israel,Israel 2 fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe," severe Covid-19 (defined with the use of the National Institutes of Health definition2 as a resting respiratory rate of >30 breaths per minute, an oxygen saturation of <94% while breathing ambient air, or a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen of <300) during the 14 days after confirmation of infection",hosp,severe,,1,0,0,0,3,60,80,,0,,,,0.705,0.6,0.787,2,0,,4,5,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age end >=80,han20
,0,556,Bar-On Y,NEJM- fourth dose VE,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2201570,85,85,Israel,Israel 2 fourth dose,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe," severe Covid-19 (defined with the use of the National Institutes of Health definition2 as a resting respiratory rate of >30 breaths per minute, an oxygen saturation of <94% while breathing ambient air, or a ratio of partial pressure of arterial oxygen to fraction of inspired oxygen of <300) during the 14 days after confirmation of infection",hosp,severe,,1,0,0,0,3,60,80,,0,,,,0.767,0.615,0.795,2,0,,5,6,Weeks after Fourth dose,,,,,0,0,0,0,0,0,0,0,Age end >=80,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.97,0.94,0.99,0,0,,1,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period end > 180 days included as 26_32,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.96,0.94,0.97,0,0,,9,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period end > 180 days included as 26_32,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.94,0.92,0.95,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period end > 180 days included as 26_32,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.9,0.79,0.95,0,0,,26,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period end > 180 days included as 26_32,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.51,0.38,0.61,0,0,,1,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period end > 180 days included as 26_32,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.31,0.2,0.41,0,0,,9,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period end > 180 days included as 26_32,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.29,0.19,0.38,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period end > 180 days included as 26_32,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.29,0.17,0.38,0,0,,26,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period end > 180 days included as 26_32,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents omicron severe,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,hospatalization and/or death from COVId-19,hosp&death,severe,,1,0,0,0,3,12,17,,0,,,,0.76,-0.1,0.95,0,0,,1,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period end > 180 days included as 26_32,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents omicron severe,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,hospatalization and/or death from COVId-20,hosp&death,severe,,1,0,0,0,3,12,17,,0,,,,0.83,0.55,0.93,0,0,,9,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period end > 180 days included as 26_32,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents omicron severe,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,hospatalization and/or death from COVId-21,hosp&death,severe,,1,0,0,0,3,12,17,,0,,,,0.82,0.64,0.91,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period end > 180 days included as 26_32,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents omicron severe,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,hospatalization and/or death from COVId-22,hosp&death,severe,,1,0,0,0,3,12,17,,0,,,,0.88,0.77,0.94,0,0,,26,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period end > 180 days included as 26_32,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents omicron booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.56,0.34,0.7,1,0,,0,1,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period end > 7 days included as 2_12,han20
,0,557,Buchan S,medrix- Adolscents VE Pfizer Omicron vs Delta,0,https://www.medrxiv.org/content/10.1101/2022.04.07.22273319v1.full.pdf,101,101,Canada,Canada adolescents omicron booster,1,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.62,0.49,0.72,1,0,,2,12,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period end > 7 days included as 2_13,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.703,0.692,0.713,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.488,0.478,0.497,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.225,0.209,0.24,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.06,-0.023,0.034,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.822,0.815,0.828,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.858,0.826,0.884,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,Pfizer & BioNTech,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.84,0.789,0.853,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.826,0.801,0.847,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.826,0.812,0.839,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.785,0.767,0.802,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.696,0.649,0.736,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.943,0.852,0.97,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.933,0.609,0.853,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,Pfizer & BioNTech,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.968,0.9,0.99,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.874,0.815,0.915,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.903,0.874,0.925,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.828,0.791,0.858,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.736,0.611,0.821,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.968,0.952,0.979,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.955,0.679,0.994,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,1,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,Pfizer & BioNTech,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.99,,,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.769,0.733,0.8,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.636,0.622,0.651,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.494,0.473,0.514,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.226,0.061,0.362,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.877,0.851,0.884,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.889,0.869,0.906,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,Moderna,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.821,0.73,0.881,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.849,0.754,0.908,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.815,0.782,0.843,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.816,0.779,0.847,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.425,-0.04,0.682,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.973,0.927,0.99,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.968,0.925,0.983,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,1,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,Moderna,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.99,,,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.777,0.307,0.928,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.841,0.75,0.899,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.833,0.746,0.89,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.797,-0.443,0.971,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,1,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.99,,,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,1,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.99,,,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,Moderna,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.841,-0.126,0.978,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.392,0.364,0.419,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.256,0.239,0.273,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,-0.05,-0.04,0.028,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,-0.14,-0.205,-0.079,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.829,0.819,0.838,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.841,0.812,0.865,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.762,0.706,0.807,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.754,0.73,0.776,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.595,0.54,0.642,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.488,0.382,0.576,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.951,0.938,0.962,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.985,0.939,0.996,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.901,0.735,0.963,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.836,0.787,0.874,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.65,0.533,0.737,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.571,0.352,0.716,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.984,0.965,0.993,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,1,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.99,,,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.393,0.361,0.424,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.457,0.43,0.482,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.359,0.325,0.392,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,Johnson & Johnson,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.909,0.846,0.946,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 18-64,0,Johnson & Johnson,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,18,64,,0,,,,0.863,0.635,0.949,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.432,0.329,0.52,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.582,0.499,0.651,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.594,0.501,0.67,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,Johnson & Johnson,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.922,0.688,0.98,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 18-64,0,Johnson & Johnson,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,18,64,,0,,,,0.767,-0.657,0.967,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.598,0.352,0.751,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.671,0.432,0.81,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.761,0.567,0.868,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,1,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,Johnson & Johnson,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.99,,,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,1,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 18-64,0,Johnson & Johnson,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,18,64,,0,,,,0.99,,,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.67,0.639,0.698,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.588,0.568,0.607,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.468,0.45,0.485,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.316,0.279,0.351,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.81,0.876,0.887,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.922,0.894,0.943,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,Pfizer & BioNTech,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.813,0.774,0.845,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.766,0.733,0.794,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.727,0.707,0.746,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.678,0.662,0.694,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.592,0.556,0.624,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.93,0.925,0.935,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.958,0.926,0.976,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,Pfizer & BioNTech,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.919,0.883,0.944,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.815,0.768,0.853,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.799,0.768,0.827,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.746,0.723,0.768,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.602,0.552,0.646,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.958,0.952,0.963,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,Pfizer & BioNTech,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.97,0.921,0.989,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,Pfizer & BioNTech,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.962,0.916,0.983,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.791,0.69,0.859,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.974,0.636,0.708,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.66,0.631,0.687,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.473,0.388,0.547,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.922,0.904,0.937,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.933,0.915,0.946,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,Moderna,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.861,0.79,0.908,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.838,0.735,0.901,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.786,0.747,0.82,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.766,0.733,0.795,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.693,0.609,0.759,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.96,0.941,0.972,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.957,0.938,0.97,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,Moderna,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.93,0.854,0.967,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.932,0.726,0.983,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.864,0.804,0.906,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.817,0.767,0.856,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.719,0.607,0.799,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,Moderna,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.962,0.935,0.978,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,Moderna,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.982,0.961,0.992,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,Moderna,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.979,0.849,0.997,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.631,0.556,0.694,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.497,0.47,0.522,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.389,0.33,0.443,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,-0.615,-2.389,0.23,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.92,0.908,0.931,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.956,0.914,0.977,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.738,0.664,0.797,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.681,0.652,0.707,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.63,0.565,0.686,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.242,-2.031,0.811,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.953,0.939,0.964,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.97,0.906,0.99,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.848,0.678,0.928,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.761,0.717,0.798,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.667,0.578,0.737,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,1,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.99,,,0,0,,35,42,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.962,0.942,0.975,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,AstraZeneca,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.979,0.848,0.997,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.178,0.034,0.301,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.491,0.386,0.577,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.421,0.299,0.522,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,Johnson & Johnson,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.888,0.7,0.958,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,1,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta 65-100,0,Johnson & Johnson,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,"The report is based on (i) Covid-19-related symptoms identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or antigen test included in the EC rapid test list",infection,infection,,1,1,1,1,3,65,100,,0,,,,0.99,,,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.264,0.079,0.413,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.59,0.462,0.687,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.467,0.299,0.595,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,Johnson & Johnson,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.921,0.685,0.98,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,1,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta hosp 65-100,0,Johnson & Johnson,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,Covid-19 related hospitalization was defined as hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to hospital,hosp,severe,,1,0,0,0,3,65,100,,0,,,,0.99,,,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.533,0.282,0.696,0,0,,2,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.576,0.325,0.733,0,0,,18,25,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.395,0.133,0.578,0,0,,26,34,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,1,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,Johnson & Johnson,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.99,,,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,1,558,Voko Z,medrix- Hungary delta VE,0,https://www.medrxiv.org/content/10.1101/2022.04.14.22273898v1.full.pdf,48,48,Hungary,Hungary delta death 65-100,0,Johnson & Johnson,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,"Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without previously declared recovery and without another clear cause of death (e.g., accident, suicide)",death,severe,,1,0,0,0,3,65,100,,0,,,,0.99,,,1,0,,2,17,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >240 days included as 35-42 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.571,0.545,0.596,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.628,0.609,0.647,0,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.494,0.474,0.513,0,0,,5,6,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.374,0.353,0.393,0,0,,7,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.296,0.275,0.317,0,0,,9,10,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.217,0.192,0.241,0,0,,11,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.166,0.137,0.195,0,0,,12,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.139,0.109,0.169,0,0,,14,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 14-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,434,434,Scotland,Scotland adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.465,0.403,0.52,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,434,434,Scotland,Scotland adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.783,0.753,0.809,0,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,434,434,Scotland,Scotland adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.708,0.666,0.745,0,0,,5,6,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,434,434,Scotland,Scotland adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.578,0.508,0.638,0,0,,7,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,434,434,Scotland,Scotland adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.412,0.288,0.514,0,0,,9,10,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,434,434,Scotland,Scotland adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.328,0.139,0.476,0,0,,11,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,434,434,Scotland,Scotland adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.247,-0.04,0.455,0,0,,12,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,434,434,Scotland,Scotland adolscents Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.313,0.048,0.505,0,0,,14,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 14-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron hosp&death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,"defined as a positive test that occurred within 14 days prior to the hospitalisation date and up to three days after hospital admission, and death occurring within 28 days after a positive test",hosp&death,severe,,1,0,0,0,3,12,17,,0,,,,0.659,0.383,0.812,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron hosp&death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,"defined as a positive test that occurred within 14 days prior to the hospitalisation date and up to three days after hospital admission, and death occurring within 28 days after a positive test",hosp&death,severe,,1,0,0,0,3,12,17,,0,,,,0.754,0.573,0.859,0,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron hosp&death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,"defined as a positive test that occurred within 14 days prior to the hospitalisation date and up to three days after hospital admission, and death occurring within 28 days after a positive test",hosp&death,severe,,1,0,0,0,3,12,17,,0,,,,0.821,0.707,0.891,0,0,,5,6,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron hosp&death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,"defined as a positive test that occurred within 14 days prior to the hospitalisation date and up to three days after hospital admission, and death occurring within 28 days after a positive test",hosp&death,severe,,1,0,0,0,3,12,17,,0,,,,0.828,0.745,0.885,0,0,,7,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron hosp&death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,"defined as a positive test that occurred within 14 days prior to the hospitalisation date and up to three days after hospital admission, and death occurring within 28 days after a positive test",hosp&death,severe,,1,0,0,0,3,12,17,,0,,,,0.812,0.734,0.867,0,0,,9,10,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron hosp&death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,"defined as a positive test that occurred within 14 days prior to the hospitalisation date and up to three days after hospital admission, and death occurring within 28 days after a positive test",hosp&death,severe,,1,0,0,0,3,12,17,,0,,,,0.83,0.751,0.884,0,0,,11,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron hosp&death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,"defined as a positive test that occurred within 14 days prior to the hospitalisation date and up to three days after hospital admission, and death occurring within 28 days after a positive test",hosp&death,severe,,1,0,0,0,3,12,17,,0,,,,0.898,0.821,0.942,0,0,,12,13,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents Omicron hosp&death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,"defined as a positive test that occurred within 14 days prior to the hospitalisation date and up to three days after hospital admission, and death occurring within 28 days after a positive test",hosp&death,severe,,1,0,0,0,3,12,17,,0,,,,0.849,0.752,0.908,0,0,,14,17,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 14-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.768,0.742,0.791,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.858,0.839,0.875,0,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.783,0.754,0.808,0,0,,5,6,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.628,0.579,0.671,0,0,,7,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,135,135,Brazil,Brazil adolscents delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.403,0.319,0.477,0,0,,9,10,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,434,434,Scotland,Scotland adolscents delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.503,0.363,0.613,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,434,434,Scotland,Scotland adolscents delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.893,0.78,0.948,0,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,434,434,Scotland,Scotland adolscents delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.907,0.787,0.96,0,0,,5,6,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,434,434,Scotland,Scotland adolscents delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.812,0.604,0.911,0,0,,7,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,559,Florentino P,Lancet preprint- Brazil and Scotland VE,0,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4074678,434,434,Scotland,Scotland adolscents delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",The primary outcome was COVID-19-symptomatic infection confirmed by rapid antigen testing or RT-PCR in Brazil and only RT-PCR in Scotland,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,12,17,,0,,,,0.784,0.538,0.899,0,0,,9,10,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,study period ends at >98 days included as 15-17 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 40-64,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,40,64,,0,,,,0.582,0.57,0.594,1,0,,1,2,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 40-64,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,40,64,,0,,,,0.638,0.63,0.645,1,0,,3,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 40-64,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,40,64,,0,,,,0.573,0.564,0.582,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 40-64,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,40,64,,0,,,,0.464,0.45,0.478,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 40-64,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,40,64,,0,,,,0.306,0.268,0.343,1,0,,15,19,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >105 days included as 15-19 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 40-64,1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,40,64,,0,,,,0.612,0.409,0.746,1,0,,1,2,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 40-64,1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,40,64,,0,,,,0.517,0.389,0.618,1,0,,3,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 40-64,1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,40,64,,0,,,,0.53,0.426,0.616,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 40-64,1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,40,64,,0,,,,0.408,0.186,0.569,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 40-64,1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,40,64,,0,,,,0.372,-0.441,0.726,1,0,,15,19,Weeks after booster,,,,,0,0,0,0,0,0,0,0,study period ends at >105 days included as 15-19 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 65+,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,65,90,,0,,,,0.581,0.516,0.638,1,0,,1,2,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >=65. study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 65+,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,65,90,,0,,,,0.685,0.657,0.712,1,0,,3,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >=65. study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 65+,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,65,90,,0,,,,0.541,0.505,0.575,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >=65. study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 65+,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,65,90,,0,,,,0.401,0.352,0.445,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >=65. study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 65+,1,AstraZeneca,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,65,90,,0,,,,0.231,0.151,0.305,1,0,,15,19,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >=65. study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 65+,1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,65,90,,0,,,,0.661,0.166,0.863,1,0,,1,2,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >=65. study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 65+,1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,65,90,,0,,,,0.516,0.208,0.704,1,0,,3,4,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >=65. study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 65+,1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,65,90,,0,,,,0.445,0.224,0.602,1,0,,5,9,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >=65. study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 65+,1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,65,90,,0,,,,-0.272,-1.136,0.301,1,0,,10,14,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >=65. study period ends at >105 days included as 15-18 for sake of the analysis,han20
,1,560,Kirsebom F,medrix- UK booster Omicrom,0,https://www.medrxiv.org/content/10.1101/2022.04.29.22274483v1.full.pdf,95,95,United Kingdom,UK Omicron booster 65+,1,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.1.529,,"Mild, Moderate + severe","positive PCR in o persons who had reported symptoms and gave a symptom onset
date within the 10 days before testing",Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,65,90,,0,,,,,,,1,0,,15,19,Weeks after booster,,,,,0,0,0,0,0,0,0,0,Age end >=65. study period ends at >105 days included as 15-18 for sake of the analysis,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.255,0.086,0.384,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.122,0.03,0.203,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.058,-0.047,0.136,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.064,-0.013,0.127,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.065,-0.005,0.131,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.05,-0.025,0.12,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,-0.005,-0.067,0.052,0,0,,25,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,-0.049,-0.13,0.007,0,0,,29,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,-0.07,-0.16,0.006,0,0,,33,36,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,-0.04,-0.15,0.072,0,0,,37,40,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.035,-0.18,0.224,0,0,,41,44,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.408,0.158,0.59,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.357,0.241,0.459,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.286,0.161,0.388,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.196,0.098,0.279,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.111,0.028,0.194,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.068,-0.03,0.148,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.047,-0.02,0.115,0,0,,25,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.056,-0.02,0.137,0,0,,29,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.079,-0.01,0.168,0,0,,33,36,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.12,-0.01,0.218,0,0,,37,40,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 Omicron,1,,Moderna,mRNA-1273,mRNA,B.1.1.529,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.155,-0.11,0.369,0,0,,41,44,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.753,0.689,0.82,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.686,0.645,0.72,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.622,0.578,0.663,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.592,0.567,0.634,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.581,0.544,0.612,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.564,0.532,0.594,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.56,0.53,0.582,0,0,,25,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.552,0.52,0.58,0,0,,29,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.564,0.534,0.589,0,0,,33,36,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.582,0.531,0.623,0,0,,37,40,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.614,0.511,0.687,0,0,,41,44,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.723,0.593,0.83,0,0,,0,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.742,0.683,0.79,0,0,,5,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.731,0.673,0.781,0,0,,9,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.697,0.652,0.735,0,0,,13,16,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.659,0.621,0.7,0,0,,17,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.642,0.602,0.683,0,0,,21,24,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.64,0.607,0.676,0,0,,25,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.662,0.635,0.683,0,0,,29,32,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.661,0.623,0.692,0,0,,33,36,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.642,0.592,0.687,0,0,,37,40,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,561,Accorsi E,JAMA- mRNA VE Omicron vs Delta,0,https://jamanetwork.com/journals/jama/fullarticle/2788485,95,95,United Kingdom,UK 5 delta,1,,Moderna,mRNA-1273,mRNA,B.1.617.2,,"Mild, Moderate + severe",symptomatic SARS-CoV-2 infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,65,,0,,,,0.6,0.471,0.702,0,0,,41,44,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=65.,han20
,0,562,Gray G,NEJM- J&J and Pfized Omicron VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2202061,196,196,South Africa,SA 1 Omicron booster,0,Johnson & Johnson,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.529,,severe,defined as hospitalization or admission to an intensive care unit (ICU) or to high care,hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.55,0.22,0.74,1,0,,0,2,Weeks after booster dose,,,,,0,0,0,0,0,0,0,0,Age end >=80.,han20
,0,562,Gray G,NEJM- J&J and Pfized Omicron VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2202061,196,196,South Africa,SA 1 Omicron booster,0,Johnson & Johnson,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.529,,severe,defined as hospitalization or admission to an intensive care unit (ICU) or to high care,hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.74,0.57,0.84,1,0,,3,4,Weeks after booster dose,,,,,0,0,0,0,0,0,0,0,Age end >=80.,han20
,0,562,Gray G,NEJM- J&J and Pfized Omicron VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2202061,196,196,South Africa,SA 1 Omicron booster,0,Johnson & Johnson,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.529,,severe,defined as hospitalization or admission to an intensive care unit (ICU) or to high care,hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.72,0.59,0.81,1,0,,5,12,Weeks after booster dose,,,,,0,0,0,0,0,0,0,0,Age end >=80.,han20
,0,562,Gray G,NEJM- J&J and Pfized Omicron VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2202061,196,196,South Africa,SA 1 Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,defined as hospitalization or admission to an intensive care unit (ICU) or to high care,hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.81,0.41,0.94,0,0,,0,2,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=80.,han20
,0,562,Gray G,NEJM- J&J and Pfized Omicron VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2202061,196,196,South Africa,SA 1 Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,defined as hospitalization or admission to an intensive care unit (ICU) or to high care,hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.88,0.62,0.96,0,0,,3,4,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=80.,han20
,0,562,Gray G,NEJM- J&J and Pfized Omicron VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2202061,196,196,South Africa,SA 1 Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,defined as hospitalization or admission to an intensive care unit (ICU) or to high care,hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.7,0.64,0.76,0,0,,5,12,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=80.,han20
,0,562,Gray G,NEJM- J&J and Pfized Omicron VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2202061,196,196,South Africa,SA 1 Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,defined as hospitalization or admission to an intensive care unit (ICU) or to high care,hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.71,0.68,0.74,0,0,,13,21,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=80.,han20
,0,562,Gray G,NEJM- J&J and Pfized Omicron VE,0,https://www.nejm.org/doi/full/10.1056/NEJMc2202061,196,196,South Africa,SA 1 Omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,defined as hospitalization or admission to an intensive care unit (ICU) or to high care,hosp,severe,,1,0,0,0,3,18,80,,0,,,,0.67,0.63,0.71,0,0,,22,29,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >=80.,han20
,0,563,Braeye T,Vaccine- VE delta time since vaccination,0,https://www.sciencedirect.com/science/article/pii/S0264410X22004418?via%3Dihub#s0105,78,78,Belgium,Belgium females delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,,infection,infection,,1,1,1,1,2,45,64,,0,,,,0.63,0.62,0.65,0,0,,0,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,563,Braeye T,Vaccine- VE delta time since vaccination,0,https://www.sciencedirect.com/science/article/pii/S0264410X22004418?via%3Dihub#s0105,78,78,Belgium,Belgium females delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,,infection,infection,,1,1,1,1,2,45,64,,0,,,,0.43,0.42,0.44,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,563,Braeye T,Vaccine- VE delta time since vaccination,0,https://www.sciencedirect.com/science/article/pii/S0264410X22004418?via%3Dihub#s0105,78,78,Belgium,Belgium females delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,,infection,infection,,1,1,1,1,2,45,64,,0,,,,0.74,0.7,0.76,0,0,,0,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,563,Braeye T,Vaccine- VE delta time since vaccination,0,https://www.sciencedirect.com/science/article/pii/S0264410X22004418?via%3Dihub#s0105,78,78,Belgium,Belgium females delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,,infection,infection,,1,1,1,1,2,45,64,,0,,,,0.55,0.54,0.57,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,563,Braeye T,Vaccine- VE delta time since vaccination,0,https://www.sciencedirect.com/science/article/pii/S0264410X22004418?via%3Dihub#s0105,78,78,Belgium,Belgium females delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,,infection,infection,,1,1,1,1,2,45,64,,0,,,,0.48,0.45,0.51,0,0,,0,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,563,Braeye T,Vaccine- VE delta time since vaccination,0,https://www.sciencedirect.com/science/article/pii/S0264410X22004418?via%3Dihub#s0105,78,78,Belgium,Belgium females delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,,infection,infection,,1,1,1,1,2,45,64,,0,,,,0.34,0.32,0.36,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,563,Braeye T,Vaccine- VE delta time since vaccination,0,https://www.sciencedirect.com/science/article/pii/S0264410X22004418?via%3Dihub#s0105,78,78,Belgium,Belgium females delta,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,,infection,infection,,1,1,1,1,2,45,64,,0,,,,0.33,0.28,0.37,0,0,,0,7,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,563,Braeye T,Vaccine- VE delta time since vaccination,0,https://www.sciencedirect.com/science/article/pii/S0264410X22004418?via%3Dihub#s0105,78,78,Belgium,Belgium females delta,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,infection,,infection,infection,,1,1,1,1,2,45,64,,0,,,,0.22,0.18,0.24,0,0,,21,28,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,,han20
,0,564,Grannis SJ,USA 9 States Delta,0,https://www.cdc.gov/mmwr/volumes/70/wr/mm7037e2.htm?s_cid=mm7037e2_w#T1_down,102,102,United States,US delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,COVID-19 hospitalizations,Hosp,Severe,,1,0,0,0,3,18,75,,0,,,,0.8,0.73,0.85,0,1,16,,,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,All adults (aged ?18 yrs). Age end: ?75 yrs,han20
,0,564,Grannis SJ,USA 9 States Delta,0,https://www.cdc.gov/mmwr/volumes/70/wr/mm7037e2.htm?s_cid=mm7037e2_w#T1_down,102,102,United States,US delta hosp,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,severe,COVID-19 hospitalizations,Hosp,Severe,,1,0,0,0,3,18,75,,0,,,,0.95,0.92,0.97,0,1,14,,,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,All adults (aged ?18 yrs). Age end: ?75 yrs,han20
,0,564,Grannis SJ,USA 9 States Delta,0,https://www.cdc.gov/mmwr/volumes/70/wr/mm7037e2.htm?s_cid=mm7037e2_w#T1_down,102,102,United States,US delta hosp,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.617.2,,severe,COVID-19 hospitalizations,Hosp,Severe,,1,0,0,0,3,18,75,,0,,,,0.6,0.31,0.77,0,1,13,,,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,All adults (aged ?18 yrs). Age end: ?75 yrs,han20
,0,565,McLean H,medrix- US Wisconsin cohort VE Nov 2020- December 2021,0,https://onlinelibrary.wiley.com/doi/10.1111/irv.12970,102,102,United States,US delta,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"A qualifying illness was a new illness onset in the past 7 days and at least one of the following symptoms: cough, fever or chills, sore throat, muscle or body aches, loss of smell or taste, shortness of breath, or diarrhea.",infection,infection,,1,1,1,1,3,12,65,,0,,,,0.52,0.2,0.71,0,1,31,,,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,Age end >= 65,han20
,0,565,McLean H,medrix- US Wisconsin cohort VE Nov 2020- December 2021,0,https://onlinelibrary.wiley.com/doi/10.1111/irv.12970,102,102,United States,US delta,0,,Moderna,mRNA-1273,mRNA,B.1.617.2,,infection,"A qualifying illness was a new illness onset in the past 7 days and at least one of the following symptoms: cough, fever or chills, sore throat, muscle or body aches, loss of smell or taste, shortness of breath, or diarrhea.",infection,infection,,1,1,1,1,3,12,65,,0,,,,0.59,0.24,0.78,0,1,31,,,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,Age end >= 65,han20
,0,566,Olson S.M,NEJM- Pfizer VE Adolescents severe disease,0,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2117995?articleTools=true,102,102,United States,US adolescents delta hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Case patients were selected among adolescents who were hospitalized with Covid-19 as the primary reason for admission or who had a clinical syndrome consistent with acute Covid-19 (one or more symptoms of fever, cough, shortness of breath, loss of taste, loss of smell, gastrointestinal symptoms, respiratory support, or new pulmonary findings on chest imaging). All case patients had positive results for SARS-CoV-2 on reverse transcriptase–polymerase-chain-reaction (RT-PCR) assay or on antigen testing within 10 days after symptom onset or within 72 hours after hospitalization",hosp,severe,,1,0,0,0,3,12,18,,0,,,,0.94,0.9,0.96,0,1,13,,,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,567,Natarajan K,MMWR- Janssen booster Omicron,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7113e2.htm,102,102,United States,US booster Omicron,0,Johnson & Johnson,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.529,,severe, infection that occurred within 14 days before to less than 72 hours after a hospital admission that lasted for more than 24 hrs,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.93,0.92,0.94,1,1,8,,,weeks after booster,,,,,0,0,0,0,0,0,0,0,age end >= 85,han20
,0,567,Natarajan K,MMWR- Janssen booster Omicron,0,https://www.cdc.gov/mmwr/volumes/71/wr/mm7113e2.htm,102,102,United States,US Omicron,0,,Johnson & Johnson,Ad26.COV2.S,Adenovirus,B.1.1.529,,severe, infection that occurred within 14 days before to less than 72 hours after a hospital admission that lasted for more than 24 hrs,hosp,severe,,1,0,0,0,3,18,85,,0,,,,0.67,0.52,0.77,0,1,8,,,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,age end >= 85,han20
,0,568,Satwik r,EJIM- India Astrazeneca Delta VE,0,https://www.ejinme.com/article/S0953-6205(21)00271-5/fulltext,163,163,India,India delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,"Mild, Moderate + severe",,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,,,,0,,,,0.28,0.1,0.41,0,1,7,,,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,568,Satwik r,EJIM- India Astrazeneca Delta VE,0,https://www.ejinme.com/article/S0953-6205(21)00271-5/fulltext,163,163,India,India delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,death due to COVID-19,death,severe,,1,0,0,0,3,,,,0,,,,0.97,0.43,0.998,0,1,7,,,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1009,Altarawneh H,medrix- Qatar previous infection immunity BA.1 vs BA.2,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2203965,151,151,Qatar,Qatar omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,"Mild, Moderate + severe",Symptomatic SARS-CoV-2 reinfection is conventionally defined as a documented infection ?90 days after an earlier infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,-0.049,-0.164,0.054,0,1,38,,,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1009,Altarawneh H,medrix- Qatar previous infection immunity BA.1 vs BA.2,0,https://www.nejm.org/doi/full/10.1056/NEJMoa2203965,151,151,Qatar,Qatar omicron,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.2,,"Mild, Moderate + severe",Symptomatic SARS-CoV-2 reinfection is conventionally defined as a documented infection ?90 days after an earlier infection,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,20,70,,0,,,,-0.011,-0.071,0.046,0,1,38,,,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.836,0.764,0.886,0,0,,0,1,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.968,0.944,0.982,0,0,,2,3,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.967,0.957,0.975,0,0,,4,7,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.962,0.953,0.969,0,0,,8,11,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.952,0.941,0.962,0,0,,12,15,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.909,0.877,0.932,0,0,,16,19,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.584,0.059,0.816,0,0,,0,1,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.634,0.214,0.83,0,0,,2,3,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.577,0.372,0.716,0,0,,4,7,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.408,0.232,0.544,0,0,,8,11,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.377,0.227,0.497,0,0,,12,15,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.475,0.376,0.558,0,0,,16,19,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.339,0.241,0.424,0,0,,20,23,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1011,Ionescu I,medrix- VE against delta and omicron for adolscents,0,https://www.medrxiv.org/content/10.1101/2022.06.27.22276790v1.full.pdf,101,101,Canada,Canada Omicron Adolscents,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,infection,Cases were adolescents 12-17 years old with NAAT-confirmed SARS-CoV-2 infection during the study period,infection,infection,,1,1,1,1,3,12,17,,0,,,,0.222,0.084,0.339,0,0,,24,27,Weeks since full vaccination,,,,,0,0,0,0,0,0,0,0,,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"SARS-CoV-2 infections were identified using SGSS testing records and based on swab date. Both polymerase chain reaction (PCR) and lateral flow test results are included, without differentiation between symptomatic and asymptomatic infection",infection,infection,,1,1,1,1,3,18,90,,0,,,,0.31,0.294,0.34,1,0,,0,1,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"SARS-CoV-2 infections were identified using SGSS testing records and based on swab date. Both polymerase chain reaction (PCR) and lateral flow test results are included, without differentiation between symptomatic and asymptomatic infection",infection,infection,,1,1,1,1,3,18,90,,0,,,,0.504,0.484,0.53,1,0,,1,2,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"SARS-CoV-2 infections were identified using SGSS testing records and based on swab date. Both polymerase chain reaction (PCR) and lateral flow test results are included, without differentiation between symptomatic and asymptomatic infection",infection,infection,,1,1,1,1,3,18,90,,0,,,,0.684,0.664,0.702,1,0,,2,4,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"SARS-CoV-2 infections were identified using SGSS testing records and based on swab date. Both polymerase chain reaction (PCR) and lateral flow test results are included, without differentiation between symptomatic and asymptomatic infection",infection,infection,,1,1,1,1,3,18,90,,0,,,,0.579,0.551,0.604,1,0,,4,6,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,"SARS-CoV-2 infections were identified using SGSS testing records and based on swab date. Both polymerase chain reaction (PCR) and lateral flow test results are included, without differentiation between symptomatic and asymptomatic infection",infection,infection,,1,1,1,1,3,18,90,,0,,,,0.435,0.405,0.465,1,0,,6,10,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,COVID-19 hospitalisations were identified using HES in-patient hospital records with U07.1 or U07.2 reason for admission ICD-10 codes,hosp,severe,,1,0,0,0,3,18,90,,0,,,,0.712,0.61,0.784,1,0,,0,1,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,COVID-19 hospitalisations were identified using HES in-patient hospital records with U07.1 or U07.2 reason for admission ICD-10 codes,hosp,severe,,1,0,0,0,3,18,90,,0,,,,0.622,0.509,0.712,1,0,,1,2,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,COVID-19 hospitalisations were identified using HES in-patient hospital records with U07.1 or U07.2 reason for admission ICD-10 codes,hosp,severe,,1,0,0,0,3,18,90,,0,,,,0.839,0.789,0.879,1,0,,2,4,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,COVID-19 hospitalisations were identified using HES in-patient hospital records with U07.1 or U07.2 reason for admission ICD-10 codes,hosp,severe,,1,0,0,0,3,18,90,,0,,,,0.86,0.798,0.903,1,0,,4,6,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,COVID-19 hospitalisations were identified using HES in-patient hospital records with U07.1 or U07.2 reason for admission ICD-10 codes,hosp,severe,,1,0,0,0,3,18,90,,0,,,,0.856,0.796,0.897,1,0,,6,10,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Deaths were classified as from COVID-19 if deaths with the same ICD-10 codes were mentioned anywhere on the death certificate (i.e., as an underlying or contributing cause of death)",death,severe,,1,0,0,0,3,18,90,,0,,,,0.99,0.99,0.99,1,0,,0,1,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Deaths were classified as from COVID-19 if deaths with the same ICD-10 codes were mentioned anywhere on the death certificate (i.e., as an underlying or contributing cause of death)",death,severe,,1,0,0,0,3,18,90,,0,,,,0.858,0.607,0.953,1,0,,1,2,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Deaths were classified as from COVID-19 if deaths with the same ICD-10 codes were mentioned anywhere on the death certificate (i.e., as an underlying or contributing cause of death)",death,severe,,1,0,0,0,3,18,90,,0,,,,0.851,0.7,0.925,1,0,,2,4,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Deaths were classified as from COVID-19 if deaths with the same ICD-10 codes were mentioned anywhere on the death certificate (i.e., as an underlying or contributing cause of death)",death,severe,,1,0,0,0,3,18,90,,0,,,,0.948,0.856,0.981,1,0,,4,6,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,"Deaths were classified as from COVID-19 if deaths with the same ICD-10 codes were mentioned anywhere on the death certificate (i.e., as an underlying or contributing cause of death)",death,severe,,1,0,0,0,3,18,90,,0,,,,0.907,0.808,0.957,1,0,,6,10,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"SARS-CoV-2 infections were identified using SGSS testing records and based on swab date. Both polymerase chain reaction (PCR) and lateral flow test results are included, without differentiation between symptomatic and asymptomatic infection",infection,infection,,1,1,1,1,3,18,90,,0,,,,0.305,0.288,0.326,1,0,,0,1,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"SARS-CoV-2 infections were identified using SGSS testing records and based on swab date. Both polymerase chain reaction (PCR) and lateral flow test results are included, without differentiation between symptomatic and asymptomatic infection",infection,infection,,1,1,1,1,3,18,90,,0,,,,0.474,0.452,0.493,1,0,,1,2,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"SARS-CoV-2 infections were identified using SGSS testing records and based on swab date. Both polymerase chain reaction (PCR) and lateral flow test results are included, without differentiation between symptomatic and asymptomatic infection",infection,infection,,1,1,1,1,3,18,90,,0,,,,0.681,0.662,0.701,1,0,,2,4,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"SARS-CoV-2 infections were identified using SGSS testing records and based on swab date. Both polymerase chain reaction (PCR) and lateral flow test results are included, without differentiation between symptomatic and asymptomatic infection",infection,infection,,1,1,1,1,3,18,90,,0,,,,0.598,0.581,0.617,1,0,,4,6,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,"SARS-CoV-2 infections were identified using SGSS testing records and based on swab date. Both polymerase chain reaction (PCR) and lateral flow test results are included, without differentiation between symptomatic and asymptomatic infection",infection,infection,,1,1,1,1,3,18,90,,0,,,,0.467,0.409,0.495,1,0,,6,10,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,COVID-19 hospitalisations were identified using HES in-patient hospital records with U07.1 or U07.2 reason for admission ICD-10 codes,hosp,severe,,1,0,0,0,3,18,90,,0,,,,0.771,0.713,0.816,1,0,,0,1,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,COVID-19 hospitalisations were identified using HES in-patient hospital records with U07.1 or U07.2 reason for admission ICD-10 codes,hosp,severe,,1,0,0,0,3,18,90,,0,,,,0.709,0.642,0.764,1,0,,1,2,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,COVID-19 hospitalisations were identified using HES in-patient hospital records with U07.1 or U07.2 reason for admission ICD-10 codes,hosp,severe,,1,0,0,0,3,18,90,,0,,,,0.836,0.799,0.864,1,0,,2,4,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,COVID-19 hospitalisations were identified using HES in-patient hospital records with U07.1 or U07.2 reason for admission ICD-10 codes,hosp,severe,,1,0,0,0,3,18,90,,0,,,,0.905,0.866,0.931,1,0,,4,6,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,COVID-19 hospitalisations were identified using HES in-patient hospital records with U07.1 or U07.2 reason for admission ICD-10 codes,hosp,severe,,1,0,0,0,3,18,90,,0,,,,0.774,0.707,0.826,1,0,,6,10,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Deaths were classified as from COVID-19 if deaths with the same ICD-10 codes were mentioned anywhere on the death certificate (i.e., as an underlying or contributing cause of death)",death,severe,,1,0,0,0,3,18,90,,0,,,,0.908,0.299,0.991,1,0,,0,1,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Deaths were classified as from COVID-19 if deaths with the same ICD-10 codes were mentioned anywhere on the death certificate (i.e., as an underlying or contributing cause of death)",death,severe,,1,0,0,0,3,18,90,,0,,,,0.643,0.239,0.833,1,0,,1,2,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Deaths were classified as from COVID-19 if deaths with the same ICD-10 codes were mentioned anywhere on the death certificate (i.e., as an underlying or contributing cause of death)",death,severe,,1,0,0,0,3,18,90,,0,,,,0.803,0.684,0.876,1,0,,2,4,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Deaths were classified as from COVID-19 if deaths with the same ICD-10 codes were mentioned anywhere on the death certificate (i.e., as an underlying or contributing cause of death)",death,severe,,1,0,0,0,3,18,90,,0,,,,0.917,0.828,0.96,1,0,,4,6,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,1012,Hulme W,medrix- booster VE against delta,0,https://www.medrxiv.org/content/10.1101/2022.06.06.22276026v1.full.pdf,95,95,United Kingdom,UK booster delta,0,AstraZeneca,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,severe,"Deaths were classified as from COVID-19 if deaths with the same ICD-10 codes were mentioned anywhere on the death certificate (i.e., as an underlying or contributing cause of death)",death,severe,,1,0,0,0,3,18,90,,0,,,,0.964,0.88,0.984,1,0,,6,10,Weeks since booster dose,,,,,0,0,0,0,0,0,0,0,Age end >= 90,han20
,0,569,Sritipsukho P,VE delta Thailand,0,https://www.tandfonline.com/doi/full/10.1080/22221751.2022.2037398,18,18,Thailand,Thailand delta,0,,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,infection,positive PCR regardless of symptoms,infection,infection,,1,1,1,1,3,18,60,,0,,,,0.6,0.49,0.7,0,1,11,,,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,Age end >= 60,han20
,0,569,Sritipsukho P,VE delta Thailand,0,https://www.tandfonline.com/doi/full/10.1080/22221751.2022.2037398,18,18,Thailand,Thailand delta,0,,AstraZeneca,ChAdOx1,Adenovirus,B.1.617.2,,infection,positive PCR regardless of symptoms,infection,infection,,1,1,1,1,3,18,60,,0,,,,0.83,0.7,0.9,0,1,8,,,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,Age end >= 60,han20
,0,569,Sritipsukho P,VE delta Thailand,0,https://www.tandfonline.com/doi/full/10.1080/22221751.2022.2037398,18,18,Thailand,Thailand delta,0,AstraZeneca,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,infection,positive PCR regardless of symptoms,infection,infection,,1,1,1,1,3,18,60,,0,,,,0.85,0.73,0.94,1,1,3,,,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,Age end >= 60,han20
,0,569,Sritipsukho P,VE delta Thailand,0,https://www.tandfonline.com/doi/full/10.1080/22221751.2022.2037398,18,18,Thailand,Thailand delta,0,Pfizer & BioNTech,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,infection,positive PCR regardless of symptoms,infection,infection,,1,1,1,1,3,18,60,,0,,,,0.97,0.87,0.99,1,1,7,,,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,Age end >= 60,han20
,0,1013,Tartof S,Lancet preprint- VE Omicron,0,https://deliverypdf.ssrn.com/delivery.php?ID=750066083101064099069070093119097076039056010023061049023040117013044029125099013037079066012017086080076011087118041120113093007084074014062127018073115094078082024001093020007070010089076103118033013101004089075003075071116086005099028024106003074122029114125077025115029095023081127004065&EXT=pdf&INDEX=TRUE,102,102,United States,US omicron hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,Controls were patients with a hospital admission for ARI and a KPSC laboratory-confirmed negative SARS-CoV-2 PCR test collected within 14 days prior to through three days after admission and no positive COVID-19 tests within 90 days prior to the admission,hosp,severe,,1,0,0,0,3,18,65,,0,,,,0.54,0.38,0.65,0,0,,2,23,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, interval started at <6 months, included as 2-23, interval ended at >= 6 months, included as 24-48 for sake of analysis",han20
,0,1013,Tartof S,Lancet preprint- VE Omicron,0,https://deliverypdf.ssrn.com/delivery.php?ID=750066083101064099069070093119097076039056010023061049023040117013044029125099013037079066012017086080076011087118041120113093007084074014062127018073115094078082024001093020007070010089076103118033013101004089075003075071116086005099028024106003074122029114125077025115029095023081127004065&EXT=pdf&INDEX=TRUE,102,102,United States,US omicron hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,Controls were patients with a hospital admission for ARI and a KPSC laboratory-confirmed negative SARS-CoV-2 PCR test collected within 14 days prior to through three days after admission and no positive COVID-19 tests within 90 days prior to the admission,hosp,severe,,1,0,0,0,3,18,65,,0,,,,0.32,0.16,0.48,0,0,,24,48,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, interval started at <6 months, included as 2-23, interval ended at >= 6 months, included as 24-48 for sake of analysis",han20
,0,1013,Tartof S,Lancet preprint- VE Omicron,0,https://deliverypdf.ssrn.com/delivery.php?ID=750066083101064099069070093119097076039056010023061049023040117013044029125099013037079066012017086080076011087118041120113093007084074014062127018073115094078082024001093020007070010089076103118033013101004089075003075071116086005099028024106003074122029114125077025115029095023081127004065&EXT=pdf&INDEX=TRUE,102,102,United States,US omicron hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.2,,severe,Controls were patients with a hospital admission for ARI and a KPSC laboratory-confirmed negative SARS-CoV-2 PCR test collected within 14 days prior to through three days after admission and no positive COVID-19 tests within 90 days prior to the admission,hosp,severe,,1,0,0,0,3,18,65,,0,,,,0.56,-0.02,0.81,0,0,,2,23,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, interval started at <6 months, included as 2-23, interval ended at >= 6 months, included as 24-48 for sake of analysis",han20
,0,1013,Tartof S,Lancet preprint- VE Omicron,0,https://deliverypdf.ssrn.com/delivery.php?ID=750066083101064099069070093119097076039056010023061049023040117013044029125099013037079066012017086080076011087118041120113093007084074014062127018073115094078082024001093020007070010089076103118033013101004089075003075071116086005099028024106003074122029114125077025115029095023081127004065&EXT=pdf&INDEX=TRUE,102,102,United States,US omicron hosp,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.2,,severe,Controls were patients with a hospital admission for ARI and a KPSC laboratory-confirmed negative SARS-CoV-2 PCR test collected within 14 days prior to through three days after admission and no positive COVID-19 tests within 90 days prior to the admission,hosp,severe,,1,0,0,0,3,18,65,,0,,,,0.56,0.28,0.73,0,0,,24,48,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, interval started at <6 months, included as 2-23, interval ended at >= 6 months, included as 24-48 for sake of analysis",han20
,0,1013,Tartof S,Lancet preprint- VE Omicron,0,https://deliverypdf.ssrn.com/delivery.php?ID=750066083101064099069070093119097076039056010023061049023040117013044029125099013037079066012017086080076011087118041120113093007084074014062127018073115094078082024001093020007070010089076103118033013101004089075003075071116086005099028024106003074122029114125077025115029095023081127004065&EXT=pdf&INDEX=TRUE,102,102,United States,US omicron hosp,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,Controls were patients with a hospital admission for ARI and a KPSC laboratory-confirmed negative SARS-CoV-2 PCR test collected within 14 days prior to through three days after admission and no positive COVID-19 tests within 90 days prior to the admission,hosp,severe,,1,0,0,0,3,18,65,,0,,,,0.8,0.74,0.84,1,0,,2,11,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, interval started at <3 months, included as 2-11, interval ended at >= 3 months, included as 2-11 for sake of analysis",han20
,0,1013,Tartof S,Lancet preprint- VE Omicron,0,https://deliverypdf.ssrn.com/delivery.php?ID=750066083101064099069070093119097076039056010023061049023040117013044029125099013037079066012017086080076011087118041120113093007084074014062127018073115094078082024001093020007070010089076103118033013101004089075003075071116086005099028024106003074122029114125077025115029095023081127004065&EXT=pdf&INDEX=TRUE,102,102,United States,US omicron hosp,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.1,,severe,Controls were patients with a hospital admission for ARI and a KPSC laboratory-confirmed negative SARS-CoV-2 PCR test collected within 14 days prior to through three days after admission and no positive COVID-19 tests within 90 days prior to the admission,hosp,severe,,1,0,0,0,3,18,65,,0,,,,0.76,0.7,0.82,1,0,,12,24,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, interval started at <3 months, included as 2-11, interval ended at >= 3 months, included as 2-11 for sake of analysis",han20
,0,1013,Tartof S,Lancet preprint- VE Omicron,0,https://deliverypdf.ssrn.com/delivery.php?ID=750066083101064099069070093119097076039056010023061049023040117013044029125099013037079066012017086080076011087118041120113093007084074014062127018073115094078082024001093020007070010089076103118033013101004089075003075071116086005099028024106003074122029114125077025115029095023081127004065&EXT=pdf&INDEX=TRUE,102,102,United States,US omicron hosp,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.2,,severe,Controls were patients with a hospital admission for ARI and a KPSC laboratory-confirmed negative SARS-CoV-2 PCR test collected within 14 days prior to through three days after admission and no positive COVID-19 tests within 90 days prior to the admission,hosp,severe,,1,0,0,0,3,18,65,,0,,,,0.74,0.47,0.87,1,0,,2,11,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, interval started at <3 months, included as 2-11, interval ended at >= 3 months, included as 2-11 for sake of analysis",han20
,0,1013,Tartof S,Lancet preprint- VE Omicron,0,https://deliverypdf.ssrn.com/delivery.php?ID=750066083101064099069070093119097076039056010023061049023040117013044029125099013037079066012017086080076011087118041120113093007084074014062127018073115094078082024001093020007070010089076103118033013101004089075003075071116086005099028024106003074122029114125077025115029095023081127004065&EXT=pdf&INDEX=TRUE,102,102,United States,US omicron hosp,0,Pfizer & BioNTech,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529.2,,severe,Controls were patients with a hospital admission for ARI and a KPSC laboratory-confirmed negative SARS-CoV-2 PCR test collected within 14 days prior to through three days after admission and no positive COVID-19 tests within 90 days prior to the admission,hosp,severe,,1,0,0,0,3,18,65,,0,,,,0.7,0.53,0.81,1,0,,12,24,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 65, interval started at <3 months, included as 2-11, interval ended at >= 3 months, included as 2-11 for sake of analysis",han20
,0,570,Suah JL,VE CoronaVac vs Pfizer delta,0,https://www.ijidonline.com/article/S1201-9712(22)00167-9/fulltext,13,13,Malaysia,Malaysia delta death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,a positive Covid-19 PCR >14 days after full vaccination,infectoin,infection,,1,1,1,1,3,15,60,,0,,,,0.908,0.89,0.921,0,0,,2,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >60,han20
,0,570,Suah JL,VE CoronaVac vs Pfizer delta,0,https://www.ijidonline.com/article/S1201-9712(22)00167-9/fulltext,13,13,Malaysia,Malaysia delta death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,infection,a positive Covid-19 PCR >14 days after full vaccination,infectoin,infection,,1,1,1,1,3,15,60,,0,,,,0.793,0.761,0.821,0,0,,9,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >60,han20
,0,570,Suah JL,VE CoronaVac vs Pfizer delta,0,https://www.ijidonline.com/article/S1201-9712(22)00167-9/fulltext,13,13,Malaysia,Malaysia delta death,0,,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,infection,a positive Covid-19 PCR >14 days after full vaccination,infectoin,infection,,1,1,1,1,3,15,60,,0,,,,0.745,0.706,0.78,0,0,,2,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >60,han20
,0,570,Suah JL,VE CoronaVac vs Pfizer delta,0,https://www.ijidonline.com/article/S1201-9712(22)00167-9/fulltext,13,13,Malaysia,Malaysia delta death,0,,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,infection,a positive Covid-19 PCR >14 days after full vaccination,infectoin,infection,,1,1,1,1,3,15,60,,0,,,,0.304,0.188,0.403,0,0,,9,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >60,han20
,0,570,Suah JL,VE CoronaVac vs Pfizer delta,0,https://www.ijidonline.com/article/S1201-9712(22)00167-9/fulltext,13,13,Malaysia,Malaysia delta death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths (using the COVID-19 deaths line listing),death,severe,,1,0,0,0,3,15,60,,0,,,,0.915,0.898,0.929,0,0,,2,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >60,han20
,0,570,Suah JL,VE CoronaVac vs Pfizer delta,0,https://www.ijidonline.com/article/S1201-9712(22)00167-9/fulltext,13,13,Malaysia,Malaysia delta death,0,,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,deaths (using the COVID-19 deaths line listing),death,severe,,1,0,0,0,3,15,60,,0,,,,0.912,0.886,0.931,0,0,,9,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >60,han20
,0,570,Suah JL,VE CoronaVac vs Pfizer delta,0,https://www.ijidonline.com/article/S1201-9712(22)00167-9/fulltext,13,13,Malaysia,Malaysia delta death,0,,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,severe,deaths (using the COVID-19 deaths line listing),death,severe,,1,0,0,0,3,15,60,,0,,,,0.792,0.768,0.814,0,0,,2,8,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >60,han20
,0,570,Suah JL,VE CoronaVac vs Pfizer delta,0,https://www.ijidonline.com/article/S1201-9712(22)00167-9/fulltext,13,13,Malaysia,Malaysia delta death,0,,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,severe,deaths (using the COVID-19 deaths line listing),death,severe,,1,0,0,0,3,15,60,,0,,,,0.762,0.688,0.819,0,0,,9,20,Weeks after second dose,,,,,0,0,0,0,0,0,0,0,Age end >60,han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain delta,0,,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.375,0.342,0.406,0,0,,0,2,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain delta,0,,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.51,0.496,0.524,0,0,,3,8,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain delta,0,,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.369,0.353,0.384,0,0,,9,25,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain delta,0,,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.335,0.317,0.353,0,0,,26,40,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain omicron,0,,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.243,0.2,0.283,0,0,,0,2,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain omicron,0,,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.269,0.251,0.286,0,0,,3,8,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain omicron,0,,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.05,0.042,0.059,0,0,,9,25,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain omicron,0,,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.081,0.07,0.091,0,0,,26,40,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain delta,0,,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.749,0.636,0.827,0,0,,0,2,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain delta,0,,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.867,0.838,0.892,0,0,,3,8,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain delta,0,,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.698,0.673,0.721,0,0,,9,25,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain delta,0,,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.573,0.534,0.609,0,0,,26,40,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain omicron,0,,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.39,-0.249,0.72,0,0,,0,2,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain omicron,0,,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.499,0.07,0.637,0,0,,3,8,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain omicron,0,,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.626,0.585,0.663,0,0,,9,25,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,Spain omicron,0,,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.57,0.535,0.602,0,0,,26,40,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >180 days included as 26-40 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain delta booster,0,CoronaVac/SinoVac,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.486,0.313,0.615,1,0,,0,1,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain delta booster,0,CoronaVac/SinoVac,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.598,0.533,0.653,1,0,,2,8,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain delta booster,0,CoronaVac/SinoVac,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.455,0.181,0.637,1,0,,9,25,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain delta booster severe,0,CoronaVac/SinoVac,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.775,0.613,0.869,1,0,,0,1,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain delta booster severe,0,CoronaVac/SinoVac,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.803,0.737,0.852,1,0,,2,8,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain delta booster severe,0,CoronaVac/SinoVac,CoronaVac/SinoVac,,inactivated virus,B.1.617.2,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.658,0.297,0.834,1,0,,9,25,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain omicron booster,0,CoronaVac/SinoVac,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.061,-0.029,0.144,1,0,,0,1,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain omicron booster,0,CoronaVac/SinoVac,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.15,0.12,0.18,1,0,,2,8,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain omicron booster,0,CoronaVac/SinoVac,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.004,-0.02,0.029,1,0,,9,25,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain omicron booster severe,0,CoronaVac/SinoVac,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.606,-0.169,0.871,1,0,,0,1,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain omicron booster severe,0,CoronaVac/SinoVac,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.713,0.603,0.792,1,0,,2,8,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain omicron booster severe,0,CoronaVac/SinoVac,CoronaVac/SinoVac,,inactivated virus,B.1.1.529,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.654,0.615,0.688,1,0,,9,25,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain delta booster,0,CoronaVac/SinoVac,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.407,0.363,0.447,1,0,,0,1,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain delta booster,0,CoronaVac/SinoVac,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.866,0.859,0.873,1,0,,2,8,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain delta booster,0,CoronaVac/SinoVac,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.843,0.809,0.872,1,0,,9,25,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain delta booster severe,0,CoronaVac/SinoVac,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.768,0.714,0.812,1,0,,0,1,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain delta booster severe,0,CoronaVac/SinoVac,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.917,0.904,0.929,1,0,,2,8,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain delta booster severe,0,CoronaVac/SinoVac,Pfizer & BioNTech,BNT162b2,mRNA,B.1.617.2,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.884,0.807,0.93,1,0,,9,25,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain omicron booster,0,CoronaVac/SinoVac,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.173,0.153,0.193,1,0,,0,1,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain omicron booster,0,CoronaVac/SinoVac,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.568,0.563,0.574,1,0,,2,8,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain omicron booster,0,CoronaVac/SinoVac,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,"Mild, Moderate + severe",Covid-19 symptoms and a positive SARS-CoV-2 RT-PCR/antigen test result,Symptomatic,"Mild, Moderate + Severe",,1,1,1,0,3,18,80,,0,,,,0.349,0.343,0.356,1,0,,9,25,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain omicron booster severe,0,CoronaVac/SinoVac,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.667,0.558,0.749,1,0,,0,1,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain omicron booster severe,0,CoronaVac/SinoVac,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.855,0.838,0.87,1,0,,2,8,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
,0,571,Ranzani O,medrix- CoronaVac VE + booster VE omicron vs delta,0,https://www.medrxiv.org/content/10.1101/2022.03.30.22273193v1.full.pdf,92,92,Spain,spain omicron booster severe,0,CoronaVac/SinoVac,Pfizer & BioNTech,BNT162b2,mRNA,B.1.1.529,,severe,covid case that was hospitalized or died,hosp&death,severe,,1,0,0,0,3,18,80,,0,,,,0.861,0.85,0.871,1,0,,9,25,Weeks after last dose,,,,,0,0,0,0,0,0,0,0,"Age end >= 80, interval end at >=60 days included as 9-25 for sake of analysis",han20
